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Urine contains exosomes originating from the circulation and all cells lining the 
urinary tract. Exosomes are a route of inter-cellular communication along the 
nephron potentially able to transfer of protein and/or RNA. It is not known whether 
this is a regulated process analogous to other cell-to-cell signalling systems. The 
aims of this study were to develop nanoparticle tracking analysis (NTA) as a 
technique to quantify exosomes in urine. Secondly, the hormonal regulation of 
exosome uptake in vitro and in vivo was investigated. Thirdly, exosome excretion in 
a central diabetes insipidus (DI) patient and a patient group after radiocontrast 
exposure was measured to investigate exosome excretion along the kidney in injury.   
Using the fluorescent capabilities of NTA, urinary exosomes were quantified in urine 
samples. NTA was able to detect changes in aquaporin 2 levels in vitro and in vivo.  
Storage conditions for human urinary exosomes were also optimised using NTA. A 
kidney cortical collecting duct cell line (CCDs) was used to model regulation of 
exosome uptake in vitro. CCDs were stimulated with desmopressin, a vasopressin 
analogue, and uptake of fluorescently-loaded or microRNA-loaded exosomes was 
measured. Desmopressin stimulated exosome uptake into collecting duct cells via V2 
receptor stimulation. Intra-cellular uptake of exosomes was confirmed by microRNA 
specific mRNA down-regulation. Mechanistically, exosome uptake in response to 
desmopressin required cyclic AMP production, was mediated by clathrin-dependent 
endocytosis and was selective for exosomes from kidney tubular cells. In mice, 
fluorescently-loaded exosomes were systemically injected before and after 
administration of the V2 antagonist, tolvaptan, and urinary exosome excretion was 
measured. Basally, 2.5% of injected exosomes were recovered in urine; tolvaptan 
treatment resulted in a 5-fold increase. By combining antibodies to nephron segment-
specific proteins with NTA we measured human urinary exosome excretion in 
central diabetes insipidus (DI) and after radiocontrast exposure (n=37). In DI, 
desmopressin reduced the excretion of exosomes derived from upstream glomerular 
and proximal tubule cells. In patients exposed to radiocontrast, urinary exosomes 
from the glomerulus were positively correlated with the tubular injury markers KIM-
1 and NGAL. 
ii 
These findings therefore show that tubular exosome uptake is a specific, hormonally 
regulated process that is reduced with injury. Physiologically, exosomes are a 
mechanism of inter-cellular communication; therapeutically, exosomes represent a 
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Chapter 1: Introduction 2 
Intercellular signalling controls a diverse range of cellular processes and activities in 
multicellular organisms. In the kidney, understanding intercellular signalling is vital, 
not only in physiology but also pathological states, particularly the development and 
progression of kidney disease.  The unidirectional flow of urine along the renal 
tubule provides a natural transport system for cell-to-cell communication. The kidney 
is therefore the ideal anatomical model to study intercellular signalling mediated by 
components of urine.  
There has been increased interest in the emerging role of extracellular vesicles as 
mediators of intercellular signalling and communication. Exosomes are a subset of 
extracellular vesicles, distinguished by their unique biogenesis in the endosomal 
pathway and identified by their physico-chemical properties. Exosomes are of 
specific interest in renal function due their ubiquitous nature and recognised function 
as vehicles of cellular information and function. A major ongoing challenge in the 
field, however, is to discriminate between exosomes and other extracellular vesicles 
such as microvesicles and apoptopic bodies (Table 1.1): the literature contains 
nomenclature that can be ambiguous. For clarity, in this study, “exosomes” are 
defined as extracellular vesicles sized between 20-100nm. These vesicles are derived 
from extracellular fluid such as cell culture supernatant or biological fluids such as 
urine and will not be distinguished based on cellular origin. Further distinguishing 
properties such as specific surface markers and purification methods will also be 





Chapter 1: Introduction 3 
Table 1.1 Extracellular vesicles and their characteristics 














100 000g Cytoplasmic and membrane proteins, 
mRNA, miRNA,  
non-coding proteins, mtDNA and gDNA 












10 000g Cytoplasmic and Membrane proteins 


















1 200g –  
10 000g  
Nuclear fractions,  
cell organelles  
Adapted from Andaloussi et al., 2013 and Braicu et al., 2015 
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1.1 Biogenesis of exosomes  
Exosomes are small vesicles of endocytic origin which are homogenous in shape and 





, and B and T cells
4
 amongst others. In vivo, exosomes have 









. Currently, exosomes can be 
distinguished from other extracellular vesicles by a set of specific physico-chemical 
properties and their unique biogenesis within the endosomal pathway. The physico-
chemical properties that distinguish exosomes from other extracellular vesicles 
include: their density when floated on a sucrose gradient (1.13 g/ml – 1.19 g/ml); 
unique ‘cup-shaped’ morphology with a distinct limiting lipid bi-layer and size 
between 20-100nm when viewed under transmission electron microscopy (TEM)
9
; 
and specific proteins central to their production and formation such as heat shock 
proteins (HSP) and tetraspannins
10,11
.  
The first step in the biogenesis of exosomes is the inward invagination of clathrin-
coated micro-domains on the plasma membrane. Once these vacuoles enter the cells, 
the Endosomal Sorting Complex Required for Transport (ESCRT) facilitates the 
development into late endosomes. Maturation of early endosomes into late 
endosomes results in changes in contents and increased accessibility and subsequent 
accumulation of plasma membrane derived vesicles. This leads to an increased 
number of internal vesicles and total vesicle size. Late endosomes are therefore 
referred to as multivesicular endosomes (MVEs) (Figure 1.1).  Vacuolar endosomes 
form vesicles by reversed budding into the lumen resulting into a ‘right-side out’ 
orientation in relation to the plasma membrane. These accumulated intraluminal 
vesicles (ILVs) have three fates: targeted to lysosomes for degradation; acting as 
vesicular intermediates to deliver histocompatibility complexes to the plasma 
membrane and finally, following fusion of these ILVs with the plasma membrane, 
these vesicles are released into the extracellular space and are now termed 
“exosomes”
12
. Secretion of exosomes into the extracellular environment is promoted 
by the RAB family of small GTPase such as RAB27A and 27B, with different 






Figure 1.1: Exosome biogenesis within the endosomal pathway 
Exosomes are represented by small heterogeneous vesicles that are formed following 
the inward invagination of clathrin-coated vesicles (CCV) on the plasma membrane. 
Maturation of early endosomes into late endosomes results in changes in contents 
and increased accessibility and subsequent accumulation of plasma membrane 
derived vesicles. Late endosomes are therefore referred to as multivesicular 
endosomes (MVEs). Exosomes are released by fusion of MVEs with the plasma 
membrane. Other MVEs fuse with lysosomes. Red spots symbolise clathrin 
associated with vesicles at the plasma membrane (clathrin-coated vesicles [CCV]). 
Membrane-associated and transmembrane proteins on vesicles are represented as 
triangles and rectangles, respectively. Arrows represent proposed directions of 
protein and lipid transport between organelles and between MVEs and the plasma 






1.2 Exosome purification, characterisation and 
detection methods  
There is currently no clear consensus on the most efficient methods for obtaining 
high yields of pure exosomes from cell culture supernatant and complex biological 
fluids. The nano-sized scale of an exosome presents a challenge for accurate 
characterisation and detection but these needs to be addressed in order to harness 
their potential as biomarkers or therapeutics.  
The International Society of Extracellular Vesicles has recently proposed the 
minimal experimental requirements required to define sub-populations of 
extracellular vesicles. The requirements state that the vesicles must be purified from 
extracellular fluid in a cell disruption limiting manner; at least three proteins 
characteristic of exosomes should be identified in a semi-quantitative manner; and 
finally, at least two different technologies of detecting and characterising exosomes 
should be used
1
. Here, purification and detection methods routinely being used will 
be discussed.  
1.2.1 Differential ultracentrifugation 
The most widely applied, and basic, method - due to its ease and high capacity - for 
separating exosomes from cells, apoptotic bodies, and microvesicles is differential 
ultracentrifugation. Ultracentrifugation has long been seen as the gold standard for 
the isolation of relatively homogenous size populations of exosomes. Briefly, this 
method involves slow centrifugation (~2000g) of the cell culture supernatant or fluid 
which will sediment cell debris, followed by pelleting of the exosomal fraction by a 
high g-force ultracentrifugation (~100 000g) step. This centrifugation approach, 
however, will also co-purify other non-exosomal components present in the cell 
culture supernatant or biological fluid. Sedimentation profiles were shown to be cell 
line dependent, in terms of both protein yield and purity
15
. In a complex biological 
fluid, for example urine, pelleting of urinary exosomes by ultracentrifugation showed 
40% of exosome proteins remaining in the supernatant post-ultracentrifugation
16
.  
Ultracentrifugation is also not always applicable to clinical samples due to the large 
starting volume required and low throughput of this method coupled with variable 
7 
 
user-dependent recovery rates: a recent study showed 100% exosome recovery in a 
complex biological fluid such as plasma could not be achieved despite using spike-in 
control exosomes 
17
. Indeed, even in cell culture supernatant, a 5-25% exosome 




A few groups have developed ultrafiltration as an alternative and relatively rapid 
method of concentrating exosomes. Ultrafiltration is also recommended and 
increasingly incorporated as an additional step within the differential centrifugation 
isolation protocol to further remove non-exosomal proteins or larger particles
20
. 
Briefly, this method involves using a filter of a defined size to exclude or include 
only particles of a particular size. A further advancement using this method was the 
development of a nanomembrane concentrator which is able to concentrate urinary 
exosomes comparable to, and as effectively as, standard ultracentrifugation
21
. 
Supporting this, another study combined ultrafiltration with size-exclusion 
chromatography and was able to consistently demonstrate a lower protein/vesicle 
ratio compared to ultracentrifugation methods, suggesting a higher extracellular 
vesicle ratio
22
. Using ultrafiltration on a complex biological fluid such as urine, 
however, remains challenging, as soluble proteins tend to be retained and 
concentrated in urine in addition to exosomes, thereby reducing the sensitivity of 
subsequent detection and analysis methods
23
.  
1.2.3 Sucrose gradient 
The use of a sucrose gradient can be seen as both a purification and detection 
method. The method of purification using a 30% sucrose cushion, is routinely added 
to differential ultracentrifugation to yield an exosome pellet with less larger protein 
particles or aggregates
24
. This method relies on the characteristic density of 
exosomes which will result in them floating at a defined density on the sucrose 
cushion. Recent studies have indicated a large loss in the total number of particles 
recovered using a sucrose gradient, but a lower protein/exosome ratio, again, 
suggesting a more pure preparation
20
. More refined variations of this method are in 
development, such as OptiPrep™ (Sigma-Aldrich, Dorset, UK), which is an 
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iodixanol-based density gradient which better preserves all sizes of vesicles by 
forming iso-osmotic solutions at all densities
25
.  
1.2.4 Commercial exosome precipitation reagents 
In attempts to address the challenges associated with exosome purification, a number 
of commercial products have been developed to precipitate exosomes without the 
need of ultracentrifugation and the large required starting volumes associated with it, 
for example: ExoQuick™ (System Bioscience, California, USA) and Exo-Spin™ 
(Cell Guidance Systems, Cambridge, UK). The exact mode-of-action for either has 
not been disclosed or validated
26
, but these products rely on polymer interactions to 
precipitate the exosomal fraction from a biological fluid. However, there has been 
considerable evidence that these products also co-precipitate soluble RNA-binding 





ExoQuick™ has been shown to also enrich the RNA-binding ribonucleotide 
Argonaute-2 (Ago2) complex along with exosomes. This suggests significant 
contamination by RNA/protein complexes 
25
 which greatly biases down-stream RNA 
analyses of “exosomal” contents.  Furthermore, contamination of the exosome 
preparation with undisclosed chemicals from the reagent could affect assays of 
exosomal biological activity. 
1.2.5 Immuno-isolation 
Immuno-isolation is a method using immune-magnetic extraction. Briefly, this 
method involves magnetic beads coated with antibodies directed to specific proteins 
exposed on the exosomal membrane, thereby providing a simple and rapid method 
not involving ultracentrifugation
28
. This bead-exosome complex is then of a suitable 
size for analysis by standard flow cytometry, immunoblotting or electron 
microscopy
24
. However, the major disadvantage of this isolation method is that it 
only allows the analysis of a subpopulation of exosomes and not the exosome 
population as a whole in any given sample. This method does, however, hold great 
potential in recent microfluidic developments of ‘on-chip’ exosome capture 
suggesting higher specificity and a shorter isolation time
19
. Supporting this, an 
exosome analysis platform, using ‘on-chip’ immunoaffinity to isolate tumor 
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exosomes from plasma from cancer patients, was reported to increase sensitivity 
whilst decreasing sample preparation time
29
.  
1.2.6 Transmission electron microscopy 
Transmission electron microscopy (TEM) is a type of electron microscopy which 
uses electron voltage instead of traditional light microscopy to visualise a sample
28
. 
TEM is widely used to distinguish the unique ‘cup-shaped’ morphology of exosomes 
in comparison to other extracellular vesicles or apoptotic bodies. Briefly, TEM 
involves a number of steps involving fixation, dehydration, resin-embedding and 




1.2.7 Western Blot 
In keeping with the required minimal requirements of classification of exosomes
1
, 
western blots are routinely used to identify specific proteins by separating protein 
bands by SDS-polyacrilamide gel electrophoresis (SDS-page). Several proteins have 
been identified and are well defined as exosomal markers, for example – tumours 




 Furthermore, a small, glycosylated 
protein CD24 has been shown to be a convenient exosome marker in urine
31
. The 
main disadvantage of using western blots to detect and characterise exosome 
populations is the large starting volume required for effective protein detection. To 
address this challenge, real-time detection and molecular profiling of exosomes are 
currently being developed using immunoaffinity
29
. 
1.2.8 Fluorescence microscopy 
Using a fluorescence microscope, exosomes conjugated to specific fluorophores can 
be excited and detected within specified emission ranges. This allows live cell 
imaging of exosomes in vitro 
32
 and in vivo
33
 and permits tracking of exosomal 
uptake/internalisation by using real-time fluorescence microscopy. However, this 
detection method still involves the time-consuming pre-processing steps of isolating 
and purifying exosomes before a fluorophore can be conjugated to the exosome.   
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1.2.9 Nanoparticle Tracking Analyses  
Nanoparticle tracking analyses (NTA) is a relatively new technology within the field 
of light scatter microscopy, which measures the size and total number concentration 
of particles in solution. This method is based on direct and real-time tracking of 
nano- and microparticles’ Brownian movement, which results in a description of the 
particle size and concentration distribution of a given solution. NTA is based on the 
principle that at any particular temperature, the rate of Brownian motion of particles 
in solution is determined solely by their size. In this method, laser light is directed at 
a fixed angle to the vesicle suspension, and the scattered light is captured using a 
microscope and high-sensitivity camera. By tracking the movement of individual 
particles over time, the software rapidly calculates their concentration and size. NTA 
also has fluorescent capabilities with a single long pass filter, thereby allowing 
quantification of a single fluorophore population. Indeed, by using fluorescent 
antibodies to specific surface proteins, studies have shown that it is possible to track 
specific subgroups of a defined size, such as exosomes, within the whole 
heterogeneous vesicle population found in complex biological fluids
34,35
.  
1.3 Exosome content 
Exosomes isolated by the above methods are shown to contain proteins, lipids, DNA 




1.3.1 Exosomal protein content 
Large scale proteomics has been used to examine the exosomal protein content in a 




. These studies consistently 
define exosomes as a specific subcellular compartment, containing a specific, limited 
subset of proteins originating from the plasma membrane, endocytic pathway and 
cytosol, with little representation of proteins from intracellular organelles
38
. The set 
of proteins include: annexins and flotilins involved in membrane transport and 
fusion, proteins associated with multivesicular body biogenesis (TSG101 and Alix), 
protein families associated with lipid domains (integrins and tetraspanins) and heat 
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shock proteins (HSP70 and HSP90) involved in antigenic presentation. Indeed an 
interesting study further revealed a potential new role for urinary exosomes based the 
exosomal protein content: maintaining urine sterility by virtue of their antibacterial 
activity. In-depth proteomic analyses of human urinary exosomes showed significant 
enrichment for innate immune proteins which included antimicrobial proteins and 
bacterial and viral receptors with a combined inherent function of inhibiting bacterial 
growth and inducing bacterial lysis
39
. Additionally, further studies showed, 
functional proteins, such as proteins associated with intracellular transport, protein 
folding, stress response, cellular homeostasis and lipid metabolism show significant 





 and B cells
42
. Although exosomes do not contain the 
entire proteome of the cell of origin, they do contain proteins specific to the cell of 
origin
43
. This characteristic allows exosomes from specific cell types to be identified 





. The exosomal protein can reflect the physiological 
condition of the cells and any changes in cellular conditions. In vitro, in endothelial 
cells, the protein content of exosomes were significantly increased similar to 
increases in their cell of origin, in conditions stimulating hypoxia, hyperglycaemia 
and inflammation
43
. The exosomal protein content of aquaporin-2 (AQP2) was also 
shown to be reflective of differences in the collecting duct cell following vasopressin 
stimulation
45
. Similarly, in vivo, proteins associated with the response to 
inflammatory stimuli were higher in serum exosomes from a mouse model of 
ischaemia-reperfusion injury
46
. Fewer studies have investigated the lipid composition 
of exosomes, but generally cholesterol and sphingomyelin are enriched
47
 combined 
with lipid-related enzymes, suggesting exosomes may be a unit of lipid production
48
. 
Exosomes have different lipid profiles compared to their cell of origin, suggesting 
different mechanisms allowing lipid sorting into vesicles 
49
.   
1.3.2 Exosomal mRNA content 
The discovery that exosomes contain mRNA was a major finding with great 
consequences for the field
50
. However, a number of subsequent studies have reported 





Indeed, it has been reported that exosomes may only contain around 8% of the total 
mRNA compared to donor mast cells
50
. Further studies have revealed that exosome 
mRNA species have clear differences compared to their cell of origin, with the 
majority of exosomal mRNAs being associated with intracellular transport and 
receptor-ligand interactions
53
. This was supported by a study that reported exosomes 
to contain mainly mRNA fragments and being enriched for mRNA degradation 
products
54
. These differences in mRNA do, however, suggest selective packaging as 
some gene transcripts are found to be present in exosomes, but not in the cell of 
origin and vice versa
50
. mRNA content of exosomes is further altered depending on 
the cellular condition that they are released under, with the key function of exosomal 
mRNA being cellular development, protein synthesis and RNA post-transcriptional 
modification
50
. The general assumption has been that exosomal delivery of mRNA to 
a recipient cell leads to protein translation, but there has been convincing evidence 




1.3.3 Exosomal miRNA content 
MiRNAs are short (19-25 nucleotides in length), non-protein coding RNA transcripts 
which regulate post-transcriptional gene expression through repression of mRNA 
translation or cleavage. MiRNAs are stably conserved across species, protected from 
RNase-dependent degradation in the circulation and can be detected in plasma, 
serum and urine
56
. Exosomes contain miRNAs from their cell of origin, leading to  
increased interest in biomarker studies
50
. Consistently, in a number of different cell 




, some miRNAs are significantly 
more abundant in exosomes compared to miRNA levels in the cell of origin, 
suggesting a specific sorting mechanism 
4,50,53
. The mechanisms which control 
miRNA sorting and packaging into exosomes are still not fully defined. Recently, 
SUMOylation – small ubiquitin-like modifier proteins – by a specific nuclear 
ribonucleoprotein (HnRNPA2b1) was reported to recognise and preferentially 
package targeted miRNAs into exosomes
57
. Better understanding of this process is 
crucial for understanding exosome physiology.  Changes in the exosomal miRNA 
cargo do reflect changes in cellular conditions. Treatment of pancreatic B cells with 
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pro-inflammatory cytokines showed upregulation of exosomal miRNAs associated 
with cell death
58
. Similarly, exosomes from mast cells exposed to reactive oxidative 
species showed a different miRNA profile compared to exosomes from control 
cells
59
. As a caveat, a number of studies have indicated that it might not be the 
circulating exosomal compartment that contains the majority of miRNA, but rather 
the Ago2 complex
60,61
 with up to 90% of miRNA present in a non-vesicle form 
bound to a ribonucleotide protein such as the Ago2 complex
62
. The authors 
hypothesised that vesicle-associated versus Ago2-associated miRNA populations 
originate from different cell types with different release mechanisms. For example 
let7a associates with vesicles from cells known to release exosomes such as 
reticulocytes maturing into erythrocytes
63
, compared to miR-122 which reports 
hepatocyte injury seen to be Ago2 protein associated
64
. The exosomal miRNA cargo 
still necessitate better understanding and definition as it consistently induces a 
biological effect in vitro, this is possibly due to the potentially high number of 
exosomes circulating physiologically coupled with the suggested differential cargo 
packaging. 
1.3.4 Exosomal DNA content 
Exosomes have been shown to contain both mitochondrial and genomic DNA. 
Mitochondrial DNA (mtDNA) is only 1 chromosome and codes for specific proteins 
which are used in metabolic process. Genomic DNA (gDNA) is the standard 46 
chromosomes containing the genomic lineage. Exosomal mtDNA has been identified 
in a number of different cell types including astrocytes and gliablastoma cells
65
. In 
human mast cells, 75% of the secreted mtDNA could be found in the exosomal 
cargo
66
. Recently, gDNA, representing the entire genome, was found within 
exosomes
67
. Available data are currently limited, but a study in pancreatic cancer 
patients was able to demonstrate that serum exosomes contain double stranded 
genomic DNA and furthermore that mutations frequently associated with pancreatic 
cancer are readily detectible in exosomal gDNA
68
. This was further supported by a 
study showing changes in the exosomal gDNA reflecting changes in the mutational 
status of the parental tumour cell
67
. There are, however,  differences between the 
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donor cancer cell and exosomal gDNA, suggesting different recycling processes 
sensitive to post-translational modifications
69
. 
1.4 Exosomes as biomarkers of disease  
Exosomes have great potential as a source of disease biomarkers due to their inherent 
ability to contain information from their cell of origin. As they express surface 
markers from specific organs, there is the potential to isolate organ-specific 
exosomes from complex fluids such as plasma and urine. Additionally, the structural 
integrity of a distinctive lipid bi-layer of an exosome protects the RNA cargo from 
degradation by RNAses
50
. Isolation of exosomes can also significantly increase the 
sensitivity and specificity of the biomarker analysis when compared to whole 
biological fluids. Exosomes, therefore, potentially provide a minimally invasive, 
rapid, liquid biopsy of the tissue of origin.  Here, different exosomal contents as 
biomarkers of disease will be discussed.  
1.4.1 Exosomal protein as biomarker of disease 
The protein composition and surface markers associated with exosomes provides 
diagnostic biomarker potential. Large-scale proteomics of exosomes derived from a 
number of different cell types and different biological fluids, allowed large scale 
identification of exosome associated proteins as potential biomarkers for a number of 
diseases (Table 1.2). In cancer, exosome enriched glypican-1, a cell-surface 
proteoglycan, reported early stages of pancreatic cancer with a high degree of 
specificity and sensitivity
70
. Similarly, in bowel cancer, heat HSP60 has been 
demonstrated to be an early biomarker of tumour formation
71
. In sarcoidosis, 
exosome isolation from bronchiolar lavage fluid showed neuregulin-1 to be a reliable 
marker of inflammation
72
. The exosome proteome is also a rich reservoir of 
information in neurodegenerative diseases such as Alzheimers’ disease (AD) and 
Parkinson’s disease (PD). Proteomics on neural-derived exosomes revealed different 
profiles for autolysosomal proteins, such as lysosome-associated membrane protein 1 
(LAMP-1) in patients with AD, reflecting pathology up to 10 years before clinical 
onset, compared to case control patients
73
. In PD, immunophenotyping CSF and 
serum exosomal protein populations identified a number of proteins differentially 
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expressed in PD patients compared to controls, highlighting the potential of a panel 
of exosomal proteins as a biomarker of PD
74
. Urinary exosome proteins also hold 
great potential as non-invasive biomarkers of kidney disease. Urinary exosomal 
fetuin-A protein is increased following cisplatin-induced acute kidney injury, this 
increase preceding serum creatinine elevation
75
. Wilms tumor 1 (WT1) concentration 
in urinary exosomes are also reported to be an early biomarker of diabetic 
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Table 1.2 Recent exosomal proteins identified as potential biomarkers in complex biological fluids in various diseases 
Biofluid Disease Associated proteins 
Early diagnostic/prognostic/ 
response to treatment 
Reference 
Plasma Prostate cancer Survivin Early diagnostic 
77
 
Ovarian carcinoma TGF-β; MAGE-3 Prognostic, response to treatment 
78
 
Pancreatic cancer Glypican-1  Early diagnostic 
70
 
Large bowel carcinoma  HSP-60 Therapeutic response 
71
 





Serum Melanoma  MDA-9 & GRP78 Prognostic 
79
 




Breast cancer CD95-L Therapeutic response 
81
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Biofluid Disease Associated proteins 
Early diagnostic/prognostic/ 
response to treatment 
Reference 
Saliva Lung cancer CD63 & GADPH Early diagnostic 
82
 
Oral cancer 139 peptides Early diagnostic 
83
 
Pancreatic cancer ASPN, Foxp1, Ging2, Daf2  Early diagnostic 
84
 
Urine Acute kidney injury Fetuin-A Early diagnostic 
75
 
 Diabetic nephropathy Wilms tumour 1  Early diagnostic 
76
 
 Polycystic kidney disease Ca2+ & cytoskeleton regulating 
proteins  
TMEM2  
Response to treatment 
85
 
Parkinson’s Disease DJ-1  Prognostic 
86
 
Primary Aldosteronism Phosphorylated NCC Early diagnostic 
87
 
Obstructive nephropathy TGFβ & L1CAM Early diagnostic 
88
 
Diabetic kidney disease Dipeptidyl peptidase 1V Prognostic 
89
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1.4.2 Exosomal mRNA as biomarkers of disease   
Exosomal mRNA is not gathering as much interest as protein or miRNA as potential 
biomarkers of disease (Table 1.3) due to a number of challenges associated with 
mRNA biomarker studies. Firstly, exosomal mRNA is not reflective of the cell of 
origin due to the selective packaging observed and the informative value of the cargo 
is questionable as it has been shown to be both fragmented 
55
 and associated with 
degradation machinery
54
. Secondly, there is currently no RNA internal control 
available to account for different exosome yields or degradation in complex 
biological fluids such as plasma or urine, with standard 18S or 28S measurements 
yielding variable results
55,90
. A recent, exciting study was able to circumvent these 
challenges by using microfluidic chip-based analyses to measure exosomal mRNA 
levels of two enzymes known to correlate with glioblastoma multiforme treatment. 
The authors demonstrated a strong correlation between these mRNA candidates and 
levels in the parental cell and furthermore, that these changes in exosomal mRNA 
were able to rapidly, and minimally invasively, track changes as treatment 
progressed
91
. This work was building on previous work identifying specific mRNA 
epithelial growth factor receptor (EGFR) mutations to be specifically found in serum 
derived exosomes from gliablastoma patients
92
.  Other studies investigating 
exosomal mRNA reported that melanoma-derived exosomes have differential mRNA 
expression associated with metastasis and cancer progression
93
. In kidney disease, 
specifically podocyte injury induced kidney disease, urinary exosomal cystatin-C 
mRNA was identified as a potential biomarker of injury
94
 and urinary exosomal 
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Table 1.3 Limited exosomal mRNA identified as biomarker of various diseases in complex biological fluids  
Biofluid Disease Associated mRNAs 
Early diagnostic/prognostic/ 
response to treatment 
Reference 
Serum Gliablastoma multiforme RNU6-1 – noncoding RNA Early diagnostic 
96
 
Plasma Gliablastoma MGMT & APNG Early diagnostic 
91
 
Gastric cancer RNA 152  Early diagnostic 
97
 
Urine Kidney disease CD2AP Prognostic 
95
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1.4.3 Exosomal miRNA as biomarkers of disease  
Considerably more studies have indicated differential exosomal miRNA 





 and kidney disease
100
. Specific identified miRNAs have also been identified 
in a variety of diseases (Table 1.4). In cancer, a panel of serum derived exosomal 
miRNAs including miR-1246 and miR-155 has been proposed as a more sensitive 
and specific biomarker in acute myeloid leukemia, rather than reliance on a single 
miR
101
. This combined approach was supported by a study combining differential 
protein and miRNA expression in serum derived exosomes to allow earlier and more 
specific and sensitive detection of pancreatic cancer
80
.  Single, potential exosomal 
miRNAs are being identified as potential biomarkers in a number of disease states 
including cancer, diabetes and kidney injury and a select few examples will be 
highlighted. Serum exosomal miR-19a expression levels were shown to be increased 
in colorectal cancer patients compared to control
98
. Similarly, serum derived 
exosomal miR-21 levels were upregulated in patients with oesophageal squamous 
cell cancer with a positive correlation shown between miR-21 levels and tumour 
progression
102
. In incipient diabetic nephropathy patients, urinary exosomal miR-145 
was enriched and upregulated
103
. miR-143 is upregulated in patients with type 2 
diabetes and this upregulation can be detected in the early stages of the disease
104
. 
Urinary exosome levels of miR-29c were identified as a marker of early progression 
of fibrosis
100
 and urinary exosomal miR-146a was able to discriminate the presence 
of active lupus nephritis in patients with systemic lupus erythematosus
105
.  A major 
challenge in exosome miRNA biomarker discovery, however, similar to exosomal 
mRNA biomarker studies, is there is currently no endogenous control for exosomal 
miRNA in complex biological fluids. In serum, miR-221, miR-191, let-7a, miR-
181a, and miR-26a were recently identified to be an optimal gene reference set for 
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Table 1.4 Recent exosomal miRNAs identified as potential biomarkers in complex biological fluids in various diseases 
Biofluid Disease Associated mRNAs 
Early diagnostic/prognostic/ 
response to treatment 
Reference 









 Pancreatic cancer 
miR-1246, miR 4644, 
miR-3976, miR-4306 
Early diagnosis and therapeutic response 
80
 
 Colorectal cancer miR-17-92a  Prognostic 
98
 












Laryngeal squamous cell 
carcinoma 










Non-alcoholic fatty liver 
disease 
miR-122 & miR-192 Early diagnostic and prognostic 
113
 
 Alzheimer disease miR-342-3p Early diagnostic 
114
 
 Prostate cancer miR-1290 & miR-375 Prognostic 
115
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Biofluid Disease Associated mRNAs 
Early diagnostic/prognostic/ 
response to treatment 
Reference 
 Lung cancer 
miR-151a-5p, miR-200b, 
miR-629, miR-100 & 
miR-154 
















Urine Prostate cancer miR-34a Therapeutic response 
118
 
 Diabetic nephropathy miR-145 Early diagnostic 
103
 
 Type 2 diabetes miR-143 Early diagnostic  
104
 










Renal fibrosis in IgA 
nephropathy 
miR-21, miR29 & miR-
93 
Early diagnostic & prognostic 
120
 
Chapter 1: Introduction 23 
Biofluid Disease Associated mRNAs 
Early diagnostic/prognostic/ 
response to treatment 
Reference 


















miR-26a Early diagnostic 
123
 
 Lupus nephritis miR-29C Prognostic 
124
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1.4.4 Exosomal DNA as biomarker of disease  
There are very limited data available on exosomal DNA as a biomarker of disease. A 
recent study was able to demonstrate that exosomal DNA reflects mutations from 
parental tumour cells and thereby indicated exosomal DNA as a potential biomarker 
the early detection of cancer and metastasis
67
. Supporting this, the methylation status 
of gastric juice-derived exosomal DNA was recently reported to be a potential early 
biomarker of gastric cancer
125
. Exosomes from prostate cancer cell  lines and 
pancreatic patient plasma samples also contain double-stranded gDNA fragments 
which could be used to detect specific mutations, making exosomes 
potential biomarkers for cancer diagnostics and prognostics in prostate cancer
126
. In 
this study, exosome subpopulations differed from each other in terms of total protein 
and DNA content. Further analysis of gDNA fragments from the prostate cancer cell 
line-derived exosome subpopulations demonstrated that different exosomes 
contained different gDNA content, which could even harbour specific mutations. 
These results suggest and support previous findings that not only proteins and RNA 
species, but also DNA is selectively and cell-dependently packed into the exosome 
subtypes.  DNA biomarker candidates are slowly gaining interest and research effort, 
with limited results currently available to corroborate these findings. The inherent 
stability of DNA within exosomes coupled with the ability to enrich exosomes in 
whole vesicle populations using specific surface markers certainly proposes this an 
exciting area for future development.  
1.5 Exosomes as mediators of intercellular 
communication  
Exosomes were traditionally viewed as an alternative removal pathway to lysosomal 
degradation for the removal of senescent or excess lipids or proteins from cells. 
While a definitive physiological role of exosomes remains unclear, there has been 
accumulating evidence in the field towards intercellular signalling involvement. 
Here, exosomal content - protein, RNA species and DNA- as mediators of 
intercellular communication will be discussed.  
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1.5.1 Exosomal protein as mediators of intercellular 
communication 
Initial studies centred on exosomal protein content and the role that changes in 
protein expression might play in physiological events. In the immune system, the 
presence of molecules involved in antigen presentation gave immune-cell derived 
exosomes a status of potential modulators of the immune response. In epithelial cell 
monolayers, exosomes were shown to be released across both apical and basolateral 
membranes. The protein content of the apically released exosomes was suggestive of 
clearance processes; antigen presentation associated proteins were found in the 
basolaterally released exosomes.  Recently, exosomes were also demonstrated to 
control cell mobility by promoting cell adhesion through their fibronectin rich 
cargo
127
. The majority of research on exosomal proteins as mediators of intercellular 
communication remain, however, centred on pathophysiological states. In cancer, 
several studies have reported that tumour derived exosomes can alter the 
extracellular matrix through secretion of matrix metalloproteinases (MMPs) or 
activators of MMPs, such as HSPs, with exosomes shown to be generally pro-
tumorigenic
128
. HSP70, which has been well-characterised within the exosomal 
protein cargo, has been reported to be an effective inducer of inflammation following 
infection. Exosomal protein delivery was also shown to be central to the spread of 
viral disease such as human immunodeficiency virus type 1 (HIV)
129
 and hepatitis 
C
130
, and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s 
disease
73
. Even though a number of studies have indicated the function and potential 
of exosomes as intercellular signalling vectors, the mechanism of exosomal 
trafficking and specifically exosome internalisation into target cells remain unclear. 
Receptor-ligand interactions between both the exosome and recipient cell are widely 
accepted as the initial cell communication point
47
. A step further, a number of studies 
have indicated endocytosis as a mechanism of exosome internalisation. Endocytic 
mechanisms which has been identified for exosome internalisation include: clathrin-
dependent endocytosis; caveolae-dependent endocytosis; phagocytosis and 
macropinocytosis
131,132
. An additional consideration would be the micro-environment 
of the cells, as a low pH was reported to be conducive to greater exosomal uptake 
133
. 
A recent study presented real time data on exosomes attaching to the plasma 
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membrane through receptor binding and entering cells through endocytosis in a renal 
tumour cell line
134
. Whether exosomes of various cellular origins preferentially target 
specific cell types and how they are packaged remain unclear.  
1.5.2 Exosomal mRNAs as mediators of intercellular 
communication 
The first study to suggest a role for exosomes as intercellular messengers found that 
systemically injected exosomes could deliver targeted short interfering RNA to the 
mouse brain
135
. From this starting point, it is now clear that exosomal mRNA can be 
delivered into a cell where it can be transcribed into new, functional proteins, thereby 
changing the function of the cell. Exosomes themselves do not have the machinery 
for functional protein synthesis and are only capable of inducing functional protein 
changes when the RNA cargo is delivered into a recipient cell 
50
. Indeed, by using 
murine cell line derived exosomes, functional delivery mediated by exosomes was 
demonstrated in a human mast cell line, further supporting cross species functional 
exosome delivery 
50,136
. Further support for this is a study showing horizontal transfer 
of functional mRNA in glioblastoma cells. Glioblastoma-derived microvesicles 
including exosomes were transduced with mRNA for a secreted luciferase and, after 
incubation of these loaded vesicles with healthy cells, luciferase activity continued to 
increase over 24 hours, supporting translation of the luciferase mRNA 
92
. 
1.5.3 Exosomal miRNA as mediators of intercellular 
communication 
miRNAs are one of the most abundant gene regulatory molecules and are estimated 
to regulate the expression of more than 60% of all protein coding genes
137
. There has 
been considerable interest in the contribution of the exosomal miRNA cargo to the 
inherent physiological function of exosomes in vitro and in vivo. Recent evidence 
suggests that miRNAs in exosomes can be released through ceramide-dependent 
secretory machinery regulated by neutral sphingomyelinase 2 (nSMase2) enzyme 
encoded by the smpd3 gene that triggers exosome secretion
138
. In metastatic breast 
cancer cells, nSMase2 or ceramide were shown to promote the exosome-mediated 
miR-10b secretion whereas ceramide inhibitor suppressed this secretion. There are a 
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large number of studies focused on exosomal miRNA mediating intercellular 
communication (Table 1.5); examples relating to cancer, cardiovascular disease and 
liver disease will be discussed.  In pancreatic cancer, the differential profile of 
exosomal miRNAs compared to the parental cell, suggest a specific sorting 
mechanism and a specific role of exosomes in tumour-progression. Incubation with 
exosomes originating from pancreatic beta-cells treated with cytokines, induced 
apoptosis in healthy, untreated cells. Interestingly, by inhibiting Ago2, this effect was 
prevented
58
.  In cardiovascular disease, embryonic stem cell derived exosomes 
delivered a protective effect by delivering miR-294 in a myocardial infarction mouse 
model 
139
. This protective effect delivered by exosomes is also corroborated by a 
study in mice where exosomes delivered a regenerative effect in cardiomyopathy to 
improve heart function and fibrosis through miR-146a enrichment
140
 An interesting 
study relating to alcohol-related liver disease reported that ethanol-treated exosomes 
contained miRNA-122 and were able to horizontally transfer this miR to monocytes 
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Table 1.5 The role of exosomal miRNA in physiological and pathophysiological processes  




lymphoma cells  








Primary hepatocytes and 
Kuppfer cells 
Induction of pro-inflammatory 











miR-155 or miR-146a 
knockdown primary 
dendritic cells  
miR-155: Pro-inflammatory response 
to LPS 
miR-146a: Anti-inflammatory  









In vivo  
Neonatal rat 
cardiomyocytes  
Regenerative, pro-angiogenic & 
promoting survival and proliferation   
IRAK1 and TRAF6 
140
 
Chapter 1: Introduction 29 
miRNA Donor cell Recipient cell Biological function of miRNA Target gene Reference 
miR-223 Mesenchymal 
stem cells 
Cardiomyocytes Cardioprotective effects by reducing 
inflammation and cell death  
Sema3A & Stat3 
145
 
miR-122 Ethanol treated 
hepatocytes  












Pro-migratory and pro-angiogenic  
146
 
miR-214 Primary hepatic 
stellate cells 
(HSC) 















Increased proliferation, decreased 
apoptosis, increased colony forming 
ability 
P27 and ERα 
149
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T-cells Inhibiting T-cell proliferation; 
























miR-133a Myotubes Myoblasts Commitment of myoblasts in the 




miR-214 Endothelial cells Endothelial cells  Represses senescence; pro-aniogenic  ATM 
154
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1.5.4 Exosomal DNA as mediators of intercellular 
communication 
There is very little available research on the role the exosomal DNA cargo plays in 
mediating intercellular communication in either physiological or pathophysiological 
states, reflecting limited available knowledge on exosomal DNA content. The 
discovery of both single-stranded mtDNA and double-stranded gDNA will 
undoubtedly lead to increased research efforts into the possible roles exosomes may 
play in DNA regulation. One study was able to show horizontal mtDNA delivery by 
exosomes in human fibrosarcoma cells and human alveolar epithelial cells
155
. 
Whether this delivery is functional however, remains unclear. Another study reported 
transfer of foreign DNA by exosomes through electroporation of exogenous DNA, 
but functional changes in the recipient cells were not seen
156
. 
1.6 Exosomes and the kidney 
Urine contains exosomes from all segments of the nephron. The identification and 
proteomic discovery of urinary exosomes containing proteins specific to each 
segment from the podocyte to the epithelium of the bladder
8
 has led to an substantial 
increase in research interest to better defining the role of exosomes within the 
kidney. Proteomic analysis of urine can therefore potentially provide insight into the 
physiological and pathophysiological processes in every cell type facing the lumen. 
The proteins identified in large-scale proteomics are not only proteins  directly 
involved with vesicle formation but also known proteins associated with kidney 
diseases (Table 1.6)
157
. This has highlighted the potential of urinary exosomes as an 
easily accessible, reservoir of proteomic information from the renal epithelial cell of 
origin and subsequent biomarker of disease.   
The second wave of interest in urinary exosomes were the identification of nucleic 
acids in human urinary exosomes encoding all segments of the nephron and 
collecting duct
158
. This ground-breaking study further revealed exosome mRNA 
levels reflect mRNA levels in the renal tissue of origin and thereby highlighted the 
use of urinary exosomes for pathophysiological analysis in the kidney. Similarly, 
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miRNA were also identified in urinary exosomes
159
. A large number of studies are 
exploring urinary exosomes as kidney disease biomarkers and the role in the 
pathophysiology of the kidney, but little is known about its physiological relevance. 
The identification of CD24 – a small glycosylated protein as a convenient marker of 
urinary exosomes conserved across species, has helped gain some further insight into 
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Table 1.6 Segment of nephron with identified proteins and associated kidney disease 
Segment of nephron Protein Associated kidney disease  Reference 
Glomerular podocytes Podocin and podocalyxin Steroid-resistant nephrotic syndrome 
8
 
Proximal tubule Cubilin,  Imerslund-Gräsbeck syndrome 
160,161
 
 Type IV carbonic anhydrase Proximal renal tubular acidosis 
157,162
 
 Aquaporin-1  Renal ischemia-reperfusion 
163
 
Thick ascending limb of Henle THP, CD9, Type-2-Na-K-2Cl 
cotransporter 
Bartter syndrome type 1 
162,164
 
Distal convoluted tubule Sodium co-transporter Gitelman’s syndrome 
162,164
 
Collecting duct AQP2,  Nephrogenic diabetes insipidus 
164
 
Transitional epithelium of urinary 
bladder 
Uroplakin-1 and -2 Bladder cancer 
165
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1.7 Exosome signalling in the kidney  
There has been convincing and accumulating evidence that urinary exosomes can 
deliver protein and RNA contents to a recipient cell and thereby change the proteome 
or function of a recipient cell along the length of the nephron. Combined with the 
unidirectional flow along the nephron, the kidney is indeed the ideal anatomical 
model to investigate exosome mediated intercellular signalling. However, 
physiological exosome signalling in the kidney remains poorly defined and 
understood. The roles exosomes may play in pathophysiological states, conversely, 
have been increasingly explored. One of the first studies to show downstream 
exosome uptake was a study showing real-time exosomal transfer between human 
proximal tubular cells and 5 different distal tubule cell lines and 3 different collecting 
duct cells lines. Furthermore, stimulation of the proximal tubular cells with 
fenoldopam, a dopamine receptor agonist, increased exosome production and 
reduced the basal ROS production rates in recipient, downstream cells
166
, suggesting 
functional uptake. Here, a number of examples of exosome signalling in specifically 
relevant to kidney disease and renal cancer will be described. In a rodent 
experimental model of progressive renal disease resembling human chronic kidney 
disease, administration of culture media containing exosomes from human 
embryonic mesenchymal stem cells (MSC) rescued kidney function in rodents 
potentially through active DNA damage repair, proliferation and angiogenesis
167
. In 
acute kidney injury, human adult MSC-derived microvesicles including exosomes, 
mimicked the protection against AKI provided by intravenously administered 
MSCs
168
. This reno-protective effect has been described as a potential mechanism 
through which exosomes can horizontally transfer growth factors or growth factor 
receptors to tubular cells thereby potentiating the sensitivity of the recipient cell to 
locally produced growth factors
169,170
. This is supported by a separate study which 
was able to show exosomes can deliver genetic information and transforming growth 
factor-beta 1 mRNA that has the capacity to initiate tissue repair or regenerative 
responses in fibrotic kidneys and hypoxic epithelial cells
171
. Studies have aimed to 
elucidate the underlying molecular pathway involved. In a cisplatin-induced 
nephrotoxicity model, cisplatin-induced AKI rats treated with human MSC exosomes 
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showed a significant reduction in proximal tubular necrosis, oxidative stress, 
apoptosis and blood urea nitrogen and creatinine levels potentially through activation 
of the extracellular signal regulated kinase (ERK)1/2 pathway
172
. In contrast to this 
protective role in kidney disease, research suggests exosomes play a tumour-
promoting role in renal cancer. In renal cancer cell derived exosomes were shown to 
promote angiogenesis through the upregulation of VEGF expression and down 
regulation of hepatocyte cell adhesion molecule (HepaCAM) in HUVEC cells
173
. 
HepaCAM is well defined to mediate cancer cell proliferation, migration and 
differentiation. Indeed, exosomes isolated from adenocarcinoma cells inhibited 
Jurkat t-cell proliferation and induced apoptosis in a dose- and time-dependent 
manner. This study showed exosomes contribute to immune evasion of tumours in 
the kidney by containing fas ligands, a type-II transmembrane protein belonging to 
the tumour necrosis factor family and treatment with soluble fas abolished exosome 
mediated Jurkat t-cell apoptosis
174
. 
The mechanisms of exosome uptake and release in physiological states in the kidney 
remain unclear. Work in our own group have identified and characterised exosomes 
from cell culture supernatant from a murine collecting duct cell line. The 
characterised exosomes were shown to express the known exosomal markers 
TSG101 and flotilin-1 with the characteristic and unique exosome ‘cup’-shaped 
morphology when viewed under transmission electron microscopy. They were 
further able to show that stimulation with desmopressin, a vasopressin analogue, led 
to an increase in AQP2 expression in the exosomes which correlated with AQP2 
abundance in whole cells. Functionally, they were able to show that desmopressin 
stimulated exosomes can deliver functional water channels to recipient cells and 
increase water flow significantly, thereby representing a novel physiological 
mechanism for cell-to-cell communication within the kidney. 
1.8 Vasopressin regulation in the kidney 
Arginine vasopressin (AVP) is a small neuropeptide of nine amino acids, 
predominately produced in the hypothalamus and, to a much lesser extent in a 
number of peripheral tissues
175
. AVP has an endocrine, paracrine and autocrine 
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effect. The most potent stimulus for AVP secretion from the posterior pituitary is 
change in plasma osmolality. When plasma osmolality rises above a physiologic 
threshold, secretion from the vasopressinergic nerve endings in the neurohypophysis 
increases
176
. Changes in blood volume and blood pressure will affect secretion of 
AVP, but this requires larger changes for hormone release compare with serum 
osmolality. AVP primarily acts through receptors located in the brain and periphery: 
V1a, V1b and V2. V1a receptors are present in many tissues including smooth 
muscle cells, the brain, adrenal cortex, adipose tissue, and hepatocytes. V1b 
receptors are mainly present in the anterior pituitary, adrenal medulla, islet of 
Langerhans, and white adipose tissue. V2 receptors are mainly present in the kidney 
on the basolateral membrane of the collecting duct and alveolar epithelial cells. AVP 
binding to the V2 receptor decreases water excretion, increasing the fraction of 
filtered water returned to the blood. In the kidney, binding of AVP to the V2 receptor 
leads to increased intracellular cyclic-AMP (cAMP) which in turn leads to 
phosphorylation and apical membrane accumulation of AQP2
176
. However, 
trafficking of this basolaterally located AQP2 remains poorly understood. The V2 
receptor (gene symbol, AVPR2) is a G protein-coupled receptor with physiological 
functions mediated by heterotrimeric G-protein Gs. This results in activation of 
adenylyl cyclases to increase intracellular levels of cAMP. Mutations in the AVPR2 
gene are responsible for X-linked nephrogenic diabetes insipidus.  
1.8.1 Aquaporin 2 
AQP2 is a gene coding for aquaporin 2, functional water channels expressed 
throughout the collecting duct system of the kidney. Under vasopressin control, 
AQP2 mediates apical transepithelial water transport across the collecting duct 
epithelium. Two forms of AQP2 regulation have been identified: short term and long 
term. Short term effects are the result of membrane trafficking. In non-AVP 
stimulated states, AQP2 is stored in vesicles in the supranuclear region in the 
principal cells of the collecting duct and mostly colocalised with Rab11 – a marker 
of apical recycling endosomes
177
. This indicates that early endosomes may play a 
part in its trafficking to the plasma membrane following AVP stimulation. Following 
AVP stimulation, AQP2 at the cell surface is rapidly retrieved to the intracellular 
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vesicles by endocytosis and is concentrated in the clathrin-coated pits at the plasma 
membrane of the collecting duct principal cells 
178
. The long term effect of AVP is an 
increase in the total abundance of AQP2 protein, both by increasing the protein half-
life and increasing transcription and translation of new protein
179
.  
AQP2 trafficking and its regulation within the principal collecting duct cells is an 
interesting field of study as it is a responsive mechanism with measurable functional 
effects which could provide information and insight into exosome signalling in 
physiological states. AQP2 has been identified to be present in urinary exosomes in a 
number of studies
8,21
. As discussed previously, work in our group was able to 
demonstrate that exosomal expression of AQP2 closely reflects cellular expression in 
a dose- and time dependent manner following AVP stimulation. Secondly, the 
functional AQP2 transfer between cells and exosomes may represent a novel 
physiological mechanism for cell-to-cell communication within the kidney
45
. 
However, the mechanisms of exosome uptake and release remain unclear.   
1.9 Acute kidney injury 
Acute kidney injury (AKI) is common and is seen in about 15% of adults admitted to 
hospital.  AKI also presents poor prognosis and high mortality rates around 30-40% 
in the UK
180
. AKI is characterised by a rapid reduction in kidney function resulting 
in a failure to maintain fluid, electrolyte and acid-base homeostasis measured by 
changes in serum creatinine or urinary output. AKI has a myriad of causes, usually 
multifactorial, which can be divided and described as ‘prerenal, postrenal or 
intrinsic’
181
. Prerenal causes include any factor which may impair blood flow to the 
kidney for example renal ischemia or low blood volume. Intrinsic causes include 
damage to the kidney itself or disease of the renal parenchyma for example 
glomerulonephritis, acute tubular necrosis and acute interstitial nephritis. Post renal 
causes of AKI, on the other hand, is a consequence of urinary tract obstruction which 
may be within the urinary tract itself for example blood clots or extrinsic, for 
example formation of tumours
181
.   Contrast media induced acute kidney injury (CI-
AKI) is the development of acute kidney injury (AKI) following the administration 
of radiographic contrast media (CM)
182
 and can be described as a prerenal etiology 
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due to it renal vasoconstrictive effects. The definition of CI-AKI is variable, as it is 
challenging to exclude other causes of AKI unrelated to CM, but it is generally 
defined as ‘a sudden alteration in renal function within 24-72 hours of the 
intravascular injection of CM which cannot be attributed to any other causes’ 
183
. The 
reported incidence of CI-AKI reflects the variability in definition, varying from 2-
30%. Even though the direct mechanisms of CI-AKI are not yet fully understood, 
possible pathophysiological mechanisms of CI-AKI include: direct CM molecule 
tubular cell toxicity; haemodynamic effects primarily through afferent arteriolar 
vasoconstriction; and endogenous biochemical disturbances such as changes in nitric 
oxide levels and increases in oxygen-free radicals
184,185
.  Investigating CI-AKI within 
the context of exosome mediated intercellular signalling in the kidney is of particular 
interest as it could potentially provide more information of disease propagation along 
the length of the nephron in a clinically relevant setting.   
1.9.1 Biomarkers of AKI  
Currently, serum creatinine is the standard index of kidney function and also the gold 
standard for recognising and diagnosing AKI. Serum creatinine as a biomarker of 
kidney injury does, however, have limitations as it is slow to reflect changes in 
glomerular filtration rate which can potentially delay diagnosis
186,187
. It is also non-
specific and subject to renal and non-renal influences (such as hydration levels and 
muscle mass). Considerable research efforts aimed at discovering and developing 
new, accurate biomarkers of AKI are ongoing. Although this research speciality is 
still relatively new, a number of key points have so far became evident. Firstly, 
changes in concentration levels of newly identified biomarkers are detected relatively 
faster compared to changes in serum creatinine concentrations. Secondly, these 
biomarkers of AKI can be used to monitor the therapeutic response as it changes 
with treatment or recovery. And thirdly, the discovery of new biomarkers of AKI 
leads to better understanding of the pathogenesis of AKI through identifying possible 
mechanisms of injury. Two candidates reflecting kidney tubular damage as opposed 
to disturbed function are NGAL and KIM-1. NGAL (Neutrophil-gelatinase-
associated lipocalin) is a protein bound to gelatinase in specific granules of the 
neutrophil. It was first discovered to have a ten-fold increase in expression within 
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only a few hours following ischaemic renal injury in a mouse model
188
. 
Subsequently, numerous studies have demonstrated that NGAL is a sensitive early 
marker for AKI in humans, preceding serum creatinine concentration increases by 1-
3 days
189,190
. KIM-1 (Kidney Injury Molecule-1) is a type-1 cell membrane 
glycoprotein containing a unique immunoglobulin-like and mucin domain in its 
extracellular region. These ecto-domains are shed into urine following proximal 





number of studies have unequivocally demonstrated  both NGAL and KIM-1 to be 
novel, predictive biomarkers for AKI
193
. The limitations of serum creatinine and 
existing AKI markers, however, highlights the need for new candidates for timelier 
diagnosis of AKI - which will aid better prediction and stratification of injury and 
lead to more refined methods of safety assessment of nephrotoxic events during drug 
development
193
. It would also be of interest to develop a more comprehensive 
characterisation of kidney injury propagation along the nephron in a CI-AKI model 
to further elucidate the underlying pathophysiological mechanisms in AKI. 
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1.10 Aims of study  
Accurate assessment of urinary exosomes remains challenging, in part because of a 
lack of consensus in methodologies to measure extracellular vesicles and the inability 
of most techniques to capture the entire size range of these vesicles. However, newer 
techniques and standardized protocols to improve the detection of exosomes are in 
development. A clearer understanding of the composition and biology of exosomes 
will provide insights into their physiological and pathophysiological roles to further 
aid and develop their potential as biomarkers and therapeutic agents.  
We hypothesise that exosomes mediate intercellular communication in the kidney. 
To address this, the aims of this study were to: 
1) Develop nanoparticle tracking analysis (NTA) as a technique to quantify 
exosomes in urine.  
2) Investigate the hormonal regulation of exosome uptake in vitro and in vivo.  
3) Investigate exosome excretion in a central diabetes insipidus (DI) patient and a 
patient group after contrast media exposure to investigate exosome excretion 
along the kidney in injury.   
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Materials and Methods  
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2.1 Particle size and concentration distribution 
measurement by NTA 
Nanoparticles in the whole urine samples and isolated exosome suspensions were 
analysed using the NanoSight LM 10 instrument (NanoSight Ltd, Amesbury, UK) 
which allowed simultaneous estimation of size, size distribution and concentration of 
dilute suspensions of nanoparticles. Using a 532nm (green) diode laser beam a 60 
second video was taken with a frame rate of 30 frames/second and particle 
movement were analysed by NTA software. Each experiment was carried out in 
triplicate. All experiments were carried out at a 1:1000 dilution, yielding particle 
concentrations in the region of 1x10
8
 particles/ml in accordance with the 
manufacturer’s recommendations. For fluorescent NTA analysis a 532nm (green) 
laser diode excited the Qdots with a long pass filter (430nm) so that only fluorescent 
particles were tracked and labelled particle concentration determined by NTA 
software. In each run, fresh samples were injected three times and measurements 
were performed following each injection. Standard deviations were determined from 
concentrations obtained from replicate runs.  
2.2 Cell Culture 
The murine cortical collecting duct cell line (CCD) was a kind gift from Hans-Peter 
Gaeggeler and Bernard Rossier (University of Lausanne, Lausanne, Switzerland; 
Gaeggeler et al. 2005) and was grown following Street’s established method
45
. 
Briefly, the cells were grown in Dulbecco’s modified Eagles medium (DMEM)–F12 
medium, 1:1 (Gibco, Paisley, UK), supplemented with 2% fetal calf serum (FCS; 
Invitrogen, Paisley, UK), 1× insulin transferrin selenium (ITS) solution (Gibco), 100 
I.U/ml penicillin and 100μg/ml streptomycin (Invitrogen), 50 pM dexamethasone 
(Sigma Aldrich), 1 nM3,3,5-triiodo-L-thyronine sodium salt (Sigma Aldrich) and 10 
ng/ml epidermal growth factor (Sigma Aldrich). Passaging was achieved by two 10 
min washes with 1 mM EDTA in Dulbecco’s modified phosphate-buffered saline 
(DPBS) followed by incubation in trypsin  EDTA solution (Lonza, Basel, 
Switzerland). The presence of exosomes in FCS would interfere with our study so 
they were depleted as follows. FCS was diluted to 20% with media and then ultra-
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centrifuged for 2 hours at 200,000g. The supernatant was removed and filtered 
through a 0.22μm cellulose acetate filter.  
2.3 Isolation and fluorescent labelling of exosomes  
Culture media from CCD cells was vigorously vortexed then centrifuged at 15,000g 
for 10 min to pellet any cells, large membrane fragments and other debris. The 
supernatant was then centrifuged at 200,000g for 60 min to pellet the exosomal 
fraction. The pellet was washed with phosphate-buffered saline (PBS) and then re-
centrifuged at 200,000 g for 60 min before final resuspension in PBS. Pelleted 
exosomes were conjugated with Cell Tracker 655 (Invitrogen) following the 
manufacturer’s protocol. Briefly, pelleted exosomes were incubated with the Cell 
Tracker 655 conjugate in 200ul fresh culture media for 1hr at 37°C. The exosomal 
pellet suspension (Qdot-Exosome) was washed twice with fresh media before being 
put back on confluent cells. Exosomal size distribution was confirmed by NTA of a 
1:1000 dilution of Cell Tracker 655 conjugate. Bovine serum albumin was used as a 
control and treated in the same way as exosomal isolation.  
2.4 Antibody conjugation with quantum dots  
The anti-CD24 antibody was a kind gift of Dr P. Altevogt (German Cancer Research 
Center, Heidelberg, Germany)
31
. Following the manufacturer’s protocol, quantum 
dots (Qdots) were conjugated to anti-CD24 antibody with a Qdot 605 Antibody 
Conjugation Kit (anti-CD24 Qdots) (Invitrogen). Briefly, Qdots were activated with 
the cross-linker 4-(maleimidomethyl)-1-cyclohexanecarboxylic acid N-
hydroxysuccinimide ester (SMCC), yielding a maleimide-nanocrystal surface. 
Excess SMCC was removed by size exclusion chromatography. The antibodies were 
then reduced by dithiothreitol to expose free sulfhydryl groups, and excess 
dithiothreitol was removed by size exclusion chromatography. The activated Qdots 
were covalently coupled with reduced antibody and the reaction quenched with 
mercaptoethanol. Conjugates were concentrated by ultrafiltration and purified by size 
exclusion chromatography. Anti-AQP2 antibody was purchased from Millipore 
(Billerica, MA, USA). Mouse IgG antibody was purchased from Invitrogen. Both 
antibodies were also conjugated to Qdots as described above. The suspension (see 
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above) was diluted 1:1000 and antibody-Qdots were added to give a final sample-
Qdot concentration of 10 nM. After 1 hour incubation with the urine sample, at room 
temperature, the labelled urine samples and isolated exosomes were analysed by 
NTA. 
2.5 Data and statistical analyses 
Data were stored and analysed using GraphPad Prism Version 6 (La Jolla, California, 
USA) unless otherwise stated.  For NTA results, data from three triplicate videos 
were analysed by calculating the area under the curve (AUC) for particles sized 
between 20-100nm. The intra-assay variability was determined by the coefficient of 
variability between the calculated AUC from the triplicate videos. Throughout, 
unless otherwise stated, differences between two experimental conditions were 
calculated by paired t-tests. Differences between three different experimental 
conditions or more were analysed by non-parametric ANOVAs with suitable post-
hoc tests. Data were expressed as Tukey plots showing mean ± SD and P < 0.05 were 
seen as significant throughout. Different statistical analysis methods employed in 
further chapters will be discussed. 
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3.1 Introduction 
The potential of exosomes as biomarkers and novel therapeutic agents has been 
extensively highlighted in a number of disease states, including acute
75
 and chronic 
kidney disease
194
. Exosomes are vesicles that are released from a wide range of cell 
types into complex biological fluids, including urine
8
. Exosomal cargo, which 
includes protein and nucleic acids, changes with kidney injury
195
. This presents an 
opportunity to track changes in intracellular pathways, which may even precede a 
decline in renal function, without the need for an invasive tissue biopsy. Moreover, 
using exosomes to deliver new information to a recipient cell further highlights their 
potential as  therapeutic agents
135
.  
The first step in exploiting this two-fold potential would be the successful isolation 
and characterisation of exosomes to effectively measure the size and concentration of 
circulating exosomes in clinical biofluid specimens. Previous research has been 
constrained by the limitations of available measurement methods and has been 
hampered by lengthy isolation and characterisation methods involving 
ultracentrifugation, electron microscopy and flow cytometry to semi-quantify 
exosomes in biofluids. These methods are not only time consuming, but are also 




There is, therefore, a pressing need for new technologies that can measure 
extracellular vesicles, including exosomes, in biofluids such as urine, rapidly and 
accurately with minimal sample preparation. This would allow excretion in animal 
models and humans to be quantified and the effect of physiological changes and 
disease on vesicle release to be defined in a more time appropriate manner. The 
current lack of precise quantification of urinary exosome concentration also 
significantly compromises RNA and protein biomarker discovery studies, as existing 
methods for quality control and normalization across study groups are inadequate
196
. 
A recent technological advancement called nanoparticle tracking analyses (NTA) use 
light scatter microscopy to determine the number and distribution of micro- and 
nanoparticles in a given solution directly and in real-time
34
. NTA is based on the 
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principle that at any particular temperature, the rate of Brownian motion of particles 
in solution is determined solely by their size. In this method, laser light is directed at 
a fixed angle to the vesicle suspension, and the scattered light is captured using a 
microscope and high-sensitivity camera. By tracking the movement of individual 
particles over time, the software rapidly calculates their concentration and size. 
Published studies have demonstrated that through the use of fluorescent antibodies, 
NTA can count and size specific subgroups of particles within the wider particle 
population
34,35
, but this has not yet been applied to urine.  
Therefore, the first aim of the studies presented in this chapter was to assess the 
capability of NTA to quantify exosomes in whole urine; the second aim was to 
exploit the fluorescent antibody labelling system to track specific exosome 
populations. And the third aim was optimise storage conditions by evaluating the 
preservation of exosomes in whole urine samples using NTA.  
Ultimately, development and refinement of new approaches in more rapidly 
quantifying exosomes in complex biological fluids such as urine is crucial in further 
understanding the interaction between exosomes and kidney cells and to potentially 
deliver RNA therapies in the treatment of diseases of renal tubular dysfunction. 
3.2 Methods and materials 
3.2.1 Urine collection  
Second morning spot urine samples were obtained from healthy volunteers recruited 
from the local community. Inclusion criteria were age between 20 and 40 years (25.6 
± 3.1 years); body mass index < 30 kg/m
2
 (23.1 ± 2.2 kg/m
2
) and no history of 
cardiovascular disease, diabetes, hypercholesterolemia or renal disease. None of the 
included volunteers were taking any medication, vitamins or nutritional supplements. 
The protocol agreed with the institutional ethics rules and informed consent was 
obtained from volunteers included in the study. 
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3.2.2 Exosome isolation  
Exosomes were concentrated by ultra-centrifugation or commercial as per described 
methods in Chapter 2.  
3.2.3 Antibody-specific fluorescent labelling of quantum 
dots  
Antibody-specific fluorescent labelling with quantum dots was performed as per 
described methods in Chapter 2.  
3.2.4 Particle size and number distribution measured by 
NTA 
The size and number distribution of particles in solutions or urine were measured by 
NTA as per described methods in Chapter 2.  
3.2.5 Validation and specificity of antibody-specific labelled 
exosome quantification by NTA 
3.2.5.1 Validation by lysis of cellular membrane  
Spot urine samples were obtained from five healthy male volunteers (aged 22-30) 
following informed consent. Exosome pellets from urine samples were isolated. 
Following the final centrifugation step, the remaining pellet was re-suspended in 
PBS and divided into two aliquots. Qiazol lysis reagent (Qiagen, Hilden, Germany) 
was added to one of the aliquots and the remaining aliquot left untreated. Qiazol lysis 
reagent is routinely used as a cell and cell membrane lysis reagent during cellular or 
tissue RNA extraction. All prepared samples were diluted and labelled with anti-
CD24 Qdots prior to NTA measurements, as previously described.  
3.2.5.2 Clinical relevance of specificity of NTA measurements  
Urine samples from 10 metastatic renal clear cell (RCC) cancer patients before and 
after metastatic nephrectomy were kindly obtained from Dr G Stewart (Senior 
Lecturer in Urology, University of Edinburgh). Carbonic Anhydrase 9 (CA9) has 
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been shown to be a marker for metastasis and tumour formation in this patient 
cohort
197
. Anti-CA9 (Sigma Aldrich) antibody was conjugated to Qdots as previously 
described (anti-CA9 Qdots). Urine samples from patients before and after 
nephrectomy were incubated with the anti-CA9 Qdots and subsequently measured by 
NTA. Differences in CA9 positive exosome quantities before and after nephrectomy 
were analysed and compared by Kruskal-Wallis paired t-tests.  
3.2.6 Cell culture model of exosome release  
Murine kidney collecting duct (CCD) cells were grown in culture as described in 
Chapter 2. Briefly, following confluency, cells were stimulated with desmopressin 
(Sigma-Aldrich), 3.16 ng/ml for 48 and 96 hours. The cell culture medium (2 ml) 
was then analysed by NTA following fluorescent labelling with anti-AQP2 Qdots. 
3.2.7 Urinary exosome excretion in the mouse  
Mice (C57/BL6; n = 6) were individually housed in metabolic cages (model 
3600M021; Techniplast, Buguggiate, Italy) with free access to food and water. After 
acclimation, daily food and fluid intakes were measured, as well as body weight. 
Each mouse received a single subcutaneous injection of 0.9% NaCl (1 μl/g body 
weight) on days 1 and 2 and, after each injection; a 24 hour urine collection was 
performed. On days 3 and 4, mice received a subcutaneous injection of desmopressin 
(1 μl/g body weight of 10 μg/ml drug solution), and two further 24 hour urine 
collections were performed. A second cohort of mice (n = 5) was used as control 
animals, receiving subcutaneous injections of 0.9% NaCl on all 4 days. All studies 
were performed with the appropriate Home Office (UK) licence. 
3.2.8 Evaluating optimum storage conditions for exosomes 
by NTA 
Freshly obtained urine samples (60 ml each) from 5 volunteers were subjected to 4 
different storage protocols (6ml 1:1000 dilution per protocol in 3 x 2ml aliquots) all 
with and without protease inhibitors (1:10 final concentration: 0.5 mM 
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phenylmethylsulfonyl fluoride (PMSF; Sigma Aldrich), 20 µM leupeptin (Sigma 
Aldrich)). The protocols were: 
a) analysed immediately with NTA;  
b) stored at room temperature; 4°C; -20°C or -80 °C for 2 hours;  
c) stored at room temperature; 4°C; -20°C or -80 °C for 1 day 
d) stored at room temperature; 4°C; -20°C or -80 °C for 1 week.  
All samples were vigorously vortexed while thawing following Zhou et al.’s (2006) 
recommendation. Each NTA measurement for the different protocols for each subject 
were performed as described above. 
3.3 Results 
3.3.1 Optimising dilutions of urine sample preparation 
The analysis settings were optimised and kept constant between samples and each 
video was analysed to give the mean, mode, median and estimated number of 
particles for each particle size. Following the Sokolova et al. (2011) method and 
initial comparison between whole urine samples and 1:1000 dilution, all experiments 
were carried out at a 1:1000 dilution (Table 3.1), yielding equivalent particle 
concentrations in the region of 1x10
8
 particles/ml in accordance with the 
manufacturers’ recommendations. Hereafter, ‘whole urine sample’ refer to a 1:1000 
dilution of obtained sample. 
A representative report obtained from the NTA software is shown in Figure 3.1a, 
showing the particle size concentration distribution. A screenshot of undiluted, 
unprocessed urine (Figure 3.1b) reveals a heterogenous, and highly concentrated 
particle size distribution. Heterogenous, polydisperse biological samples will 
normally show a log-normal particle size distribution profile unless purified or 
fractioned, with different amounts of light scattered and subsequent different 
estimates of concentration. To address this potential bias introduced into a system the 
lower limit of concentration was chosen (1:1000 dilution yielding a 1 x 10
8
 
equivalent particles/ml) for all further analyses (Figure 3.1c).  
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Table 3.1: Representative comparison of the equivalent particle 
concentration from serial dilutions of urine samples as measured 
by NTA, expressed as equivalent particles x 10
8
/ml 
Dilution factor Equivalent particles x 10
8
/ml  
Undiluted 22.49 x 10
8
/ml 
1:10 dilution 15.48 x 10
8
/ml 
1:100 dilution 3.35 x 10
8
/ml 
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Figure 3.1: Representative NTA measurements of different urine sample 
dilutions 
A.) NTA report for an undiluted urine sample showing the equivalent particle 
concentration and distribution. B.) Screenshot of NTA measurement video of an 
undiluted urine sample. C.) Screenshot of NTA measurement video of a 1:1000 
dilution of a urine sample. 
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3.3.2 NTA identified nanoparticles in whole urine 
Whole urine was analysed by NTA and a variable size distribution of particles was 
present (Figure 3.2). The NTA software was able to identify and measure particles in 
the expected exosome size range (20-100nm).  Due to the light intensity of the larger 
particles causing possible over-estimation of the smaller particle size, following 
published recommendations
34,4
 the focus was set on particles sized up to 300nm.  
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Figure 3.2: Whole urine analyses by NTA  
Example NTA traces depicting the heterogeneous particle distribution profile for 4 
representative volunteer urine samples. (0-300nm diameter). The number of particles 
is expressed per mmol urinary creatinine.   
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NTA software provides the number of particles of each size between 10-1000nm. As 
the number of particles over the size range 20-100nm was the focus, the area under 
the curve (AUC) was calculated using the trapezoidal rule with values increasing 
incrementally on the x-axis, expressed as the sum of the individual trapezoids (Figure 
3.3). All values for the number of particles per ml calculated by NTA for in vivo 
urine samples were normalised with urinary creatinine values (mmol/l). 
Across the five participants the median AUC20−100 (interquartile range; IQR) was 
0.02 × 10
6
 particles/mmol creatinine (0.01−0.05 x 10
6
 particles/mmol creatinine). 
The median (IQR) particle size was 69 nm (47−92 nm) (Table 3.2). 
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Figure 3.3: AUC area of interest 
Example NTA trace showing the area of interest (particle size 20-100nm) from 
which the AUC is calculated. 
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Table 3.2: Descriptive statistics of the median particle size and the inter-quartile range across 5 volunteers following NTA 
measurements of whole urine samples and anti-CD24 conjugated urine samples and exosome pellets following 
different isolation steps 
 
Whole urine 
Anti-CD24 Qdot  
Whole urine 
Anti-CD24 








































1 81 0.051 89 0.12 60 0.21 32 0.01 
2 92 0.005 59 0.01 60 0.18 62 0.01 
3 64 0.021 54 0.28 60 0.66 60 0.24 
4 47 0.023 81 0.43 82 0.14 39 0.02 
5 62 0.009 40 0.01 78 0.32 40 0.09 
Average 69 ± 15.7 0.02 ±0.02 64 ± 20.08 0.17 ± 0.18 68 ± 11.05 0.30 ± 0.21 46 ± 13.52 0.01 ± 0.01 
Data are expressed as mean ± SD. IQR, interquartile range of particles x 10
6
 per urinary creatinine (mmol).  
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3.3.3 Fluorescent NTA identified antibody-labelled 
exosomes in human urine 
To determine whether it is possible to track exosome particles from kidney tubular 
cells specifically, an antibody-specific labelling system with antibodies specifically 
related to urinary exosomes was developed. In the first instance, conjugating anti-
CD24 to Qdots and incubating this with the urine samples, revealed differential 
populations by NTA measurements. The fluorescence capability of the NTA system 
with a long-pass filter allows tracking of fluorescently labelled particles compared to 
all particles in light scatter (Figure 3.4a and b). Figure 3.4c shows the representative 
NTA traces of 4 urine samples of all the particles in the sample, as measured by light 
scatter (dashed line) revealing a particle size range between 20-300nm. However, 
with the fluorescent long pass filter in place, the anti-CD24 positive particles were 
consistent with anti-CD24 binding to the urinary exosome surface marker (median 
size (IQR) 64nm, 89-40nm) (Table 3.2). Across the five volunteers included, the 
median anti-CD24 Qdot labelled AUC20−100 (IQR) was 0.17 × 10
6
 particles/mmol 
creatinine (0.01−0.43 × 10
6
 particles/mmol creatinine).  
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Figure 3.4: Anti-CD24 analyses by NTA 
Representative screenshots from NTA measurement videos for urine samples 
conjugated to anti-CD24 Qdots in A.) light scatter mode and B.) with the fluorescent 
long-pass filter in place C.) Representative NTA traces of whole urine samples 
labelled with anti-CD24 Qdots indicating differential populations measured by light 
scatter (dashed line) and with the fluorescent filter in place (solid line). Results from 
4 study participants are presented. Number of particles is expressed per mmol urinary 
creatinine 
C. 
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3.3.4 Comparison of standard exosome isolation protocols 
by NTA  
To determine whether isolating exosomes by standardised methods from human 
urine would improve the purity (fewer non-CD24-positive particles of size >100 
nm), two established methods were used: ultra-centrifugation (UC) and Exoquick™ 
reagent. Figure 3.5 demonstrates particle size vs. number of particles curves for the 
anti-CD24–Qdot-conjugated UC-concentrated exosomes. In light scatter mode, UC-
concentrated samples still contained non-exosomal sized particles. However, with the 
fluorescent filter in place, the anti-CD24–Qdot-labelled particles were smaller 
[median size (IQR) 68 nm (60−82 nm)], consistent with anti-CD24 binding to 
surface markers on the urinary exosomes Across the five participants included, the 
median anti-CD24 labelled AUC20−100 (IQR) was 0.30 × 10
6
 particles/mmol 
creatinine (0.14−0.66 × 10
6
 particles/mmol creatinine) (Table 3.2).   
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Figure 3.5: NTA analyses of exosome pellet isolated by ultra-centrifugation 
Representative NTA traces of exosome pellets isolated by ultracentrifugation 
labelled with anti-CD24 Qdots.  Differential populations as measured by light scatter 
mode (dashed line – all particles) and with the fluorescent filter in place (solid line – 
anti-CD24 Qdot labelled particles) are presented. Results from 4 study participants 
are presented. Number of particles is expressed per mmol urinary creatinine. 
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Figure 3.6 shows particle size vs. number of particles curves for the anti-CD24–
Qdot-conjugated Exoquick™-isolated exosomes. Similar to the data from the UC-
isolated exosomes, the light scatter trace for Exoquick™ treated samples revealed a 
range of particle sizes of 20−300 nm, consistent with the presence of non-exosomal 
particles. However, with the fluorescent filter in place, the anti-CD24–Qdot-labelled 
particles were smaller [median size (IQR) 46nm (32−62 nm)], again consistent with 
anti-CD24 selectively binding to exosomes. Across the five participants included, the 
median anti-CD24-labelled AUC20−100 (IQR) was 0.01 × 10
6
 particles/mmol 
creatinine (0.01−0.24 × 10
6
 particles/mmol creatinine) for Exoquick™-isolated 
exosomes (Table 3.2).  
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Figure 3.6: NTA analyses of exosome pellet isolated by Exoquick™ reagent 
Representative NTA traces of exosome pellets isolated by Exoquick™ reagent kit 
labelled with anti-CD24 Qdots.  Differential populations as measured by light scatter 
mode (dashed line – all particles) and with the fluorescent filter in place (solid line – 
anti-CD24 Qdot labelled particles) are presented. Results from 4 study participants 
are presented. Number of particles is expressed per mmol urinary creatinine. 
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3.3.5 Intra-assay variability of NTA measurements of 
different isolation methods compared to whole urine  
To quantify the intra-assay variability for NTA measurements of whole urine 
samples, the AUC20-100 were compared across 3 replicate measurements on the same 
sample (Table 3.3). The intra-assay variability expressed as the coefficient of 
variation (CVi) was 55.8% for AUC20−100 for whole, unprocessed urine samples. By 
using the anti-CD24 Qdots coupled with the fluorescent capabilities of the NTA, the 
within-sample variability in AUC20−100 was significantly less than unlabelled samples 
presented in (CVi = 35%, P < 0.05). Anti-CD24–Qdot-conjugated UC-isolated 
exosomes had a smaller coefficient of variation within sample (CVi = 15.6%) 
compared with whole urine samples (P < 0.05). Compared with the UC isolation 
method, anti-CD24–Qdot-conjugated Exoquick™-isolated exosomes had a high 
within-sample coefficient of variation (CVi = 55.9%, P < 0.05 compared to UC 
CVi). 
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Table 3.3: Comparison of the number of particles and the intra-assay variability of NTA measurements between different 
exosome isolation methods and whole urine samples 
 
Whole urine 
Anti-CD24 Qdot  
Whole urine 
Anti-CD24 
























1 0.04 54.3 1.41 34.8 0.35 2.5 0.07 64.8 
2 0.05 45.7 0.16 25.4 0.05 34.9 0.17 67.4 
3 0.27 67.9 0.10 32.1 0.51 3.6 2.53 43.7 
4 0.29 64.9 3.39 47.6 0.12 2.3 0.15 53.1 















*¥ P < 0.05 
0.81 ± 
1.06 
55.9% ± 9.9 
¥ P < 0.05 
Data are expressed as mean ± SD. AUC20-100, Area under the curve for the number of particles sized between 20-100nm; CVi, within-
sample coefficient of variation (%). * P < 0.05 seen as statistically significant compared to whole urine CVi; ¥ P < 0.05 seen as 
statistically significant compared to UC isolated exosome pellets.  
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3.3.6 Validation of antibody-specific labelling system by 
NTA 
3.3.6.1 Validation by isotope control  
As a control for the specificity of the antibody-Qdot conjugation, whole urine was 
labelled with mouse IgG–Qdot (Figure 3.7). The AUC20-100 with the fluorescent filter 
was ∼8-fold less than with anti-CD24 Qdots. 
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Figure 3.7: NTA analyses of mouse anti-IgG in human urine 
Representative NTA trace of whole human urine labelled with mouse IgG conjugated 
to Qdot as isotope control, measuring differential populations in light scatter mode 
(dashed line) and with the fluorescent filter in place (solid line). Note the absence of 
a ‘peak’ in the particle size range 0-100nm with the fluorescent filter in place. 
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3.3.6.2 Validation by lysis of exosome cell membrane 
As a second validation experiment, it was important to confirm whether the observed 
NTA signal was the result from antibody conjugation to specific surface markers on 
exosome membranes. UC exosome pellets were either left untreated or lysed by 
treatment with a lysis reagent, Qiazol™.  The representative NTA trace comparing 
the anti-CD24 conjugated isolated exosome pellet with and without treatment with 
Qiazol (Figure 3.8a) demonstrated the abolition of the peak in the 20-100nm size 
range. For quantification, there was a 3 fold decrease in AUC20-100 in the Qiazol 
treated sample compared to the isolated exosome sample (Figure 3.8b), consistent 
with the binding of the antibody conjugate to surface markers on the intact cellular 
membrane of vesicles in the expected exosome size range (20-100nm).  
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Figure 3.8: NTA analyses of membrane disrupted exosomes 
A.) Representative NTA trace showing number of particles of UC-isolated exosome 
pellet (black line) compared to Qiazol treated exosome pellet (grey line). Figure B. 
AUC20-100 of UC-isolated exosomes compared to isolated exosomes treated with 
Qiazol. (Values expressed as mean ± SD; n=6, *, P < 0.05, paired t-test.) 
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3.3.6.3 Validation of clinical utility of antibody-specific labelled 
NTA 
To further develop the antibody-specific NTA method of urinary exosome 
quantification, the clinical relevance utility of the antibody Qdot conjugate 
specificity needed to be established and confirmed. Carbonic Anhydrase 9 (CA9) is a 
tumor-associated carbonic anhydrase isoenzyme which is highly expressed in 
metastatic renal clear cell carcinoma (RCC) with low expression in healthy, control 
kidneys. Serum or urine CA9 levels predict disease progression and is a potential 
RCC disease biomarker 
198
, with detectable levels in urine and sera of RCC patients, 
compared to low levels in healthy individuals
199
. Urine samples from metastatic RCC 
patients undergoing nephrectomy (before and after surgery) were conjugated with 
anti-CA9 Qdots before performing NTA measurements. Figure 3.9 shows a 
significant decrease in the total number of particles expressed as AUC20-100 after 
nephrectomy compared to before surgery. 
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Figure 3.9: NTA analyses of patient cohort urine samples undergoing 
nephrectomy  
AUC20-100 values for patients before and after nephrectomy (Values expressed as 
mean ± SD; n=10, *, P < 0.05; paired t-test).  
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3.3.7 NTA can detect physiological changes in AQP2 
expression  
Previous work has demonstrated that murine kidney collecting duct (CCD) cells 
release AQP2-containing exosomes following stimulation with the vasopressin 
analogue desmopressin
45
. However, this previous study used UC processing of large 
volumes of cell culture medium and Western blotting to demonstrate AQP2 
upregulation, which is a time-consuming, labour-intensive approach. It was now of 
interest to test whether NTA could detect AQP2 upregulation in exosomes in vitro 
and in vivo, without any pre-processing of the applied samples. NTA was indeed able 
to detect significant differences in AQP2-expressing exosomal concentrations 
following desmopressin stimulation for 96 h in the CCD cell line (Figure 3.10a). 
Following this, NTA was applied to urine samples collected from mice injected over 
consecutive days first with saline and then with desmopressin. NTA detected a 
significant increase in urinary AQP2-expressing exosomes following desmopressin 
treatment (Figure 3.10b).  
To investigate the antibody-specific NTA method could be further developed to 
quantify changes in AQP2 expression in a clinical setting, urine samples from a 
central diabetes insipidus (CDI) CDI secondary to a craniopharyngioma treated with 
desmopressin were analysed.  There was a clear increase in AQP2-expressing 
exosomes immediately following administration of desmopressin (Figure 3.11). 
  































C o n tro l 4 8  h o u rs  
D e s m o p re s s in
9 6  h o u rs





























































Figure 3.10: Changes in AQP2-positive exosomes following desmopressin 
stimulation 
A.) The difference in exosome concentration in the cell culture media expressed as 
the area under the curve (AUC) for particles sized 20–100 nm labelled with anti-
AQP2 Qdots. The cells were stimulated with desmopressin (3.16 ng/ml) for 48 or 96 
h. (Values expressed as mean ± SD, n=3, *, P < 0.05, paired t-test). B.) The 
difference in exosome concentration in the urine samples from desmopressin-treated 
(n = 6) or control mice (n = 5), expressed as the AUC for particles sized 20–100 nm 
labelled with anti-AQP2 Qdots. Particle concentration is expressed per mmol urinary 
creatinine. (Values expressed as mean ± SD, ∗P < 0.05, paired t-test) 
  





































































































































































Figure 3.11: Nanoparticle tracking analysis tracked changes in AQP2-positive 
exosome concentration following desmopressin treatment of a 
patient with central diabetes insipidus 
For A and B, urine aliquots were collected over 2 separate days showing paired 
changes in urinary creatinine. The AQP2-exosome concentration in the urine samples 
is expressed as the AUC for particles sized 20–100 nm that labelled with anti-AQP2 
Qdots. Particle concentration is expressed per mmol urinary creatinine. The time of 
administration of desmopressin treatment is indicated by the dashed line. 
  
Chapter 3: Exosome quantification by NTA 75 
3.3.8 Evaluation of optimal storage methods for urinary 
exosomes in urine 
NTA was used to assess the effect of different urine storage protocols on urinary 
exosome number of particles. Whole urine was analysed immediately after 
collection, which acted as the baseline for comparison of the different storage 
conditions with and without addition of protease inhibitors (RT, 4, −20 and −80◦C). 
For each condition, the number of particles in the exosome size range (AUC20-100) 
was assessed again after 2h, 1 day and 1 week. A significant decrease in the exosome 
yield in the AUC20−100 range was observed with time, regardless of storage condition 
(p < 0.05 for all protocols). Indeed, the data suggests exosome degradation within 2h 
of urine collection. In this context, storage at −80◦C with addition of protease 
inhibitors resulted in substantially less reduction in AUC20−100 compared with other 
storage conditions (Figure 3.12). 
  









































































































































































Figure 3.12: Different storage protocols and urine particle concentration 
NTA was used to measure the particle concentration between 20 – 100 nm in 
diameter (AUC20-100). The baseline was immediate measurement after sample 
collection. The percentage change represents decrease following storage. RT = room 
temperature. n=5 per group. P <0.05 for all storage conditions vs baseline values. * P 
<0.05 for storage at -80°C with protease inhibitors compared to other -80°C without 
protease inhibitor added. 
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3.4 Discussion 
The potential of urinary exosomes as biomarkers and therapeutic agents in kidney 
disease has been extensively reviewed
196
. However, the inability to identify and 
quantify exosome populations in clinical specimens rapidly and accurately remains a 
translational roadblock
200
. Current, standardized methods for investigating the 
distributions of exosome particle size and concentration are time consuming and only 
semi-quantitative.  
The first aim of this chapter was to determine whether a technological advancement, 
NTA, holds potential for the identification of exosomes in human urine samples. 
NTA can detect and quantify the size and concentration distribution of particles sized 
between 20-700nm in whole urine samples, with a significant percentage of the 
overall particle distribution within the expected exosome size range (20-100nm). 
However, unprocessed urine had a significantly higher CVi than is acceptable when 
measured by NTA (a CVi < 20% is deemed within the acceptable limits
201
).  
To refine and further develop NTA quantification of urinary exosomes, it was of 
interest to see whether using the fluorescent capabilities of the NTA system, coupled 
with urinary exosome antibody-specific labelling, could decrease the intra-assay 
variability compared to unprocessed urine samples. The intra-assay variability was 
substantially reduced by using an anti-CD24 fluorescent label compared to 
unprocessed urine. CD24 has previously been described as a pan-tubule marker for 
the origin of urinary exosomes
31
. Antibody-specific labelling coupled with the 
fluorescent capabilities of NTA not only reduced variability, but also provided proof-
of-concept that NTA can be used to discriminately track exosomes positive for 
specific, chosen antibodies. With the fluorescent filter in place, it was also possible 
to visualize a larger concentration of particles sized between 20 and 100 nm 
compared with the light scatter mode. This may be due to the intense light scatter 
from larger particles interfering with the accurate and reproducible measurement of 
smaller particles
34
 whilst the use of the fluorescent filter avoided this interference in 
signal.  
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Using two standard methods of isolating urinary exosomes, i.e. UC and Exoquick
TM
, 
only UC resulted in a further reduction in intra-assay variability, but it is also a 
labour-intensive method. Interestingly, comparing the particle size distribution of 
both UC and Exoquick™, light scatter mode revealed a greater than expected size 
distribution indicating that both UC and Exoquick™ isolated non-exosomal particles 
from human urine, and caution must be exercised not to assume incorrectly that these 
techniques result in a pure or more pure exosome preparation. This may lead to 
incorrect conclusions regarding the protein or RNA content of exosomes or their 
biological activity. The reasons for intra-assay variability include user dependent 
errors or inexperience, technical refinements to the NTA optics and software, and 
also the nanoparticle size and light refractive properties of vesicles of biological 
origin, such as exosomes and the associated limitations of detection NTA is aiming 
to overcome.  
To further develop this method of quantifying urinary exosomes, a variety of 
approaches and controls were used. Using mouse anti-IgG conjugated to the Qdots 
similar to the anti-CD24 Qdot conjugation, auto fluorescence and unspecific binding 
of the Qdots were investigated. The decrease in the peak in anti-IgG Qdots compared 
to the peak seen within the 20-100nm size range when using anti-CD24 Qdots 
confirm that the perceived signal in the expected exosome size range in whole urine, 
is not emitted from unbound Qdots, thereby confirming specific binding of the 
antibody to the surface marker. Secondly, to investigate the specific binding of 
antibody-conjugated Qdots to surface markers on the cellular membranes, isolated 
exosome pellets were treated with a lysis reagent causing disruption of the 
membrane. Indeed, treatment with this reagent, led to a significant decrease in the 
number of particles seen within the expected exosome size range, thereby confirming 
that the antibody Qdot conjugate binds to specific surface markers on the intact 
exosome membrane. Thirdly, to validate the clinical relevance of this developed 
method, urine samples from metastatic renal cell carcinoma patients undergoing 
nephrectomy was analysed by NTA before and after the surgery. CA9 has been 
described as a good marker for tumour formation in renal cancer and therefore anti-
CA9 was chosen as the antibody to investigate CA9 positive exosome quantities in 
this patient cohort. The number of CA9 positive particles before the surgery was 
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significantly higher than the number of particles after surgery. Taken together, this 
confirmed the ability of NTA to track differences the number of exosome particles in 
a clinically relevant and specific setting.  
The protein composition of exosomes can track changes in the proteome of the cell, 
previously demonstrated in the laboratory by using a CCD cell line 
45
. However, the 
measurement of exosomal AQP2 upregulation relied on Western blotting, preceded 
by UC to concentrate exosomes from approximately 20 ml of culture medium. In this 
chapter, it was shown that NTA can clearly identify AQP2 upregulation in exosomes 
with no sample processing, using only 2ml of culture media. Following on from the 
in vitro results, NTA was applied to urine samples collected from mice before and 
after desmopressin treatment. NTA was able to report differences in urine AQP2-
positive exosomal concentrations between treated and non-treated conditions. The 
average urine flow rate in the mouse is ∼1 ml/24 h, and this small urine volume 
results in low exosome yields following current protocols, such as 
ultracentrifugation. NTA can rapidly detect exosome protein changes in small 
volumes of mouse urine without extensive sample processing, which represents a 
significant advance for non-invasive, longitudinal physiological studies in the mouse. 
Applied to urine samples from a CDI patient treated with desmopressin, NTA was 
able to track changes in AQP2-positive exosome concentrations over time. 
Desmopressin resulted in a rapid increase in AQP2-expressing exosomes, which is 
consistent with studies that have reported rapid increases in total urinary AQP2 
following subcutaneous administration of desmopressin
202
. This increase is too rapid 
to represent new protein synthesis and is likely to reflect cytoplasmic AQP2 transfer 
to the cell membrane.  
Finally, by using NTA to evaluate storage methods for urinary exosomes, −80◦C 
with protease inhibition was shown to be the optimal approach for storage of whole 
urine samples, resulting in the maximal preservation of urinary exosomes compared 
with the other temperatures (RT, 4 and −20◦C) with or without protease inhibition. 
This is consistent with previous published work that used Western blotting for 
exosomal marker proteins as a read-out for exosome concentration
203
. Importantly, 
however, a significant loss of urinary exosomes for all storage conditions was seen, 
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even within 2h of obtaining the sample. This highlights the need for developing more 
rapid approaches in analysing exosome quantities in the clinical setting such as 
which is afforded by the developed NTA method.   
In this chapter, it was demonstrated that NTA can allow rapid quantification of 
exosomes in urine. By combining NTA with an antibody-specific labelling system, 
changes in the number of relevant exosomes could be tracked, both in vitro and in 
vivo.  This method will now be further developed and refined in the next chapters to 
investigate exosome excretion and uptake in health and disease. 
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CHAPTER 4 
 
Vasopressin regulates exosome uptake in vitro  
4  
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4.1 Introduction 
Research has identified a potential role of exosomes in inter-cellular signalling - 
exosomes can deliver functional protein and RNA from one cell to another in vitro
50
. 
The mechanisms by which target cells internalise exosomes are yet to be fully 
elucidated and whether exosome transfer between cells occurs in vivo is still to be 
unequivocally confirmed. In cell culture studies, exosome uptake by cells has been 
reported via a number of mechanisms including clathrin-dependent endocytosis, 
caveolae-dependent endocytosis, phagocytosis and macropinocytosis
204
. However, it 
is not established whether exosome uptake by recipient cells is a physiologically 
regulated process and, if it is, which pathways or hormones are involved. 
Urine contains exosome originating from the circulation and from cells that line the 
urinary tract
8
. Urinary exosomes contain protein, messenger RNA (mRNA), 
microRNA and mitochondrial DNA that originates from kidney tubular cells
8,159
. 
Given the unidirectional flow of urine along the nephron, the kidney is anatomically 
designed for potential exosome transfer from proximal to distal nephron segments. In 
the kidney there is evidence of exosome signaling: exosomes from injured tubular 
cells transfer mRNA into fibroblasts resulting in cell activation and stem cell-derived 




Work in our group have previously demonstrated that vasopressin, a pituitary 
neuropeptide that regulates water homeostasis, modulates the aquaporin 2 (AQP2) 
content of these exosomes in vitro and this regulation translates into rodent models 
and humans
45, 206
. The first aim of the present study presented in this chapter was to 
investigate the role of vasopressin in the regulation of exosome uptake into the 
kidney collecting duct. The second aim was to elucidate a possible mechanism 
involved.  
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4.2 Methods 
4.2.1 Cell Culture 
The murine cortical collecting duct cell line (CCD) was cultured as per the described 
method in Chapter 2.  
For the different cell type experiments, exosomes were isolated from the supernatant 
of an immortalised human proximal tubular cell line (HK2) and a primary murine 
juxtaglomerular cell line (RG1). The HK2 cell line was a kind gift from Dr Kenneth 
Simpson (University of Edinburgh, United Kingdom). HK2 cells were grown 
following the same described method as for CCD cells. The RG1 cell line was grown 
by supplementing 1:1 DMEM/F12 (Gibco) with 10 % heat-inactivated FCS, IFN-γ 
(Peprotech, London, UK) at 100 µg/ml, and 1 % ITS containing 1 mg/ml insulin, 
0.55 ml/ml human transferrin and 0.5 µg/ml sodium selenite (Gibco). 1X glutamine, 
1X penicillin/streptomycin (pen/strep), (Life Technologies) and 1X antioxidants 
(Sigma Aldrich) were added to this, as well as 10µM Y-27632 (Tocris, Bristol, UK) 
and filtered. The cell culture supernatant was removed from either cell type at 70-
80% confluency of the cell layer for exosome isolation.    
Human umbilical vein endothelial cells (HUVECs) and human microvascular 
endothelial cells (HMVECs) (both from Lonza) were grown in EGM-2 (EBM-2 
medium supplemented with growth factors) and 2% FCS (Lonza). Lipofectamine 
RNAiMAX (Life Technologies) was used to transfect HUVECs with pre-miR-503 or 
pre-miR-control (50nM final concentration) according to the manufacturer's 
instructions. 
4.2.2 Isolation and dye loading of exosomes  
Exosomes from all cell lines were isolated and dye loaded with Cell Tracker™ as per 
the described method in Chapter 2.  
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4.2.3 CCD cell stimulation 
Desmopressin (Sigma Aldrich) stimulation concentrations were based on previous 
work in our group
45
. For short periods of cell stimulation (1-8 hours), desmopressin 
and dye loaded exosomes were added simultaneously. With longer time periods of 
cell stimulation (24-96 hours), dye loaded exosomes were added for the final 24 
hours of stimulation. At the end of the study the supernatant was collected for NTA 
analysis and cells removed by trypsinisation (as described in Chapter 2) for flow 
cytometry. In addition to desmopressin, in specific experiments for the final 24 hours 
the cells were treated with tolvaptan (10nM) (Sigma Aldrich), endothelin-1 (10pM) 
(Sigma Aldrich) or H-89 (25µM) (Sigma Aldrich)
207
. Treatment with the Dynamin 
Inhibitor I (Dynasore (150µM): Sigma Aldrich) was for 45 minutes immediately 
prior to exosome addition as per published studies
208
. Cells were treated with 10µM 
forskolin from Coleus forskohlii (Sigma Aldrich) and incubated with dye loaded 
exosomes overnight
209,210
. To polarise the CCD cells they were cultured on the 
polyester membrane of Transwell inserts (Corning Costar Co, New York, USA) at a 
high density to allow the cells to be confluent within three days. Desmopressin was 
added to the top or bottom Transwell chamber for 48 hours then dye loaded 
exosomes were added for the final 24 hours of the 96 hour period. 
4.2.4 Particle size and concentration distribution 
measurement with NTA  
The number of dye loaded exosome particles prior to cell incubation and remaining 
in the cell culture supernatant were analysed as per the described method of NTA 
analysis in Chapter 2.  
4.2.5 Flow cytometry for total cell fluorescence 
Total cell fluorescence was measured by flow cytometry on a 5LSR Fortessa 
cytometer (BD Biosciences, Oxford, UK). Cells were briefly stained with 1µM DAPI 
nucleus stain (Sigma Aldrich) and having been exposed to dye loaded exosomes as 
described, was excited with a violet laser (405 nm) and emission detected using 
450/50 and 630/70 band pass filters respectively. Gates were set using unstained cells 
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and cells stained with DAPI alone. Flow cytometry data were analysed with FloJo 
LLC software version 8 (FlowJo LLC, Oregon, USA) and the results are presented as 
the percentage of total fluorescent cells.   
4.2.6 Fluorescence microscopy  
Using control and desmopressin-stimulated cells grown on a cover slip, 
internalisation of dye loaded exosomes with DAPI stained CCD cell nuclei and 
Phalloidin stained cell membranes (Sigma Aldrich) were visualised by an Olympus 
AX-70 Provis epifluorescence microscope equipped with a Hamamatsu Orca II CCD 
camera. Images were collected with a 60 x oil immersion objective lens and acquired 
by using mDaemon software (Zenn, Manchester, UK). Each picture was acquired 
with laser intensities and amplifier gains adjusted to avoid pixel saturation and 
analysed using Adobe Photoshop CC 2014 (Adobe Systems, San Jose, California). 
4.2.7 RNA extraction and quantitative real time analysis 
Total RNA was extracted following the manufacturer’s protocol using the miReasy 
kit (Qiagen, Venlo, Netherlands). Real-time quantification to measure microRNAs 
was performed with the TaqMan microRNA reverse transcription kit and microRNA 
assay (hsa-miR-503: 4373228) (Applied Biosystems, Paisley, UK) with a Lightcycler 
480 (Roche Diagnostics, Burgess Hill, UK). For gene expression analysis, single-
strand complementary DNA (cDNA) was synthesised from 1 μg of total RNA using 
the High Capacity cDNA kit (Thermo Fisher Scientific, Waltham Massachusetts, 
USA). Quantitative PCR to measure gene expression using SYBR Green qPCR (Life 
Technologies) was used to measure vascular endothelial growth-factor A (VEGF-A), 
fibroblast growth factor-2 (FGF2), cell division cycle 25A (CDC25A), cyclin-1E 
(CCNE1) and 18S rRNA. The following primers were pre-designed from Sigma 
(KiCqStartTM Primers)
211
: VEGF-A forward: CGCAGCTACTGCCATCCAAT, 
reverse: GTGAGGTTTGATCCGCATAATCT; FGF2 forward: 
AGTGTGTGCTAACCGTTACCT, reverse ACTGCCCAGTTCGTTTCAGTG;  
CDC25A         forward:         5’-TAAGACCTGTATCTCGTGGCTG-3’, reverse: 5’- 
CCCTGGTTCACTGCTATCTCT-3’; CCNE1 forward: 5’-
GAGCCAGCCTTGGGACAATAA-3’, reverse: 5’-
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GCACGTTGAGTTTGGGTAAACC-3’;  
18s rRNA forward: 5’- TAGAGGGACAAGTGGCGTTC -3’, reverse: 5’-
TGTACAAAGGGCAGGGACTT-3.  
Data were normalized to 18S ribosomal RNA as an endogenous control.   
4.3 Results 
4.3.1 Vasopressin regulates exosome uptake in the 
collecting duct cell  
Using fluorescent microscopy, uptake of dye loaded exosomes was shown to be 
under vasopressin regulation in collecting duct cells. Stimulation with desmopressin 
resulted in an increase in the number of red-dye loaded exosomes localising adjacent 
to the DAPI stained cell nuclei (Figure 4.1.B) compared to control cells (Figure 
4.1.A).   
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A B
 
Figure 4.1: Fluorescent microscopy of control (A.) vs desmopressin stimulated 
cells (B)  
 (3.16ng/ml for 96 hours) with dye loaded exosome uptake into the cellular 
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Using different desmopressin concentrations for stimulation of CCD cells, 3.16ng/ml 
was the optimal. At a concentration of 3.16µg/ml there was apoptosis/necrosis of 
DAPI stained nuclei when viewed under confocal microscopy and 6.32pg/ml 
produced insignificant exosomal uptake (data not shown). 
To determine whether vasopressin regulates exosome uptake in CCD cells with a 
short-term effect, CCD cells were incubated with desmopressin and dye loaded 
exosomes for a short time period (1-8 hours), showing no significant differences 
between control and desmopressin stimulated cells (Figure 4.2.A). However, 
significant exosome uptake occurred after 96 hours of desmopressin stimulation 
(Figure 4.2.B.). FACS analysis was able to detect differences in total cell 
fluorescence between control and desmopressin stimulated cells (Figure 4.2.C). At 
concentrations similar to the physiological concentration of vasopressin
212
, 96 hours 
of desmopressin incubation approximately doubled the proportion of recipient cells 
taking up dye loaded exosomes (Figure 4.2.C and D) (desmopressin stimulated 28.01 
± 9.21% vs control 13.74 ± 6.79%; 3896 ± 1785 MFI vs control 1394 ± 254.4 MFI). 
Reciprocally, NTA was able to quantify the amount of dye loaded exosomes 
remaining in the cell culture supernatant following incubation with the CCD cells 
(control or desmopressin stimulated) (Figure 4.2.E). A significant decrease (p<0.05) 
in the number of dye loaded exosomes remaining in the cell culture supernatant of 
desmopressin cells (Mean AUC20-100 106.1 ± 53.75 number of particles/ml) compared 
to control CCD cells (Mean AUC20-100 376.28 ± 253.5 number of particles/ml) 
(Figure 4.3.F) was found. 
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Figure 4.2: Exosome uptake by CCD cells is increased by desmopressin 
stimulation 
A.) Flow cytometry data demonstrating no significant dye loaded exosome uptake 
following desmopressin stimulation (3.16ng/ml) for up to 8 hours (n=3).  B.) Flow 
cytometry data demonstrating an effect on exosome uptake following longer 
desmopressin stimulation. (n=3, * P < 0.05: 3.16ng/ml desmopressin stimulation vs 
control). C.) Desmopressin (3.16ng/ml for 96 hours) stimulated CCD cells had 
significantly increased fluorescence after incubation with dye loaded exosomes. 
Fluorescent cells expressed as % of total cell number (n=6, * P < 0.05, paired t-test) 
D.) Mean fluorescence intensity of control and desmopressin stimulated cells 
(3.16ng/ml for 96 hours) (n=6, * P < 0.05, paired t-test). E.) Representative NTA 
trace of dye loaded exosomes in control (grey) vs desmopressin stimulated (black) 
cell culture supernatant. F.) NTA analyses of cell culture supernatant from control 
and desmopressin (3.16ng/ml for 96 hours) stimulated cells presented as the area 
under the concentration curve (AUC20-100) (n=6, * P < 0.05, paired t-test). 
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4.3.2 Vasopressin regulated receptor mediated exosome 
uptake by the collecting duct 
Tolvaptan; a selective V2 receptor antagonist, abolished the increase in exosome 
uptake induced by desmopressin (Figure 4.3.A and B) (10nM tolvaptan + 3.16ng/ml 
desmopressin 11.2 ± 6.4% vs desmopressin alone 33.6 ± 5.7% fluorescent cells of 
total; 1090 ± 133.2 MFI vs desmopressin alone 2239 ± 578.5 MFI), combined with a 
reciprocal significant decrease in the number of dye loaded exosomes remaining in 
the cell culture supernatant (10nM tolvaptan + 3.16ng/ml desmopressin (AUC20-100) 
429.9 ± 231.3 number of particles/ml vs desmopressin alone  (AUC20-100) 106.5 ± 
46.56 number of particles/ml) (Figure 4.3.D). To investigate the effect of a 
physiological control, we used endothelin-1, a peptide which inhibits sodium 
transport in the collecting duct 
213
. Endothelin-1 had no effect on exosome uptake by 
CCD cells when applied alone, but physiologically antagonised the effect of 
desmopressin as could be seen in the total number of fluorescent cells (10pM 
endothelin-1 + 3.16ng/ml desmopressin 22.88 ± 5.19% vs desmopressin 33.6 ± 5.7% 
fluorescent cells of total; 2357 ± 486.7 MFI vs desmopressin alone 4207 ± 1355 
MFI) (Figure 4.3. C and D) and dye loaded exosomes remaining in the cell culture 
supernatant as measured by NTA (10pM endothelin-1 + 3.16ng/ml desmopressin 
(AUC20-100) 299.2 ± 158.1 number of particles/ml vs desmopressin alone  (AUC20-100) 
113.0 ± 60.78 number of particles/ml) (Figure 4.3.F). 
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Figure 4.3: V2 receptor mediated mechanism following desmopressin 
stimulation 
A.) Fluorescence of control and desmopressin stimulated cells (3.16ng/ml for 96 
hours) in the absence and presence of tolvaptan (10nM). Expressed as % of total 
number of fluorescent cells. B.) Mean fluorescence intensity of control and 
desmopressin stimulated cells (3.16ng/ml for 96 hours) in the absence and presence 
of tolvaptan (10nM). C.) Fluorescence of control and desmopressin stimulated cells 
(3.16ng/ml for 96 hours) in the absence and presence of endothelin-1 (10pg/mL). 
Fluorescent cells expressed as % of total cell number. D.) Mean fluorescence 
intensity of control and desmopressin stimulated cells (3.16ng/ml for 96 hours) in the 
absence and presence of endothelin-1 (10pg/ml). E.) NTA analysis of cell culture 
supernatant of control, desmopressin stimulated cells (3.16ng/ml for 96 hours) in the 
absence and presence of tolvaptan (10nM).  (, n=5. * p < 0.05 seen as significant 
between control and desmopressin stimulated cells and desmopressin and 10nM 
tolvaptan treated cells. Non-parametric ANOVA). E.) NTA analysis of cell culture 
supernatant of control, desmopressin stimulated cells (3.16ng/ml for 96 hours) in the 
absence and presence of endothelin-1 (10pM).  (, n=5. * p < 0.05 seen as significant 
between control and desmopressin stimulated cells and desmopressin and 10pM 
endothelin-1 treated cells. Non-parametric ANOVA). 
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4.3.3 cAMP and clathrin-dependent endocytosis mediates 
desmopressin-induced exosome uptake  
The V2 receptor is coupled with Gs proteins and causes activation of the cAMP 
pathway
212
. Inhibition of cAMP-dependent protein kinase A (PKA) with H-89 
prevented the increase in uptake of dye loaded exosomes following desmopressin 
stimulation (25µM H-89 + 3.16ng/ml desmopressin 9.60 ± 1.71% vs 3.16ng/ml 
desmopressin 31.52 ± 10.31% fluorescent cells; 1388 ± 127.8 MFI vs desmopressin 
alone 2398 ± 523.5 MFI) (Figure 4.4.A and 4.5. A). Stimulation of CCD cells with 
forskolin increased uptake of dye loaded exosomes independent of desmopressin 
stimulation (forskolin 19.65 ± 4.58% vs 7.72 ± 8.82% control cells; 1477 ± 27.35 
MFI vs control cells 1380 ± 69.34 MFI) (Figure 4.4.B and 4.5. B). Endocytosis can 
be cAMP dependent
214
 and, taken together with previous studies showing that 
exosomes enter cells through the endocytic pathway
204
, the role of  clathrin-
dependent endocytosis was investigated. Dynasore, a non-competitive inhibitor of 
GTPase dynamin activity
208,215,
 significantly reduced desmopressin-stimulated 
exosome uptake to a level below that of control cells (150nM dynasore + 3.16ng/ml 
desmopressin 3.25 ± 1.85% vs control 15.71 ± 10.18% fluorescent cells; 996.0 ± 
75.31 vs desmopressin alone 2044 ± 661.6 MFI) (Figure 4.4.C and 4.5. C.). In 
combination, these data indicate that basal and desmopressin-induced uptake of 
exosomes requires cAMP activation of clathrin-dependent endocytosis. As a final 
control to confirm whether increased exosome uptake following desmopressin 
stimulation is through activation of the V2 receptor and its concomitant cAMP 
activation, desmopressin stimulated cells (3.16ng/ml) were treated with a V1 
receptor anatagonist – OPC-21268 (1µM) and exosome uptake were compared to 
desmopressin stimulated cells without OPC-21268 treatment. No significant 
differences were seen (desmopressin stimulated cells 23.2±5.2% vs desmopressin 
stimulated cells treated with OPC-21268 (1uM) 18.8±1.4% fluorescent cells; 1166 ± 
10.54 MFI vs desmopressin alone 1182 ± 30.69 MFI) (Figure 4.4.D and 4.5. D).  
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Figure 4.4: Exosome uptake following desmopressin stimulation is mediated 
by cAMP and clathrin-dependent endocytosis 
A.) Desmopressin (3.16ng/ml for 96 hours) stimulated exosome uptake which was 
decreased by PKA inhibition (H-89 – 25µM) of the cAMP pathway. B.) Exosome 
uptake was by cAMP stimulation through forskolin (10µM). C.)  Dynasore (150nM) 
inhibiton of dynamin activity decreased exosome uptake by desmopressin stimulated 
cells below that of the control cells. Fluorescent cells expressed as % of total cell 
number, n= 6, * P <0.05, non-parametric ANOVA. D.) No significant difference in 
exosome uptake between desmopressin stimulated cells and desmopressin stimulated 
cells treated with a V1 receptor antagonist – OPC-21268 (1µM). Fluorescent cells 
expressed as % of total cell number, n= 3, ns, non-significant, paired t-test. 
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Figure 4.5: Mean fluorescent intensities for exosome uptake following 
desmopressin stimulation mediated by cAMP and clathrin-
dependent endocytosis 
A.) Mean fluorescent intensitity of increased exosome uptake of desmopressin 
(3.16ng/ml for 96 hours) stimulated cells which were decreased by PKA inhibition 
(H-89 – 25µM) of the cAMP pathway. B.) Exosome uptake was by cAMP 
stimulation through forskolin (10µM). C.)  Dynasore (150nM) inhibiton of dynamin 
activity decreased exosome uptake by desmopressin stimulated cells below that of 
the control cells. Data expressed as mean fluorescent intensity, n= 6, * P <0.05, non-
parametric ANOVA. D.) No significant difference in exosome uptake between 
desmopressin stimulated cells and desmopressin stimulated cells treated with a V1 
receptor antagonist – OPC-21268 (1µM). n= 3, ns, non-significant, Kruskal-Wallis t-
test. 
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4.3.4 Functional delivery of miRNA by exosomes following 
desmopressin stimulation  
To complement and confirm the data from fluorescence-based exosome tracking, 
exosomes loaded with a specific microRNA were used with cellular target mRNA 
suppression as the readout of functional exosome uptake. Exosomes were harvested 
from a HUVEC line transduced to over-express miR-503 and a control cell HUVEC 
line. This cell line was chosen as the mRNA targets of miR-503 are well-
described
211,216
. The expression of miR-503 in the isolated exosome pellet was 
confirmed by qPCR (overexpressing Ct value 26.6 vs control Ct value >35, Figure 
4.6.A). Using NTA, exosome uptake regulated by vasopressin was confirmed by the 
number of exosome particles remaining in the cell culture supernatant of 
desmopressin stimulated and control cells (Figure 4.6.B). Exosomes from both cell 
lines were added to control or desmopressin-stimulated CCD cells. Target genes 
influenced by miR-503 identified: mRNA expression of VEGF-A, FGF2, CDC25A 
and CCNE1 were measured. Data is expressed as the delta delta Ct value or Livak 
method, which computes the ratio of the target gene in a specific condition (no 
exosomes, control HUVEC exosomes or miR-503 HUVEC exosomes) in a treated 
sample (desmopressin stimulation) relative to an untreated sample (control). In the 
absence of added exosomes, desmopressin stimulation increased target gene 
expression in CCD cells. However, with the addition of miR-503 overexpressing 
exosomes, we found a significant down-regulation of these target genes in the 
presence of desmopressin stimulation compared to cells which were subjected to 
control HUVEC exosome (i.e. not miR-503 overexpressing) addition. (Figure 4.6C-
F) 
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Figure 4.6: Exosomes deliver functional microRNA into desmopressin-
stimulated CCD cells 
A.) Raw Ct values of miR-503 in control and miR-503 loaded exosomes. B.) 
Representative NTA trace of differential miR-503 exosome uptake regulated by 
desmopressin stimulation. Relative change in gene expression following 
desmopressin treatment in the absence of ECVs, with control HUVEC derived ECVs 
and miR-503 loaded ECVs. C.) vascular endothelial growth factor-A (VEGF-A), D.) 
fibroblast growth-factor 2 (FGF2), E.) cyclin E-1 (CCNE1) and F.) cell division 
cycle 25A (CDC25A) using ∆∆Ct method relative to control cells. Values are 
expressed as the difference between Ct values of control cells – Ct value of 
desmopressin simulated cells with 18S as endogenous control. Negative values 
indicate down-regulation and positive values indicate up-regulation of target genes 
following desmopressin treatment. n=9, * p < 0.05, paired t-test. 
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4.3.5 Cell specific derived exosome uptake in collecting 
duct cells  
Next, we determined whether exosomes derived from different cell types are also 
internalised by CCD cells under vasopressin regulation. CCD cells (without and with 
desmopressin stimulation) were incubated with equal numbers of exosomes isolated 
from the following renal cell types: CCD (mouse); proximal tubule (HK2 - human); 
and juxtaglomerular (RG1 - mouse). The exosomes from all cell types had similar 
size distributions, as quantified by NTA (Figure 4.7A). Treating recipient CCD cells 
with desmopressin increased uptake of the proximal tubule and collecting duct-
derived exosomes but not of those from juxtaglomerular cells (Figure 4.7B). This 
tubular cell selectivity was confirmed by NTA analysis, which demonstrated 
decreased proximal and collecting duct exosomes in the CCD cell culture 
supernatant, but no change in exosomes from juxtaglomerular cells (Figure 4.7C).  
The V2 receptor is expressed on the basolateral membrane of the renal principal cell. 
Therefore exosome uptake in CCD cells was investigated by using polarised CCD 
cells grown on transwell plates and stimulated with desmopressin on either the apical 
or basolateral side. Basolateral desmopressin stimulated uptake of apically applied 
exosomes, whereas desmopressin applied to the apical membrane had no effect 
(Figure 4.7D).  
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Figure 4.7: Cell type specificity for exosome uptake 
A.) NTA measurement of exosomes from different cell types prior to incubation with 
CCD cells. CCD = collecting duct, HK2 = proximal tubule and RG1 = 
juxtaglomerular cell derived B.) Comparing total cell fluorescence between control 
and desmopressin (3.16ng/ml for 96 hours) stimulated CCD cells following labelled 
exosome incubation from 3 cell types: CCD, HK2 (human proximal tubular cell line) 
and RG1 (murine juxtaglomerular cell line). Equal numbers of exosomes were added 
to all experiments (n=6. * p < 0.05, non-parametric ANOVA). C.) NTA analyses of 
cell culture supernatant incubated with different cell type derived exosomes (CCD, 
HK2 and RG1) from control and desmopressin (3.16ng/ml for 96 hours) stimulated 
cells presented as the area under the concentration curve (AUC) for particles sized 
between 20-100nm. Desmopressin stimulation reduced the concentration of CCD 
and HK2 exosomes in the supernatant but not in cells incubated with RG1 exosomes. 
D.) Polarised cells take up exosomes under desmopressin regulation. Total cell 
fluorescence of CCD cells stimulated with desmopressin (3.16ng/ml for 96 hours) 
either apically or basolaterally compared to unstimulated cells. Labelled exosomes 
were applied to apical compartment of Transwell (n=6. * p < 0.05, non-parametric 
ANOVA). 
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4.4 Discussion 
Vasopressin is released from the posterior pituitary in response to an elevation in 
blood osmolality
212
. Its principal role is to stimulate water reabsorption by the renal 
collecting duct. This is achieved through activation of the V2 receptor on the 
basolateral membrane of renal principal cells which, via a cAMP/PKA cascade, 
phosphorylates the water channel AQP2 permitting trafficking to the apical cell 
membrane from sub-apical recycling endosomes. In parallel, vasopressin stimulates 
endocytosis of vesicles from the cellular plasma membrane to maintain membrane 
equilibrium.   
In this chapter, vasopressin as a hormonal regulator of exosome uptake in collecting 
duct cells was demonstrated. 4 complementary read-outs of exosome uptake were 
used – fluorescent microscopy, flow cytometry and microRNA transfer into cells, 
combined with NTA of exosomes remaining in the culture medium. The data 
generated by these different methodologies consistently demonstrated that 
desmopressin stimulated exosome uptake into CCDs. The mechanism was V2 
receptor-mediated and cAMP/PKA dependent, in keeping with the established 
physiological pathway that increases water uptake. In the cell model, desmopressin-
induced exosome uptake was reduced by endothelin-1, suggesting that exosome 
uptake is under opposing physiological regulation by vasopressin and endothelin-1. 
Thus, the mechanism of vasopressin-induced exosome uptake into CCDs is 
consistent with the known physiology of this hormone and is likely to be a 
consequence of hormone-induced plasma membrane endocytosis. Hormonal 
regulation of exosome entry into cells has not been demonstrated in any cell line and 
provides support for exosome inter-cellular signalling being a tightly regulated 
process. 
In conclusion, in this chapter, vasopressin regulation of exosome uptake in kidney 
collecting duct cells was shown. Vasopressin regulation occurs in collecting duct 
cells through a regulated process which can result in intra-cellular modulation of 
target mRNA species. This finding will now be investigated in vivo in the studies 
presented in the following chapter.  
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5.1 Introduction 
Exosomes derived from different segments of the nephron have been well 
characterised in urine. In depth proteomic analysis of the urinary exosomal 
compartment has demonstrated the presence of proteins specific to each cell along 
the nephron epithelium: the podocyte/glomerular epithelial cell, proximal tubule, 
distal tubules and the collecting duct
8
.  
The development of urinary exosomes as biomarkers has mainly been focussed on 




 and bladder 
cancer
217
. However, other studies have suggested that the urinary exosome cargo 
may contain proteins from non-renal cells. Large-scale proteomic analysis of 
podocyte-specific urinary exosomes revealed 14 new, previously unidentified brain-
specific proteins
218
. Similarly, in a mouse model for acute and chronic liver injury, 
urinary exosomes showed differential expression of specific proteins
219
. Urinary 
exosomes may therefore provide a reservoir of information about renal and non-renal 
proteins and RNA species, which presents the opportunity for developing urinary 
exosomes biomarkers for multiple diseases.  
Studies have demonstrated that exosome uptake is mediated through various forms of 
endocytosis including clathrin-dependent endocytosis and macropinocytosis with 
resultant delivery of proteins and RNA species
135,220
 to the recipient cell. The 
mechanisms of exosome uptake and exosome mediated intercellular communication 
remain unclear and need to be elucidated to develop exosomes as possible 
therapeutic agents. 
In Chapter 4, in vitro exosome uptake in the kidney collecting duct was demonstrated 
to be regulated by vasopressin in a cell type specific, receptor mediated, clathrin-
dependent process of endocytosis. The aims of this chapter were to build upon this 
work and examined whether exosome uptake occurs in vivo. Two complementary 
approaches were used: first, the effect of tolvapatan on urinary exosome excretion in 
the mouse was assessed; second the effect of desmopressin on urinary exosome 
excretion in a patient with central diabetes insipidus was examined.  
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5.2 Methods 
5.2.1 Cell culture 
Cells were grown and cultured as per described method in Chapter 2.  
5.2.2 Exosome isolation 
Exosomes from CCD cell culture supernatant were isolated as per described ultra-
centrifugation method in Chapter 2. The isolated exosome pellet was labelled with 
Cell Tracker™ (dye-labelled exosomes) followed by quantification of the number of 
particles in the exosome preparation per the described NTA method in Chapter 2.  
5.2.3 Animals  
All experiments were conducted in accordance with UK Home Office regulations 
and the Animals (Scientific Procedures) Act 1986 and complied with the ethical 
regulations of the institution. The study design was a crossover study which 
consisted of three experimental groups. The group of animals in each separate 
experimental group was seen as the experimental unit. 
Adult wild type (C57BL6/J and CD1) mice were sex and age matched across 
experiments. Before experimentation, mice were housed in standard cages with free 




, and 0.67% K
+
. 
A total number of 15 mice were included with 5 mice in each of the experimental 
groups. The number of mice used were kept to the advised minimum 
221
 as no 
previous data were available to calculate an applicable sample size for this proof of 
concept study.  
 The weight of the animals ranged from 20.8g to 36.4g (median 30.84g). General 
anaesthesia was induced by intra-peritoneal injection of 100mg/kg Inactin 
(thiobutabarbital sodium salt hydrate, Sigma, Paisley, UK). The anaesthesia was 
chosen for its limited effect on renal function in mice 
222
 combined with its inhibitory 
effect on proximal tubular reabsorption 
223
 which was ideal for this study design 
investigating exosome uptake in the collecting duct. Venous access was gained via 
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the jugular vein. Urine flow was maintained throughout with a 0.9% saline infusion 
(0.2mL/10gbw/hour i.v). For each experimental group, dye-labelled exosomes from 
CCD cells were injected in a final volume of 0.1ml (i.v). The injection of exosomes 
was repeated without or with preceding tolvaptan administration (0.3mg/kg i.v) or 
furosemide (1mg/1kg, i.v). The injected tolvaptan dose was consistent with previous 
published murine studies with the injected furosemide dose adjusted to yield a 
similar increase in urine flow rate comparable to tolvaptan. Urine was collected via a 
urinary catheter for 30 minutes following different conditions. Following the final 
time point, the mouse was euthanized by cervical dislocation.  All experiments were 
performed during similar times of the day, within the local designated surgical 
laboratory. 
The primary experimental outcome was to measure the urinary output of dye-labelled 
exosomes by NTA (as per described method in Chapter 2). Secondary, it was of 
importance to determine whether tolvaptan or furosemide treatment would have an 
effect on the urinary output of dye-labelled exosomes.  
5.2.4 Clinical case study 
Repeated urine samples were obtained from a 16-year-old male with stable central 
diabetes insipidus (CDI) secondary to a craniopharyngioma, who was being routinely 
treated with daily desmopressin (dDAVP nasal spray; 0.1ml (10mcg) desmopressin 
acetate per spray). The CDI patient samples were initially stored at 4°C then frozen 
at -80 °C. Analysis of the CDI patient samples were performed by a researcher 
blinded to the timing of desmopressin treatment. The protocol was agreed by the 
institutional ethical review body and informed consent was obtained. Urinary 
creatinine was analysed as per described method in Chapter 2. Antibodies to each 
segment of the nephron were identified and labelled with quantum dots (antibody-
Qdots) as per described in Chapter 2.  
Chapter 5: Vasopressin regulation of urinary exosome excretion in vivo 104 
5.2.5 Measurement of particle size and concentration 
distribution with NTA 
Mouse urine samples were collected for 30 minutes following treatment and diluted 
1:100. The diluted urine samples were then analysed using the Nanosight LM 10 
instrument (Nanosight Ltd.) with the fluorescent long-pass filter in place as 
previously described in Chapter 2. 
Human urine samples were diluted 1:100, divided into five aliquots and then labelled 
with different antibody-Qdots to yield a final particle concentration in the region of 1 
x 10
8
 particles / ml as per the manufacturer’s recommendations. The diluted urine 
samples were then analysed using the Nanosight LM 10 instrument (Nanosight Ltd.) 
as previously described in Chapter 2.   
5.2.6 Statistical analyses  
Except where stated otherwise, data are presented as means and standard deviation. 
Experimental groups were compared by Student's t-test or ANOVA with appropriate 
post hoc testing using GraphPad Prism (version 6). 
5.3 Results 
5.3.1 Intravenous injection of labelled exosomes measured 
in mouse urine 
Firstly, it was of interest to determine whether intravenously injected dye-labelled 
exosomes would appear in the urine and whether this could be detected and 
quantified by NTA. NTA quantification of urine prior to dye-loaded exosome 
injection yielded no signal. Prior to i.v injection, all dye-loaded exosomes were 
quantified by NTA (Figure 5.1A). Figure 5.1B presents a representative NTA trace 
of a urine sample, showing the dye-loaded exosome population in urine detected and 
quantified using the fluorescent filter capabilities of NTA.  The median particle size 
of fluorescently labelled particles in whole urine for this representative sample were 
64nm, indicative of particles within the expected exosomal size range.  
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Figure 5.1: Representative NTA trace of dye-labelled exosomes in exosome 
preparation compared to urinary output  
Representative NTA analysis of the labelled isolated exosome preparation derived 
from CCD cells (A) compared to urine sample from one mouse following i.v 
injection of labelled exosomes (B).  
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5.3.2 Vasopressin regulation of exosome uptake in a mouse 
model 
As a control, mice were intravenously injected with exosome free Cell Tracker™ 
nanocrystals in solution and there was no signal detected in their urine by NTA. Mice 
were subsequently intravenously injected with dye-labelled exosomes derived from 
CCD cells. The urinary excretion of these fluorescent exosomes was measured by 
NTA. Qiazol treatment of the urine substantially reduced the number of particles 
measured by NTA which is consistent with the presence of dye-labelled membrane 
bound exosomes (Figure 2A). Comparing the area under the curve for particles sized 
between 20-100nm, revealed a significant decrease following Qiazol treatment of 
urine (501.5 ± 624.8 compared to 101.8 ± 106.9 x 10
6
 particles/ml) confirming a 
decrease in number of particles of dye-labelled exosomes (Figure 5.2B).  
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Figure 5.2: NTA analyses of membrane disrupted exosomes 
A.) Representative NTA traces showing number of particles of whole urine (black 
line) compared to Qiazol treated urine (grey line). B). AUC20 - 100 of whole urine 
compared to Qiazol treated urine. (Values expressed as mean ± SD; n=5, *, P < 0.05, 
unpaired t-test.) 
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Following confirmation of the integrity of dye-labelled membrane bound exosomes, 
mice in the control group received two consecutive injections of labelled exosomes 
and a similar percentage were recovered in the urine (3.82% vs 3.85%). The area 
under the curve for particles sized between 20-100nm (AUC20-100) was also similar 
between two consecutive i.v injections of labelled exosomes (11.40 ± 9.56 vs 12.55 ± 
17.65 x 10
6 
particles/ml) (Table 5.1, Figure 5.3).   
In the experimental groups, mice were first injected with dye-labelled exosomes and 
urine was collected to determine the basal excretion. Then the mice were treated with 
either tolvaptan or furosemide followed by a second i.v injection of the same number 
of exosomes. Tolvaptan treatment increased the exosome excretion from 2.75% to 
20.34%, (Table 5.1, Figure 5.3), whereas treatment with furosemide (n=4) had no 
effect (3.24% compared to 3.98%), despite inducing a similar diuresis.  
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Table 5.1: Comparison of urinary exosome excretion (urine collection for 30 minutes) in control, tolvaptan and furosemide 









 i.v injection 2
nd
 i.v injection 1
st
 i.v injection 2
nd
 i.v injection 1
st
 i.v injection 2
nd
 i.v injection 
Number of particles 
(AUC20-100) 
11.40 ± 9.56 12.55 ± 17.65  3.72 ± 4.98 35.96 ± 20.35 1.33 ± 1.54 2.18 ± 1.59 
Urine volume in 30 min 
collection (uL) 
55 60 60.05 79 22.5 30 
Fold Change in urine flow  ~ 1.09 ~ 1.3 ~ 1.33 
Percentage exosomes 
recovered in 30 minute 
collection 
3.82± 3.21% 3.86 ± 5.42% 
2.75 ± 3.68% 
*P < 0.05 
20.34± 11.45% 
*P < 0.05 
3.24 ± 3.75% 3.98 ± 2.92% 
Data are expressed as mean ± SD. *, P < 0.05 defines statistical significance between 2 consecutive i.v injections of exosomes within the 
same experimental group. 
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Figure 5.3: Vasopressin V2 receptor regulates urinary exosome excretion in 
mice  
A.) Urinary excretion of i.v injected exosomes in mice. Group 1 – control group 
(n=5); urine exosome excretion following 2x i.v injections of dye-labelled exosomes. 
Group 2 – urine exosome excretion after 2 i.v injections of dye-labelled exosomes of 
mice treated with tolvaptan (0.3mg/kg) (n=5) between injections. Group 3 – Urinary 
exosome excretion after 2 i.v injections of dye-labelled exosomes of mice treated 
with furosemide (1mg/kg) (n=4) between injections. Data are expressed as 
percentage of the total number of injected exosomes excreted in the urine over 30 
minute urine collection (mean ± SD, * P < 0.05, non-parametric Mann-Whitney t-
test).    
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5.3.3 Vasopressin regulation of exosome uptake in a clinical 
case study  
In a complementary in vivo proof-of-concept study, the urinary excretion of nephron 
segment specific exosomes was measured in a patient with central diabetes insipidus. 
In this approach Qdot labelled antibodies were used to target segment specific 
proteins and these populations of exosomes were measured by NTA combined with 
Qdot labelled antibodies for segment specific proteins
206
. Changes in urinary 
creatinine following intra-nasal desmopressin administration are shown in 
Figure 5.4A. Following self-directed desmopressin intra-nasal administration, there 
was a decrease in both glomerular (podocalyxin-like) and proximal tubular (cubilin) 
protein-expressing exosomes (Figure 5.4B). 
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Figure 5.4: NTA analysis of 24 hour exosome excretion by a patient with 
central diabetes insipidus 
A.) Changes in urinary creatinine concentration (mmol/l) following administration of 
desmopressin treatment over time. B.) Changes in the number of particles (AUC20-
100) of urinary creatinine and exosomes expressing nephron-segment specific 
proteins: glomerular (podocalyxin-like protein, PODX-L), proximal tubular (cubilin), 
and CD24 (pan-segment urinary exosome marker) over time. Exosome urine 
concentration measured by NTA and normalised by urinary creatinine concentration. 
NTA measurements were taken in triplicate for each time point. Lines represent the 
time of desmopressin treatment (dashed line). 
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5.4 Discussion  
There has been a substantial increase in publications on the biology of exosomes, 
particularly relating to their signalling potential as mediators of intercellular 
communication. However, in the kidney and other organs there is little evidence that 
regulated signalling occurs in vivo. To test whether vasopressin is important for renal 
exosome uptake and excretion in vivo, dye-labelled exosomes were systemically 
injected into mice. After injection these exosomes appeared in urine which is 
consistent with previous published studies 
119
. The small percentage recovery of dye-
labelled exosomes found in the mice urine is consistent with other research showing 
the majority of dye-labelled particles may be sequestered or transported to the lung, 
spleen or liver 
224
.  
The unique structure and filtration pathway of the nephron, including the slit 
diaphragm and meshwork structure of the glomerular basement membrane only 
allows particles with a hydrodynamic diameter size up to 6nm to be filtered 
225
.  
Exosomes are theoretically above the cut-off size for successful glomerular filtration, 
however, recently, trans-renal transport of exosomes
119
 has been reported. The 
mechanism of systemic exosome entry into urine remains to be determined. A 
process of trancystosis as possible mechanism have been proposed but it still remains 
to be elucidated
226
.   
In this chapter, it was demonstrated that tolvaptan, a selective V2 receptor antagonist, 
substantially increased the urinary excretion of systemically administered exosomes. 
The V2 receptor is located on the basolateral membrane of the principal collecting 
duct; therefore a possible explanation of the mechanisms involved with increased 
systemic exosome uptake following tolvaptan treatment, could be reduced 
intracellular shuttling of vesicles and reabsorption by the collecting duct and 
therefore increased excretion in the urine of dye-labelled exosomes. These are the 
first data that demonstrate vasopressin is a regulator of urinary exosome excretion 
and confirms the findings in Chapter 4 of vasopressin regulation of exosome uptake 
in vitro translating in vivo.   
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Combining antibodies to nephron segment-specific proteins with NTA can identify 
the cellular origin of urinary exosomes. Urine from a patient with central diabetes 
insipidus – a condition defined by lack of vasopressin – were collected and 
determined the effect of intra-nasal desmopressin on glomerular and proximal tubule 
derived exosomes. Following desmopressin stimulation, the urinary number of 
particles of these exosomes was decreased, which is consistent with vasopressin 
regulation of urinary exosomes excretion in humans. While these human data are 
hypothesis-generating, they are consistent with the data from cells and mice. An 
indirect limitation of this study to consider is the effect vasopressin has on exosome 
release and the influence this might have on the total exosome population, as shown 
in our findings in Chapter 3. An additional limitation is that the concentration of 
urinary creatinine changed as a result of desmopressin treatment making the 
normalisation of spot urine exosome numbers a challenge. In the future larger 
validation studies should be performed to confirm the human data. 
Additionally, future work should include confirming the endosomal origin and cargo 
of the dye-labelled exosomes found in the urinary output. Control experiments 
conducted, including injection of dye without exosomes present, NTA trace 
representatives of the size distribution of dye-labelled particles and confirming the 
membrane bound integrity by lysis of the urine sample, combined, proved the size 
and shape of dye-labelled exosomes in the urinary output. However, further 
experiments should be aimed at confirming the contents and functional delivery of 
the recovered exosomes. This could be achieved through the addition of an 
exogenous miRNA-species and by measuring its target gene effects. Histology of the 
kidney and other tissue samples would also be beneficial to further elucidate the 
distribution of systemically injected dye-labelled exosomes.  
In conclusion, in this chapter, vasopressin regulation of exosome uptake in a mouse 
model and clinical case study were shown. Furthermore, exosome uptake could be 
increased by inhibition of the V2 receptor. This is an important concept as a greater 
understanding of exosome uptake may allow exosome manipulation to increase their 
urinary excretion and opens further exciting avenues of urinary exosomal biomarker 
discovery and more refined therapeutic targeting of interventions in the kidney.  
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6.1 Introduction 
The unique exosomal proteome reflective of all the different segments of the nephron 
highlights the potential of urinary exosomes to provide information of cell specific 
physiological and pathophysiological changes that may occur along the nephron. 
This ability subsequently highlights the potential of urinary exosomes as nephron-
specific biomarkers of kidney injury.   
Contrast media induced acute kidney injury (CI-AKI) is the development of acute 
kidney injury (AKI) following the administration of radiographic contrast media 
(CM)
182
. Previous exposure to CM still remains among the top 3 aetiological factors 
for AKI in hospital. Even though the direct mechanisms of CI-AKI are not yet fully 
understood, possible pathophysiological mechanisms of CI-AKI include: direct CM 
molecule tubular cell toxicity; haemodynamic effects primarily through afferent 
arteriolar vasoconstriction; and endogenous biochemical disturbances such as 
changes in nitric oxide levels and increases in oxygen-free radicals
184,185
.   
Currently, serum creatinine is the standard index of kidney function and also the gold 
standard for recognising AKI. Serum creatinine as a biomarker of kidney injury does, 
however, have limitations as it is slow to reflect changes in glomerular filtration rate 
which can potentially delay diagnosis
186,187
. This limitation has led to considerable, 
ongoing research efforts aimed at discovering and developing new, accurate 
biomarkers of AKI. Two promising candidates reflecting kidney tubular damage as 
opposed to disturbed function are NGAL (Neutrophil-gelatinase-associated lipocalin) 
and KIM-1 (Kidney Injury Molecule-1). A number of studies have unequivocally 
demonstrated  both NGAL and KIM-1 to be novel, predictive biomarkers for AKI
193
. 
Whilst these two candidates are promising as early biomarkers of AKI, both are still 
variable and dependent on the underlying clinical context
227
, therefore there is still a 
need for new candidates for timelier diagnosis of AKI - which in turn will aid better 
prediction and stratification of injury and lead to more refined methods of safety 
assessment of nephrotoxic events during drug development
193
.  It would also be of 
interest to develop a more comprehensive characterisation of kidney injury 
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propagation along the nephron and further elucidate the underlying 
pathophysiological mechanisms in AKI. 
Building upon the developed method of quantifying urinary exosomes by NTA using 
an antibody-specific labelling system (Chapter 3), the first aim of this chapter was to 
determine whether this method could quantify nephron-specific exosomes in a 
human AKI model of CM exposure, and how this would compare to standardised 
biomarkers of AKI.  The second aim was to determine whether nephron-specific 
exosome populations in AKI could provide more insights into the role exosomes 
might play in pathophysiology of the kidney.  
In this chapter, urinary exosomes positive for a panel of proteins characteristic of 
each segment of the nephron (podocyte, proximal and distal tubule, collecting duct 
and a pan-tubule surface marker) were measured and compared against the 
established and standardised biomarkers for kidney tubular injury: KIM-1 and 
NGAL. It was determined whether NTA measurements of nephron-specific 
exosomes could reflect changes in patients comparable to standard kidney injury 
markers in a CI-AKI model.  
6.2 Methods  
6.2.1 Patient group, sample collection and sample 
processing 
Samples for this study were kindly obtained from Prof M Eddleston (Professor of 
Clinical Toxicology, University of Edinburgh) from a clinical trial (Protocol No 
NAC0606) investigating the mechanisms for an effect of acetylcysteine on renal 
function after exposure to radio-graphic contrast material
228
. The study was 
performed simultaneously in four groups of participants. Studies 1-3 were 
randomised, placebo-controlled, three-way, crossover human volunteer studies of 
eight participants. All studies were performed at the Wellcome Trust Clinical 
Research Facility, Royal Infirmary of Edinburgh. The applicable arm of this 4-arm 
study was Study 4: a randomised, placebo-controlled, three-way parallel group study 
in patients undergoing elective coronary angiography. Patients in this group were 
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randomised to receive either oral acetylcysteine (1200 mg twice daily for two days), 
IV acetylcysteine (200 mg/kg over 7 hours), or placebo. Patients were subsequently 
followed up 24 hours and 72 hours after acetylcysteine-administration. The local 
ethics committee approved the study and written informed consent was obtained 
from each participant. All participants were male, non-smoking and aged over 45 
with a body mass index of 22 - 40 kg/m
2
.  Exclusion criteria for this study were 
thyroid disease, asthma, atopy or myasthenia gravis, a history of allergy or sensitivity 
to acetylcysteine or CM and current intake of metformin. The primary outcome of 
this study was a change in renal blood flow, with secondary outcomes including 
changes in glomerular filtration rate, tubular function, urinary proteins and oxidative 
balance.  
The study described in this chapter included 32 chronic kidney disease (CKD) stage 
III patients, who were exposed to CM. Participants in study 4 received doses of 
Visipaque 320 as prescribed by the consultant cardiologist performing angiography 
to adequately visualise the coronary arteries and perform any procedure judged to be 
necessary. A baseline spot urine sample was collected before the administration of 
CM. Two spot urine samples were collected after CM exposure: 24 hours and 72 
hours after administration. The patient samples were initially stored at 4°C and then 
frozen at -80°C.  
6.2.2 Creatinine, KIM-1 and NGAL 
Urinary creatinine concentration was measured for every spot urine sample by a 
colorimetric method using a commercial kit from Alpha Laboratories Ltd. (Eastleigh, 
UK). KIM-1 and NGAL concentrations were also measured for every sample. Both 
KIM-1 and NGAL were assayed using a commercial kit from R&D systems, Inc. 
(Minneapolis, USA) following the manufacturer’s protocol with calibration ranges of 
0 - 2500 pg/mL. Urine was assayed undiluted for KIM-1 and diluted 1:20 with 
deionised H2O for NGAL.  
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6.2.3 Fluorescent labelling with antibody conjugated to 
quantum dots 
Proteomic analysis by Pisitkun et al. (2004) identified nephron segment-specific 
proteins in human urinary exosomes. Specific proteins relating to each segment of 
the nephron were chosen for further analyses. As per the described method in 
Chapter 2, quantum dots (Qdots) were conjugated to the different antibodies: Anti-
CD24; Anti-AQP2 (Millipore); Anti-NCC (Stressmarq biosciences Inc., Victoria, 
Canada); Anti-CU (Abcam); Anti-PODXL (Milipore) (Table 6.1). The conjugated 
Qdots were diluted to 1:1000 with deionised water. 
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Table 6.1: Nephron specific urinary exosome protein markers  
Nephron segment  Protein identified in urinary exosomes 
Podocyte/Glomerulus Podocalyxin-like protein (PODXL)
21
 
Proximal tubules Cubilin (CU)
39
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6.2.4 Measurement of particle size and concentration 
distribution with NTA 
All urine samples were diluted 1:100, divided into five aliquots and then labelled 
with different antibody-Qdots to yield a final particle concentration in the region of 1 
x 10
8
 particles/ml as per the manufacturer’s recommendations. The diluted antibody-
Qdot urine samples were then analysed using the Nanosight LM 10 instrument 
(Nanosight Ltd., Amesbury, UK) as previously described in Chapter 2.   
6.2.5 Statistical analysis 
The data from triplicate NTA results were analysed using GraphPad Prism Version 6 
as previously described in Chapter 2. Wilcoxon matched pairs signed rank tests were 
performed to determine significant differences between time points for each 
antibody-Qdot exosome concentration expressed as the area under the curve for 
particles sized between 20-100nm as measured by NTA. Data are shown with and 
without urinary creatinine correction. A non-parametric Spearman correlation test 
was performed to determine correlations between KIM-1 or NGAL and the different 
antibody-Qdot exosome concentrations.  After correlations had been found, the data 
was analysed using a linear regression analysis to compare NGAL and KIM-1 with 
antibody-Qdot NTA values. Finally, as the study is currently still blinded, patients 
were divided into 3 tertile groups according to the final KIM-1 and NGAL values (72 
hours post-exposure) and changes in antibody-Qdot exosome NTA values in the 
different tertile groups over time were compared using non-parametric Kruskal-
Wallis ANOVA.  
6.3 Results  
6.3.1 Patient demographics  
Table 6.2 summarises the demographics of the patients. In total, urine samples from 
32 patients were included, all male, with a mean age of 76 years. The average dose of 
CM was 165ml (Table 6.2).  
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Table 6.2: Patient demographics  
Factor  Mean 
Age (years) 76 (60-91) 
Height (cm) 173 (156.5–186) 
Weight (kg) 90 (64–127.6) 
Average dose (mL) 165 (50-520) 
Data are represented as the mean and range, n = 32.  
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6.3.2 Urinary levels of characterised biomarkers of kidney 
injury  
Comparing urinary creatinine levels pre- and post-exposure to CM across all 
patients, revealed a significant increase following contrast media exposure (Table 
6.3). This negated using urinary creatinine as an analyte normaliser for differences in 
concentrations in subsequent analyses.  For the total study group, KIM-1 values were 
significantly higher post-exposure (24 and 72 hours) compared to the initial pre-
exposure measurements (Table 6.3; Figure 6.1A). Figure 6.1B shows the non-
significant differences once KIM-1 values are corrected for urinary creatinine values. 
NGAL showed a significant increase 24 hours post-exposure compared to pre-
exposure values (Table 6.3; Figure 6.1C). Similarly, once NGAL values were 
corrected with urinary creatinine values, the significant differences seen pre-
correction were diminished (Figure 6.1D).  
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Table 6.3: Biomarker characteristics pre- and post (24 hours and 72 hours) 







Urinary creatinine (µg/ml) 546.6 ± 212.3 1208 ± 602.8*** 1058 ± 127.6*** 
Urinary KIM-1 (pg/ml) 535.6 ± 381.9 1629 ± 1820* 1376 ± 1498* 
Urinary NGAL (ng/ml)  7.7 ± 11.6 19.7 ± 21.4* 14 ± 20.8 ns 
Corrected KIM-1  
(pg/µg creatinine) 
0.94 ± 0.84 1.55 ± 2.11 1.45 ± 1.38 
Corrected NGAL  
(pg/µg creatinine)  
14.49 ± 20.43 19.05 ± 30.96 15.60 ± 31.57 
Comparison of the biomarker characteristics measured in patient urine samples 
obtained before (pre-exposure) and after (24 hours and 72 hours post-exposure) 
contrast media exposure. Data are represented as mean ± SD. Statistical significance 
is indicated as * P < 0.05; *** P < 0.001; and ns, non-significant for post-exposure 
biomarker characteristics compared to pre-exposure characteristics.  
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Figure 6.1: Change in urinary tubular injury biomarkers after contrast 
exposure 
KIM-1 (A), urinary creatinine corrected KIM-1 (B), and NGAL (C) and urinary 
creatinine corrected NGAL (D) pre- and post-exposure to CM (24hours & 72 hours). 
(Mean ± SEM, *** P < 0.001 seen as highly significant, * P <0.05 seen as significant 
compared to pre-exposure values, n = 32). 
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6.3.3 Comparison of protein-exosome conjugates 
concentration and urinary KIM-1 and NGAL 
The relationship between the concentration of each nephron-specific protein-
exosome conjugate and urinary KIM-1 and NGAL concentration was explored (both 
exosomes and biomarkers expressed per mL urine) (Table 6.4).  
Interestingly, 24 hours post-exposure PODXL showed a significant relationship with 
both biomarkers, KIM-1 and NGAL at the final time point, 72 hours post exposure to 
CM (Table 6.4). A linear regression analysis of the relationship between PODXL 
(72hours post-exposure) NTA values and KIM-1 and NGAL also showed a small, 
but significant fit of line (Figure 6.2).  
However, once the protein-exosome conjugate concentrations were corrected for 
urinary creatinine values, the previous statistical significance was negated (Table 
6.5) highlighting the confounding effect creatinine correction may have on this study.  
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Table 6.4: Correlations between protein-exosome conjugates (24 and 72 hour 
post-exposure) compared to urinary KIM-1 and NGAL (72 hours 
post-exposure) 







24 hours 0.19 0.03* 0.24 0.01* 
72 hours 0.25 0.01* 0.13 0.03* 
Cubilin 
24 hours 0.00 0.78 0.01 0.58 
72 hours 0.11 0.10 0.11 0.05* 
NCC 
24 hours 0.13 0.073 0.08 0.09 
72 hours  0.12 0.09 0.09 0.08 
Aquaporin-2  
24 hours -0.26 0.81 0.01 0.51 
72 hours -0.18 0.99 0.01 0.54 
CD24 
24 hours 0.03 0.42 0.18 0.04* 
72 hours 0.02 0.52 0.02 0.45 
Comparison of relationship between different time points post-exposure (24 and 72 
hours) to CM and the 72 hours post-exposure time point for biomarkers, KIM-1 and 
NGAL. Data is expressed as the R
2
 value of the interaction with * P < 0.05 seen as 
statistically significant. 
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Figure 6.2: Relationship between PODXL (24 and 72 hours post-exposure) and 
urinary KIM-1 and NGAL (72 hours post-exposure) 
Linear regression analyses between PODXL and markers KIM-1 and NGAL following 
significant correlations for 24 and 72 hours post-exposure respectively. A.) PODXL (24 
hours post-exposure) correlated with KIM-1 (72 hours post exposure). B.)  PODXL (72 
hours post-exposure) correlated with KIM-1 (72 hours post-exposure). C.) PODXL (24 
hours post-exposure) correlated with NGAL (72 hours post exposure) D.) PODXL (72 
hours post-exposure) correlated with KIM-1 (72 hours post-exposure). PODXL values 





statistical significance (* P < 0.05, n=32). 
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Table 6.5: Correlations between urinary creatinine corrected protein-
exosome conjugates (24 and 72 hour post-exposure) compared to 
urinary KIM-1 and NGAL (72 hours post-exposure) 







24 hours 0.15 0.06 0.28 0.001 
72 hours 0.05 0.26 0.07 0.10 
Cubilin 
24 hours 0.03 0.33 0.05 0.18 
72 hours 0.00 0.93 0.09 0.06 
NCC 
24 hours 0.13 0.073 0.05 0.19 
72 hours  0.12 0.09 0.02 0.34 
Aquaporin-2  
24 hours 0.00 0.95 0.02 0.43 
72 hours 0.05 0.30 0.03 0.33 
CD24 
24 hours 0.02 0.49 0.01 0.48 
72 hours 0.10 0.11 0.00 0.77 
Comparison of relationship between different time points post-exposure (24 and 72 
hours) to CM and the 72 hours post-exposure time point for urinary creatinine 
corrected biomarker concentrations, KIM-1 and NGAL. Data is expressed as the R
2
 
value of the interaction with * P < 0.05 seen as statistically significant 
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6.3.4 Comparing protein-exosome conjugate levels in 
different KIM-1 and NGAL tertiles before and after CM 
exposure   
The patients included in this particular study were subsequently divided into tertile 
groups based on final biomarker levels – both KIM-1 and NGAL (72 hours post-
exposure). Following this allocation, the third tertile based on KIM-1 values resulted 
in a sub-group (n=11) with a mean value of 3013 ± 1482 pg/ml urinary KIM-1 
(Table 6.6, Figure 6.4A). Urinary creatinine correction of protein-exosome 
conjugates in different tertile groups for KIM-1 (Table 6.7) and NGAL (Table 6.9) 
values are shown. To investigate the relationship of the panel of exosome protein 
markers with the AKI biomarkers in the different tertile groups, the final PODXL 
values (72hours post-exposure) showed a significant difference between the first 
tertile (low KIM-1 values) compared to the third tertile group (high KIM-1 values). 
No significant differences were found in any of the other nephron-specific protein-
exosome conjugates following allocation into tertile groups (Table 6.6, Figure 6.3B). 
Only PODXL from the panel of nephron-specific protein exosome conjugates 
showed a significant difference between different KIM-1 tertile groups (Figure 6.3C-
E).  
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Figure 6.3: Changes in NTA values of nephron-specific protein-exosome 
following allocation in tertile groups based on final KIM-1 value 
(72 hours post-exposure) 
A.) Tertile groups based on KIM-1 values.  Graphs are representative of AUC20-100 
for B.) Podocalyxin-like (PODXL) C.) Cubilin (CU); D.) Sodium-chloride co-
transporter (NCC); E.) Aquaporin-2 (AQP2) and F.) CD24 positive urinary 
exosomes number of particles, comparing different tertile groups as indicated. Data 
is expressed as the area under the curve for particles sized between 20-100nm 
(AUC20-100), expressed as mean ± SEM; * P < 0.05. 
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Table 6.6: Comparison of NTA measurements of nephron-specific protein-exosomes pre- and post-exposure to CM following 








KIM-1     
n 10 11 11 
Mean 
(pg/ml) 


























CD24  8.9 ± 8.0 3.5 ± 2.6 3.8 ± 3.3 5.0 ± 4.6 5.2 ± 8.1 4.2 ± 4.3 7.2 ± 5.7 6.0 ± 5.6 4.8 ± 3.5 
PODXL 
2.5 ± 3.9 3.2 ± 2.2 
1.8 ± 2.5  
* P < 0.05 
5.0 ± 5.1 5.4 ± 5.0 4.7 ± 5.1 5.5 ± 3.0 7.9 ± 4.7 
7.6 ± 4.9  
* P < 0.05 
CU 0.9 ± 1.5 0.7 ± 0.8 0.7 ± 0.9 2.8 ± 4.7 3.1 ± 4.6 1.5 ± 3.0 3.1 ± 2.5 3.4 ± 2.5 3.7 ± 2.8 
NCC 2.4 ± 3.2 1.9 ± 2.7 1.6 ± 3.1 2.7 ± 3.7 1.9 ± 2.3 2.0 ± 2.2 2.7 ± 4.2 3.8 ± 5.0 3.8 ± 5.6 
AQP2 1.4 ± 1.7 2.1 ± 2.6 1.4 ± 2.3 0.8 ± 1.1 1.9 ± 2.5 1.7 ± 2.2 0.5 ± 0.9 1.4 ± 2.1 0.8 ± 1.5 
Comparison of NTA measurements of nephron-specific protein-exosome conjugates following allocation of whole patient group into 
different tertile groups based on the final KIM-1 values (72 hours post-exposure). (Dara are expressed as the mean AUC of particles 
sized between 20-100nm (AUC20-100) ± SD. * P < 0.05 seen as statistically significant. n as indicated. Non-parametric ANOVA Kruskal-
Wallis test)   
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Table 6.7: Comparison of NTA measurements of creatinine corrected nephron-specific protein-exosomes pre- and post-
exposure to CM following allocation of patient group into tertile subgroups based on 72 hours post-exposure KIM-








KIM-1     
n 10 11 11 
Mean 
(pg/ml) 
























































































































Comparison of NTA measurements of creatinine corrected nephron-specific protein-exosome conjugates following allocation of whole 
patient group into different tertile groups based on the final KIM-1 values (72 hours post-exposure). (Dara are expressed as the mean 
AUC of particles sized between 20-100nm (AUC20-100) ± SD. * P < 0.05 seen as statistically significant. n as indicated. Non-parametric 
ANOVA Kruskal-Wallis test)   
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Similarly, allocation based on NGAL values, resulted in a third sub-group with a 
final NGAL value of 31.9 ± 27.9ng/ml (Table 6.8, Figure 6.4A).Comparable to the 
differences seen between PODXL (72 hours post-exposure) in the different KIM-1 
based tertile groups, based on NGAL values: PODXL also revealed a significant 
difference between the first tertile group (low NGAL values) compared to the third 
NGAL group (high NGAL values). Interestingly, the same pattern was revealed with 
significant differences found between high and low NGAL tertile groups based on 24 
hours post-exposure PODXL NTA values (Table 6.8, Figure 6.4B). Similarly, only 
PODXL from the panel of nephron-specific protein exosome conjugates showed a 
significant difference between different KIM-1 tertile groups (Figure 6.4C-E). No 
significant differences were seen following creatinine correction of the protein-
exosome conjugate concentrations in their respective tertile groups (Table 6.7 and 
6.9).  
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Figure 6.4: Changes in NTA values of nephron-specific protein-exosome 
following allocation in tertile groups based on final NGAL value 
(72 hours post-exposure) 
A.) Tertile groups based on NGAL values.  Graphs are representative of AUC20-100 
for B.) Podocalyxin-like (PODXL) C.) Cubilin (CU); D.) Sodium-chloride co-
transporter (NCC); E.) Aquaporin-2 (AQP2) and F.) CD24 positive urinary 
exosomes number of particles, comparing different tertile groups as indicated. Data 
is expressed as the area under the curve for particles sized between 20-100nm 
(AUC20-100), expressed as mean ± SEM; * P < 0.05. 
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Table 6.8: Comparison of NTA measurements of nephron-specific protein-exosomes pre- and post-exposure to CM following 








NGAL    
n 12 9 11 
Mean 
(pg/ml) 


























CD24  5.5 ± 3.9 3.1 ± 2.4 3.6 ± 2.7 10.7 ± 12.3 7.1 ± 7.1 4.1 ± 3.8 7.5± 5.1 6.1 ± 7.7 5.9 ± 4.6 
PODXL 3.1 ± 3.5 3.4 ± 2.2  
*P< 0.05 
2.4 ± 2.9  
¥ P< 0.05 
4.2 ± 3.6 3.7 ± 2.8 4.4 ± 4.9 5.4 ± 4.8  8.1 ± 5.2 
* P < 0.05 
6.4 ± 5.7 
¥P < 0.05 
CU 1.1 ± 1.4 0.7 ± 0.7 0.7 ± 0.8 2.8 ± 5.4 2.9 ± 3.6 2.2 ± 3.8 3.5 ± 4.1 4.1 ± 3.9 3.5 ± 3.3 
NCC 1.3 ± 1.9  1.2 ± 2.4 1.2 ± 2.6 2.9 ± 4.3 3.9 ± 4.2 4.1 ± 4.7 3.7 ± 4.4 3.5 ± 4.7 3.2 ± 4.4  
AQP2 0.9 ± 1.5 1.5 ± 2.4 0.7 ± 1.8 1.7 ± 2.5 3.4 ± 3.8 2.6 ± 3.1 0.6 ± 0.9 1.3 ± 1.6 1.2 ± 2.0  
Comparison of NTA measurements of nephron-specific protein-exosome conjugates following allocation of whole patient group into 
different tertile groups based on the final NGAL values (72 hours post-exposure). (Dara are expressed as the mean AUC of particles 
sized between 20-100nm (AUC20-100) ± SD. ¥ P < 0.05 statistically significant between 24 hours post-exposure values. * P < 0.05 
statistically significant between 72 hours post-exposure values. n as indicated. Non-parametric ANOVA Kruskal-Wallis test)   
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Table 6.9: Comparison of NTA measurements of nephron-specific protein-exosomes pre- and post-exposure to CM following 








NGAL     
n 10 11 11 
Mean 
(pg/ml) 




















































































































Comparison of NTA measurements of nephron-specific protein-exosome conjugates following allocation of whole patient group into 
different tertile groups based on the final KIM-1 values (72 hours post-exposure). (Dara are expressed as the mean AUC of particles 
sized between 20-100nm (AUC20-100) ± SD. * P < 0.05 seen as statistically significant. n as indicated. Non-parametric ANOVA Kruskal-
Wallis test)   
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6.4 Discussion 
The development of acute kidney injury (AKI) following the administration of 
contrast media remains one of the main aetiological factors of AKI in-hospital while 
the exact pathophysiological mechanisms of injury propagation along the nephron 
remain unclear. This chapter aimed to investigate whether the method developed in 
Chapter 3 could track changes in nephron-specific urinary exosomes in a patient 
group exposed to contrast media as a model of AKI and how this would relate to 
established kidney injury markers, KIM-1 or NGAL. Secondly, this chapter also 
aimed to discover whether NTA measurements of nephron-specific protein-exosome 
populations could provide some insights into the role exosomes may play during the 
development or progression of kidney injury along the nephron.  
Patient urine samples were obtained from a patient group exposed to contrast media, 
a known cause of AKI, pre- and post-exposure. The significant differences seen in 
urinary creatinine values pre- and post-exposure negated the use of urinary creatinine 
as an analyte and concentration normaliser for subsequent analyses in this study and 
also highlighted the importance of developing and refining a viable and more 
applicable urinary normaliser to lessen the variation usually seen and associated with 
urine analyses. The standard biomarkers of AKI, KIM-1 and NGAL both 
significantly increased in the whole study group 24 hours post-exposure. KIM-1 
however, also showed a significant increase 72 hours post-exposure to contrast 
media, which was not mirrored by NGAL. The increase in NGAL 24 hours post-
exposure, however, served to confirm NGAL as an early marker for AKI
190
.  
KIM-1 is released from the proximal tubules only during injury and the increase in 
KIM-1 across the whole study group confirmed that contrast media exposure may 
exert its damaging nephrotoxic effects through direct proximal tubule damage
191
. The 
evidence on KIM-1 as a biomarker of CI-AKI is limited with varying conclusions, 
but urinary KIM-1 levels have been shown to increase 12 hours following CM 
administration
229
. NGAL has been shown to be upregulated in kidney tubules during 
ischemic AKI and is seen as an indicator of kidney damage, showing an increase 
even 6 hours post-CM administration
230
. Additionally, NGAL has been suggested as 
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a therapeutic agent, through its protective or regenerative role in AKI by induced 
proliferation and inhibition of apoptosis of tubule epithelial cells
188
. Despite the 
numerous studies showing the biomarker potential of both KIM-1 and NGAL in CI-
AKI, there is still limitations that preclude their clinical utility as they do not provide 
information of injury or injury propagation for the whole nephron, with KIM-1 
localised to the proximal tubules and NGAL to distal tubular segments of the injured 
nephron
231
. Attempting to address these limitations, a combination, or panel, of these 
two biomarkers and the concomitant relationships with the panel of nephron-specific 
exosome proteins would therefore potentially provide information of tubular damage 
but also disease propagation along the nephron in an AKI model.  
Patient samples were analysed for glomerular/podocyte (PODXL), proximal- (CU) – 
and distal tubular (NCC), collecting duct (AQP2) and overall tubular (CD24) -
positive particles in the exosome size range of 20 - 100 nm by NTA quantification of 
antibody-specific fluorescently labelled particles. To investigate how NTA 
measurements of the panel of nephron-specific protein-exosome conjugates would 
compare to KIM-1 and NGAL as standard biomarkers of kidney injury, small but 
significant relationships were found, with podocalyxin-like protein correlating with 
both KIM-1 and NGAL. The significant correlation of the podocalyxin-like protein 
with both biomarkers as opposed to only one provided confidence which was further 
confirmed by podocalyxin-like protein showing significant differences between low 
and high biomarker tertile groups post-exposure, for both KIM-1 and NGAL.  
The positive correlation of the podocyte/glomerular marker (podocalyxin-like 
protein) with both AKI biomarkers, KIM-1 and NGAL, supports previous findings in 
Chapter 4 indicating increased exosome uptake in physiological states. In 
pathophysiological states, such as CM-induced AKI, the inverse should 
hypothetically be true with a decrease in exosome uptake along the nephron.  
Alternatively, this positive relationship of podocalyxin-like protein with the AKI 
biomarkers may indicate possible podocyte involvement during contrast media 
induced AKI. The understanding however is currently limited, but emerging research 
suggests the protective role podocytes play in injury progression
232,233
 and 
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podocalyxin-like protein being shown to be an indicator of the severity of disease 
and disease progression in AKI
234
.  
In this chapter it was demonstrated that NTA can rapidly quantify nephron-specific 
exosome populations in a patient group with increases comparable to other 
standardised biomarkers of AKI. Podocalyxin-like protein, as a podocyte marker, 
showed a relationship with two biomarkers of AKI, possibly providing more 
information of exosome uptake along the nephron in an AKI model, but also 
potentially highlighting glomerular involvement during contrast media induced AKI. 
This warrants further development and refinement, to not only develop podocalyxin-
like protein exosomes as a biomarker of AKI, but to provide further explanation of 
the exosomal mechanisms involved with disease propagation along the nephron.  
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The studies presented in this thesis aimed to better understand the role of exosomes 
in inter-cellular signalling in physiological and pathophysiological states in the 
kidney, both through the development of a new urinary exosome quantification 
method and investigating the hormonal regulation of exosome uptake in the 
collecting duct, in vitro and in vivo. The potential role of nephron segment-specific 
exosomes was also elucidated in an acute kidney injury model, highlighting the 
potential of urinary exosomes as biomarkers of kidney disease.  
7.1 Urinary exosome quantification using NTA 
The studies in Chapter 3, showed the development of a method for rapidly 
quantifying urinary exosomes. We were able to demonstrate that NTA can be used as 
a method to quantify exosome-sized particles in whole urine samples. Combining the 
fluorescent capabilities of NTA with an antibody-specific fluorescent labelling 
system reduced intra-assay variability, but also provided evidence that NTA can be 
used to differentially track exosome populations through the use of nephron segment 
specific antibodies. Furthermore, by using this newly developed method of urinary 
exosome quantification, we were able to show changes in AQP2 expression in vitro 
and in vivo, similar to previous findings relying on more standard methods of 
exosome quantification such as Western blotting
45
. Supporting this cell culture and 
rodent data, we were able to show that this method was able to rapidly track changes 
in AQP2 levels in a diabetes insipidus patient. The newly developed method further 
corroborated challenges within the field by highlighting the need for optimised and 
standardised methods of exosome isolation. Indeed, comparing the yield from two 
standard isolation methods: ultracentrifugation and ExoQuick™, revealed a large 
number of non-exosomal particles. This finding supports other research which 
showed that ExoQuick™ may also precipitate non-exosomal particles, larger proteins 
and aggregates and yield an altogether less pure exosome pellet
159
. NTA was also 
used to evaluate storage methods for urinary exosomes and revealed -80°C to be the 
optimal temperature for storage of whole urine samples, resulting in preservation of 
an increased total number of urinary exosomes, consistent with previous work
203
.   
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7.2 Vasopressin regulation of exosome uptake  
The studies in Chapter 4 and 5 were aimed at understanding the hormonal regulation 
of exosome uptake in the collecting duct to potentially better define the role of 
exosomes in inter-cellular signalling in the kidney and elucidate the underlying 
mechanisms involved.  In collecting duct cells, the role of vasopressin, as a hormonal 
regulator of exosome uptake was demonstrated for the first time. Using 4 different 
read-outs of exosome uptake – fluorescent microscopy, flow cytometry and miRNA 
transfer into cells, combined with NTA of the labelled exosomes remaining in the 
cell culture supernatant, consistently showed that desmopressin stimulation of 
collecting duct cells stimulated exosome uptake. Furthermore, we were able to 
demonstrate that the mechanism is V2-receptor mediated and cAMP/PKA 
dependent, which is in keeping with the established physiological pathway of 
vasopressin stimulation on the principal cells of the collecting duct
176
.  Exosomes 
isolated from different cell types had different uptake patterns into collecting duct 
cells. Combining these data with the opposing effect endothelin-1 had on exosome 
uptake compared to desmopressin stimulation, suggests that exosome uptake in cells 
is a tightly regulated, cell type specific process. To investigate whether vasopressin 
regulates exosome uptake in vivo, we were able to show systemic exosome uptake in 
a mouse model by measuring urinary output using NTA. Exosome excretion could be 
increased by inhibition of the V2 receptor, increasing the exosome recovery in the 
urine from 2% - 25%. This finding of systemically injected exosomes appearing in 
the urine is important for two reasons. First, investigators performing proteomic and 
transcriptomic analysis of urinary exosomes cannot assume that new biomarkers 
have originated from the kidney, and urinary non-renal exosomes may offer a non-
invasive way to assess the physiology and pathology on other (non-renal) organs. 
Second, the presence of plasma-derived exosomes in urine provides proof-of-concept 
that systemically administered novel therapeutic interventions, delivered within 
exosomes, could gain access to renal tubules. By using a clinical case study of a 
diabetes insipidus patient, we were able to track changes in urinary exosome 
populations following exogenous desmopressin administration. By using NTA 
combined with antibody-specific fluorescent tags, a decrease in upstream exosomes, 
i.e glomerular and proximal tubular occurred, suggesting decreased uptake in the 
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downstream tubules. These data are therefore consistent with our cell and mouse data 
revealing exosome uptake to be regulated by vasopressin.  
7.3 Quantification of nephron-specific human urinary 
exosomes in acute kidney injury 
In Chapter 6, in a cohort of patients treated with contrast media – a known cause of 
acute kidney injury - we were able to measure exosome populations from all 
different segments of the nephron using antibody specific NTA. In this chapter it was 
demonstrated that NTA can rapidly quantify nephron-specific exosome populations 
in this patient group. Podocalyxin-like protein, a podocyte-specific marker, was 
shown to correlate with two standard biomarkers of AKI: KIM-1 and NGAL. The 
biomarker potential of podocalyxin-like protein has been shown in a number of 
diseases, including bladder and colorectal cancer
235
 and diabetic nephropathy
236
. 
Additionally, podocalyxin-like protein was shown to be increased in during the 
recovery phase of AKI
232
. Our findings therefore possibly provides more information 
of exosome uptake along the nephron in pathophysiological states such as AKI, but 
may also highlight glomerular involvement during contrast media induced AKI.  
7.4 Future work 
The findings of the studies in this thesis have raised further questions that need to be 
answered and will be discussed below.  
7.4.1 Nomenclature of exosomes 
Despite the exponential increase in exosome research efforts, correct and definitive 
nomenclature of an ‘exosome’ remains unclear and contentious. Recent guidelines 
from within the field have attempted to address this by setting a number of minimal 
requirements for defining an extracellular vesicle as an ‘exosome’
1
. Within the scope 
of those guidelines we have endeavoured to define our population of vesicles based 
on their size predominantly, but also by surface markers known to be expressed on 
exosomal membranes, for example CD24 as a surface marker of urinary exosomes
31
.  
By using this approach we were able to develop a new method of rapidly tracking 
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changes in specific exosome populations, relevant to specific changes in the cell of 
origin. Development of this method will further the development of urinary 
exosomes as a biomarker of kidney injury and disease, but will undoubtedly be met 
with comparisons to more standard and time consuming methods of exosome 
quantification such as Western blotting. Therefore, it would be interesting to further 
develop NTA by using recent advances in other technologies as a complimentary 
approach to better define our vesicle population. Indeed, increased transmission 
electron microscopy capabilities should theoretically allow direct visualisation of an 
exosome containing our chosen fluorescent Cell Tracker™ quantum dots
237
. 
Similarly, increased confocal microscopy capabilities allow real-time visualisation of 
exosome uptake
134,204
. Combined, these advances should benefit the clear definition 
of an exosome and strengthen the relevancy of antibody-specific NTA to quantify 
exosomes within the field.   
7.4.2 Internal control for NTA quantification 
The development of tracking specific urinary exosome populations using antibody-
specific NTA holds great potential for rapidly quantifying changes in exosome 
concentrations. This may further develop urinary exosomes as a biomarker of kidney 
disease, but may also provide more information about the underlying physiological 
mechanisms of exosome-mediated cell signalling. We were able to discriminately 
track specific exosome populations. Whilst the measurements were comparable to 
changes measured by other standardised methods as highlighted in Chapter 3, 
development of an internal control will greatly refine and reduce the variability seen 
with this method. Currently, urinary creatinine is the standard normaliser for analyte 
concentration differences in urine. The assumption, however, that urinary creatinine 
remains constant between individuals is not true, indeed studies have shown the 
inter-assay variability of urinary creatinine values to be between 10 to 14% between 
individuals with marked diurnal variation
238
. Our findings supported this by 
revealing that urinary creatinine values were variable between our test volunteers 
even within  a relatively similar demographic background with the data further 
suggesting urinary creatinine as a read-out of renal function
239
, might not be an 
applicable normaliser for changes in nephron segment-specific exosome release. A 
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normaliser is, however, crucial to account for differences in spot urine concentration. 
A possible approach would be to develop a panel of potential biomarkers of AKI and 
measuring quantitative and relative abundances across the panel, which will in 
theory, provide both absolute data regarding kidney function and information of the 
underlying inter-cellular communication and propagation of disease along the 
nephron. A second possible approach for this challenge would be the identification 
and development of an internal control – for example CD24 as a pan-tubular marker, 
which could provide a baseline value to correct for concentration differences. 
Whether this exists in urinary exosomes, however, remains elusive.  
7.4.3 Pharmacological inhibitors of endocytosis 
The studies presented here provided a clathrin-dependent endocytic inhibition 
approach. Indeed by using Dynasore, described as an inhibitor of dynamin – a large 
GTPase necessary for clathrin-coated pit formation - we were able to demonstrate a 
significant decrease in exosome uptake even below that of the control, unstimulated 
cells (Chapter 4). Recently, however, Dynasore was also reported to inhibit lipid-raft 
organisation, a different endocytic pathway
240
. The use of pharmacological agents as 
inhibitors of the endocytic pathway will always be contentious with challenges of 
sensitivity and specificity coupled with unknown off-target effects
241
. The next step 
would be to include a variety of different pharmacological inhibitors for all the 
different endocytic pathways identified: clathrin-mediated, lipid raft/caveolae-
mediated endocytosis and macropinocytosis/phagocytosis, and measure not only 
their effect on exosome uptake but also on the function and structure of our specific 
cell type. For instance, by using amiloride as an inhibitor of macropinocytosis there 
was a large amount of cell death.  To further address the challenges associated with 
the use of  pharmacological inhibitors of endocytic pathways, a more specific 
approach may be the use of short-interfering RNA (siRNA) that could knockdown 
expression of proteins known to be involved with endocytosis such as clathrin heavy 
chain (CLTC), caveolin-1, and Rab34, respectively
242
. Once this method is better 
defined, it could potentially open exciting avenues of targeting exosome uptake and 
subsequent exosomal content delivery to a specific cell.  
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7.4.4 Targeted functional exosome uptake  
We were able to show hormonal regulation of exosome uptake in the collecting duct 
in vitro and in vivo. Subsequently, we were able to identify a possible mechanism 
involved with exosome uptake and showed it to be consistent with vasopressin action 
of plasma membrane endocytosis and vesicle shuttling inside the principal cells of 
the collecting duct
176
. However, it would be interesting to elucidate how exosomes 
preferentially target cells for uptake in the kidney – as we demonstrated different 
exosome uptake patterns from different cell type derived exosomes. Previous studies 
have reported exosome uptake to be dependent on the protein signature of the vesicle 
coupled with the signalling status of receptors on the recipient cell
128,243,244
. Recent 
improvements in available techniques will allow us to visually track exosome uptake 
in real-time whilst providing more quantitative read-outs in terms of increased flow 
cytometry capabilities and combined, should provide a better understanding of the 
interaction between exosome and recipient cell. A better understanding will provide 
evidence of the role of exosomes in physiological and pathophysiological states. The 
majority of exosome research efforts are currently centred on pathophysiological 
states. It is therefore crucial to employ these methods to investigate whether exosome 
uptake is functionally relevant in a physiological state and the mechanisms involved. 
Understanding exosome uptake physiologically, will help to better target exosomes 
as therapeutic agents – delivering specific content to a defined site of action.  
7.4.5 Podocalyxyin-like protein as biomarker of AKI 
Contrast media exposure have been shown to be a direct cause of AKI specifically 
through its nephrotoxic effects on the renal tubular cells
245
. Using our newly 
developed method of antibody-specific NTA, we however, found podocalyxin-like 
protein as a podocyte specific marker, to be well correlated with both KIM-1 and 
NGAL as standard biomarkers of AKI. It may suggest we were able to track 
propogation of AKI along the nephron by increased podocalyxin-like protein 
indicating recovery from AKI in a previous study
236
 and may similarly suggest 
tubular injury leading to reduced exosome uptake capabilities of downstream 
segments of the nephron. This, however, needs to be elucidated. It is important to 
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consider as caveats not only the small patient group, but also the researchers still 
being blinded to the patient outcome at time of study. Whether stratification of 
patients into groups who ultimately developed AKI would provide further 
information or a different exosomal pattern remains to be elucidated.  
The development of urinary exosomes as not only a biomarker, but also as a 
therapeutic agent in kidney disease is an exciting and valuable field to focus research 
efforts. To exploit this inherent potential in pathophysiological states, it is crucial to 
understand the role exosomes play in intercellular signalling in physiological states. 
The work presented in this thesis has highlighted the limitations and challenges 
related to exosome research and have addressed this with the development of a new, 
rapid method of exosome quantification. Furthermore, the work has also showed 
physiological regulation of exosome uptake in the kidney collecting duct by 
vasopressin stimulation and has elucidated the mechanism involved. Combined with 
exosome secretion in an AKI model, this provide a clearer understanding of 
regulation of exosome uptake along the nephron in both physiological and 
pathophysiological states and should support further research within the field of 




1. Lötvall, J. O. et al. Minimal experimental requirements for definition of 
extracellular vesicles and their functions: a position statement from the 
International Society for Extracellular Vesicles. J. Extracell. Vesicles 3, (2014). 
2. Van Niel, G. et al. Intestinal epithelial cells secrete exosome-like vesicles. 
Gastroenterology 121, 337–349 (2001). 
3. Van Balkom, B. W. M., Pisitkun, T., Verhaar, M. C. & Knepper, M. A. 
Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. 
Kidney Int. 80, 1138–1145 (2011). 
4. Mittelbrunn, M. et al. Unidirectional transfer of microRNA-loaded exosomes 
from T cells to antigen-presenting cells. Nat. Commun. 2, 282 (2011). 
5. Caby, M.-P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G. & Bonnerot, C. 
Exosomal-like vesicles are present in human blood plasma. Int. Immunol. 17, 
879–887 (2005). 
6. Almqvist, N., Lonnqvist, A., Hultkrantz, S., Rask, C. & Telemo, E. Serum-
derived exosomes from antigen-fed mice prevent allergic sensitization in a 
model of allergic asthma. Immunology 125, 21–27 (2008). 
7. Lässer, C. et al. Human saliva, plasma and breast milk exosomes contain RNA: 
uptake by macrophages. J. Transl. Med. 9, 9 (2011). 
8. Pisitkun, T., Shen, R.-F. & Knepper, M. A. Identification and proteomic 
profiling of exosomes in human urine. Proc. Natl. Acad. Sci. U. S. A. 101, 
13368–13373 (2004). 
9. Thery, C. et al. Molecular Characterization of Dendritic Cell-Derived 
Exosomes. J. Cell Biol. 147, 599–610 (1999). 
10. Rana, S., Malinowska, K. & Zoller, M. Exosomal Tumor MicroRNA Modulates 
Premetastatic Organ Cells. Neoplasia N. Y. N 15, 281–295 (2013). 
References 150 
11. Stoorvogel, W., Kleijmeer, M. J., Geuze, H. J. & Raposo, G. The biogenesis 
and functions of exosomes. Traffic Cph. Den. 3, 321–330 (2002). 
12. Théry, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis 
and function. Nat. Rev. Immunol. 2, 569–579 (2002). 
13. Bobrie, A., Colombo, M., Raposo, G. & Théry, C. Exosome secretion: 
molecular mechanisms and roles in immune responses. Traffic Cph. Den. 12, 
1659–1668 (2011). 
14. Raposo, G. & Stoorvogel, W. Extracellular vesicles: Exosomes, microvesicles, 
and friends. J. Cell Biol. 200, 373–383 (2013). 
15. Lobb, R. J. et al. Optimized exosome isolation protocol for cell culture 
supernatant and human plasma. J. Extracell. Vesicles 4, (2015). 
16. Musante, L., Saraswat, M., Ravidà, A., Byrne, B. & Holthofer, H. Recovery of 
urinary nanovesicles from ultracentrifugation supernatants. Nephrol. Dial. 
Transplant. 28, 1425–1433 (2013). 
17. Kalra, H. et al. Comparative proteomics evaluation of plasma exosome isolation 
techniques and assessment of the stability of exosomes in normal human blood 
plasma. Proteomics 13, 3354–3364 (2013). 
18. Lamparski, H. G. et al. Production and characterization of clinical grade 
exosomes derived from dendritic cells. J. Immunol. Methods 270, 211–226 
(2002). 
19. Liga, A., Vliegenthart, A. D. B., Oosthuyzen, W., Dear, J. W. & Kersaudy-
Kerhoas, M. Exosome isolation: a microfluidic road-map. Lab. Chip 15, 2388–
2394 (2015). 
20. Muller, L., Hong, C.-S., Stolz, D. B., Watkins, S. C. & Whiteside, T. L. 
Isolation of biologically-active exosomes from human plasma. J. Immunol. 
Methods 411, 55–65 (2014). 
References 151 
21. Cheruvanky, A. et al. Rapid isolation of urinary exosomal biomarkers using a 
nanomembrane ultrafiltration concentrator. Am. J. Physiol. Renal Physiol. 292, 
F1657–F1661 (2007). 
22. Nordin, J. Z. et al. Ultrafiltration with size-exclusion liquid chromatography for 
high yield isolation of extracellular vesicles preserving intact biophysical and 
functional properties. Nanomedicine Nanotechnol. Biol. Med. 11, 879–883 
(2015). 
23. Rood, I. M. et al. Comparison of three methods for isolation of urinary 
microvesicles to identify biomarkers of nephrotic syndrome. Kidney Int. 78, 
810–816 (2010). 
24. Théry, C., Amigorena, S., Raposo, G. & Clayton, A. in Current Protocols in 
Cell Biology (John Wiley & Sons, Inc., 2001).  
25. Van Deun, J. et al. The impact of disparate isolation methods for extracellular 
vesicles on downstream RNA profiling. J. Extracell. Vesicles 3, (2014). 
26. Huang, X. et al. Characterization of human plasma-derived exosomal RNAs by 
deep sequencing. BMC Genomics 14, 319 (2013). 
27. Zubiri, I. et al. Diabetic nephropathy induces changes in the proteome of human 
urinary exosomes as revealed by label-free comparative analysis. J. Proteomics 
96, 92–102 (2014). 
28. Park, J. & Choi, Y. Exosome identification for personalized diagnosis and 
therapy. Biomed. Eng. Lett. 4, 258–268 (2014). 
29. Im, H. et al. Label-free detection and molecular profiling of exosomes with a 
nano-plasmonic sensor. Nat. Biotechnol. 32, 490–495 (2014). 
30. Fevrier, B. et al. Cells release prions in association with exosomes. Proc. Natl. 
Acad. Sci. U. S. A. 101, 9683–9688 (2004). 
References 152 
31. Keller, S. et al. CD24 is a marker of exosomes secreted into urine and amniotic 
fluid. Kidney Int. 72, 1095–1102 (2007). 
32. Tian, T., Wang, Y., Wang, H., Zhu, Z. & Xiao, Z. Visualizing of the cellular 
uptake and intracellular trafficking of exosomes by live-cell microscopy. J. 
Cell. Biochem. 111, 488–496 (2010). 
33. Suetsugu, A. et al. Imaging exosome transfer from breast cancer cells to stroma 
at metastatic sites in orthotopic nude-mouse models. Adv. Drug Deliv. Rev. 65, 
383–390 (2013). 
34. Dragovic, R. A. et al. Sizing and phenotyping of cellular vesicles using 
Nanoparticle Tracking Analysis. Nanomedicine Nanotechnol. Biol. Med. 7, 
780–788 (2011). 
35. Gardiner, C., Ferreira, Y. J., Dragovic, R. A., Redman, C. W. G. & Sargent, I. 
L. Extracellular vesicle sizing and enumeration by nanoparticle tracking 
analysis. J. Extracell. Vesicles 2, (2013). 
36. Mathivanan, S. & Simpson, R. J. ExoCarta: A compendium of exosomal 
proteins and RNA. Proteomics 9, 4997–5000 (2009). 
37. Gonzales, P. A. et al. Large-Scale Proteomics and Phosphoproteomics of 
Urinary Exosomes. J. Am. Soc. Nephrol. 20, 363–379 (2009). 
38. Kowal, J., Tkach, M. & Théry, C. Biogenesis and secretion of exosomes. Curr. 
Opin. Cell Biol. 29, 116–125 (2014). 
39. Conde-Vancells, J. et al. Characterization and Comprehensive Proteome 
Profiling of Exosomes Secreted by Hepatocytes. J. Proteome Res. 7, 5157–
5166 (2008). 
40. Laulagnier, K. et al. Mast cell- and dendritic cell-derived exosomes display a 
specific lipid composition and an unusual membrane organization. Biochem. J. 
380, 161–171 (2004). 
References 153 
41. Wubbolts, R. et al. Proteomic and Biochemical Analyses of Human B Cell-
derived Exosomes POTENTIAL IMPLICATIONS FOR THEIR FUNCTION 
AND MULTIVESICULAR BODY FORMATION. J. Biol. Chem. 278, 10963–
10972 (2003). 
42. De Jong, O. G. et al. Cellular stress conditions are reflected in the protein and 
RNA content of endothelial cell-derived exosomes. J. Extracell. Vesicles 1, 
(2012). 
43. Rastaldi, M. P. et al. Glomerular podocytes possess the synaptic vesicle 
molecule Rab3A and its specific effector rabphilin-3a. Am. J. Pathol. 163, 889–
899 (2003). 
44. Street, J. M. et al. Exosomal transmission of functional aquaporin 2 in kidney 
cortical collecting duct cells. J. Physiol. 589, 6119–6127 (2011). 
45. Yang, J. C.-S. et al. Altered exosomal protein expression in the serum of NF-κB 
knockout mice following skeletal muscle ischemia-reperfusion injury. J. 
Biomed. Sci. 22, 40 (2015). 
46. Colombo, M., Raposo, G. & Théry, C. Biogenesis, Secretion, and Intercellular 
Interactions of Exosomes and Other Extracellular Vesicles. Annu. Rev. Cell 
Dev. Biol. 30, 255–289 (2014). 
47. Record, M., Carayon, K., Poirot, M. & Silvente-Poirot, S. Exosomes as new 
vesicular lipid transporters involved in cell-cell communication and various 
pathophysiologies. Biochim. Biophys. Acta 1841, 108–120 (2014). 
48. Carayon, K. et al. Proteolipidic Composition of Exosomes Changes during 
Reticulocyte Maturation. J. Biol. Chem. 286, 34426–34439 (2011). 
49. Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a 
novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659 
(2007). 
50. Zomer, A. et al. Exosomes. Commun. Integr. Biol. 3, 447–450 (2010). 
References 154 
51. Pegtel, D. M. et al. Functional delivery of viral miRNAs via exosomes. Proc. 
Natl. Acad. Sci. 107, 6328–6333 (2010). 
52. Ekström, K. et al. Characterization of mRNA and microRNA in human mast 
cell-derived exosomes and their transfer to other mast cells and blood CD34 
progenitor cells. J. Extracell. Vesicles 1, (2012). 
53. Van Balkom, B. W. M., Eisele, A. S., Pegtel, D. M., Bervoets, S. & Verhaar, 
M. C. Quantitative and qualitative analysis of small RNAs in human endothelial 
cells and exosomes provides insights into localized RNA processing, 
degradation and sorting. J. Extracell. Vesicles 4, 26760 (2015). 
54. Batagov, A. O. & Kurochkin, I. V. Exosomes secreted by human cells transport 
largely mRNA fragments that are enriched in the 3′-untranslated regions. Biol. 
Direct 8, 12 (2013). 
55. Alvarez, S. et al. Urinary exosomes as a source of kidney dysfunction 
biomarker in renal transplantation. Transplant. Proc. 45, 3719–3723 (2013). 
56. Villarroya-Beltri, C. et al. Sumoylated hnRNPA2B1 controls the sorting of 
miRNAs into exosomes through binding to specific motifs. Nat. Commun. 4, 
2980 (2013). 
57. Guay, C., Menoud, V., Rome, S. & Regazzi, R. Horizontal transfer of exosomal 
microRNAs transduce apoptotic signals between pancreatic beta-cells. Cell 
Commun. Signal. 13, 17 (2015). 
58. Eldh, M. et al. Exosomes Communicate Protective Messages during Oxidative 
Stress; Possible Role of Exosomal Shuttle RNA. PLoS ONE 5, e15353 (2010). 
59. Chevillet, J. R. et al. Quantitative and stoichiometric analysis of the microRNA 
content of exosomes. Proc. Natl. Acad. Sci. 111, 14888–14893 (2014). 
60. Turchinovich, A., Weiz, L., Langheinz, A. & Burwinkel, B. Characterization of 
extracellular circulating microRNA. Nucleic Acids Res. 39, 7223–7233 (2011). 
References 155 
61. Arroyo, J. D. et al. Argonaute2 complexes carry a population of circulating 
microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. 
S. A. 108, 5003–5008 (2011). 
62. Johnstone, R. M., Adam, M., Hammond, J. R., Orr, L. & Turbide, C. Vesicle 
formation during reticulocyte maturation. Association of plasma membrane 
activities with released vesicles (exosomes). J. Biol. Chem. 262, 9412–9420 
(1987). 
63. Szabo, G. & Bala, S. MicroRNAs in liver disease. Nat. Rev. Gastroenterol. 
Hepatol. 10, 542–552 (2013). 
64. Guescini, M. et al. C2C12 myoblasts release micro-vesicles containing mtDNA 
and proteins involved in signal transduction. Exp. Cell Res. 316, 1977–1984 
(2010). 
65. Zhang, B., Asadi, S., Weng, Z., Sismanopoulos, N. & Theoharides, T. C. 
Stimulated Human Mast Cells Secrete Mitochondrial Components That Have 
Autocrine and Paracrine Inflammatory Actions. PLoS ONE 7, (2012). 
66. Thakur, B. K. et al. Double-stranded DNA in exosomes: a novel biomarker in 
cancer detection. Cell Res. 24, 766–769 (2014). 
67. Kahlert, C. et al. Identification of Double-stranded Genomic DNA Spanning 
All Chromosomes with Mutated KRAS and p53 DNA in the Serum Exosomes 
of Patients with Pancreatic Cancer. J. Biol. Chem. 289, 3869–3875 (2014). 
68. Montermini, L. et al. Inhibition of Oncogenic Epidermal Growth Factor 
Receptor Kinase Triggers Release of Exosome-like Extracellular Vesicles and 
Impacts Their Phosphoprotein and DNA Content. J. Biol. Chem. 290, 24534–
24546 (2015). 
69. Melo, S. A. et al. Glypican-1 identifies cancer exosomes and detects early 
pancreatic cancer. Nature 523, 177–182 (2015). 
References 156 
70. Campanella, C. et al. Heat shock protein 60 levels in tissue and circulating 
exosomes in human large bowel cancer before and after ablative surgery. 
Cancer 121, 3230–3239 (2015). 
71. Qazi, K. R. et al. Proinflammatory exosomes in bronchoalveolar lavage fluid of 
patients with sarcoidosis. Thorax (2010). 
72. Goetzl, E. J. et al. Altered lysosomal proteins in neural-derived plasma 
exosomes in preclinical Alzheimer disease. Neurology (2015). 
73. Tomlinson, P. R. et al. Identification of distinct circulating exosomes in 
Parkinson’s disease. Ann. Clin. Transl. Neurol. 2, 353–361 (2015). 
74. Zhou, H. et al. Exosomal Fetuin-A identified by proteomics: a novel urinary 
biomarker for detecting acute kidney injury. Kidney Int. 70, 1847–1857 (2006). 
75. Kalani, A. et al. Wilm’s tumor-1 protein levels in urinary exosomes from 
diabetic patients with or without proteinuria. PloS One 8, e60177 (2013). 
76. Khan, S. et al. Plasma-Derived Exosomal Survivin, a Plausible Biomarker for 
Early Detection of Prostate Cancer. PLoS ONE 7, (2012). 
77. Szajnik, M. et al. Exosomes in Plasma of Patients with Ovarian Carcinoma: 
Potential Biomarkers of Tumor Progression and Response to Therapy. Gynecol. 
Obstet. Sunnyvale Calif Suppl 4, 3 (2013). 
78. Guan, M. et al. MDA-9 and GRP78 as potential diagnostic biomarkers for early 
detection of melanoma metastasis. Tumour Biol. J. Int. Soc. Oncodevelopmental 
Biol. Med. 36, 2973–2982 (2015). 
79. Madhavan, B. et al. Combined evaluation of a panel of protein and miRNA 
serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity 
and specificity. Int. J. Cancer 136, 2616–2627 (2015). 
References 157 
80. Olimón-Andalón, V. et al. Proapoptotic CD95L levels in normal human serum 
and sera of breast cancer patients. Tumour Biol. J. Int. Soc. Oncodevelopmental 
Biol. Med. 36, 3669–3678 (2015). 
81. Yang, J., Wei, F., Schafer, C. & Wong, D. T. W. Detection of Tumor Cell-
Specific mRNA and Protein in Exosome-Like Microvesicles from Blood and 
Saliva. PLoS ONE 9, (2014). 
82. Sivadasan, P. et al. Human salivary proteome — a resource of potential 
biomarkers for oral cancer. J. Proteomics 127, Part A, 89–95 (2015). 
83. Lau, C. et al. Role of pancreatic cancer-derived exosomes in salivary biomarker 
development. J. Biol. Chem. 288, 26888–26897 (2013). 
84. Choi, D.-S., Kim, D.-K., Kim, Y.-K. & Gho, Y. S. Proteomics of extracellular 
vesicles: Exosomes and ectosomes. Mass Spectrom. Rev. n/a–n/a (2014). 
doi:10.1002/mas.21420 
85. Ho, D. H., Yi, S., Seo, H., Son, I. & Seol, W. Increased DJ-1 in urine exosome 
of Korean males with Parkinson’s disease. BioMed Res. Int. 2014, 704678 
(2014). 
86. Van der Lubbe, N. et al. The phosphorylated sodium chloride cotransporter in 
urinary exosomes is superior to prostasin as a marker for aldosteronism. 
Hypertension 60, 741–748 (2012). 
87. Trnka, P., Ivanova, L., Hiatt, M. J. & Matsell, D. G. Urinary biomarkers in 
obstructive nephropathy. Clin. J. Am. Soc. Nephrol. CJASN 7, 1567–1575 
(2012). 
88. Sun, A. et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in 
diabetic kidney disease. Diab. Vasc. Dis. Res. 9, 301–308 (2012). 
89. Jenjaroenpun, P. et al. Characterization of RNA in exosomes secreted by 
human breast cancer cell lines using next-generation sequencing. PeerJ 1, e201 
(2013). 
References 158 
90. Shao, H. et al. Chip-based analysis of exosomal mRNA mediating drug 
resistance in glioblastoma. Nat. Commun. 6, (2015). 
91. Skog, J. et al. Glioblastoma microvesicles transport RNA and protein that 
promote tumor growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 
1470–1476 (2008). 
92. Xiao, D. et al. Identifying mRNA, MicroRNA and Protein Profiles of 
Melanoma Exosomes. PLoS ONE 7, e46874 (2012). 
93. Spanu, S., van Roeyen, C. R. C., Denecke, B., Floege, J. & Mühlfeld, A. S. 
Urinary Exosomes: A Novel Means to Non-Invasively Assess Changes in Renal 
Gene and Protein Expression. PLoS ONE 9, e109631 (2014). 
94. Lv, L.-L. et al. CD2AP mRNA in urinary exosome as biomarker of kidney 
disease. Clin. Chim. Acta Int. J. Clin. Chem. 428, 26–31 (2014). 
95. Manterola, L. et al. A small noncoding RNA signature found in exosomes of 
GBM patient serum as a diagnostic tool. Neuro-Oncol. 16, 520–527 (2014). 
96. Li, Q. et al. Plasma long noncoding RNA protected by exosomes as a potential 
stable biomarker for gastric cancer. Tumour Biol. J. Int. Soc. 
Oncodevelopmental Biol. Med. 36, 2007–2012 (2015). 
97. Matsumura, T. et al. Exosomal microRNA in serum is a novel biomarker of 
recurrence in human colorectal cancer. Br. J. Cancer 113, 275–281 (2015). 
98. Bala, S. et al. Circulating microRNAs in exosomes indicate hepatocyte injury 
and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. 
Hepatol. Baltim. Md 56, 1946–1957 (2012). 
99. Lv, L.-L. et al. MicroRNA-29c in urinary exosome/microvesicle as a biomarker 
of renal fibrosis. Am. J. Physiol. Renal Physiol. 305, F1220–1227 (2013). 
100. Hornick, N. I. et al. Serum Exosome MicroRNA as a Minimally-Invasive Early 
Biomarker of AML. Sci. Rep. 5, 11295 (2015). 
References 159 
101. Tanaka, Y. et al. Clinical impact of serum exosomal microRNA-21 as a clinical 
biomarker in human esophageal squamous cell carcinoma. Cancer 119, 1159–
1167 (2013). 
102. Barutta, F. et al. Urinary Exosomal MicroRNAs in Incipient Diabetic 
Nephropathy. PLoS ONE 8, (2013). 
103. Gallagher, I. J. et al. Integration of microRNA changes in vivo identifies novel 
molecular features of muscle insulin resistance in type 2 diabetes. Genome Med. 
2, 9 (2010). 
104. Perez-Hernandez, J. et al. Increased Urinary Exosomal MicroRNAs in Patients 
with Systemic Lupus Erythematosus. PloS One 10, (2015). 
105. Li, Y. et al. Identification of Endogenous Controls for Analyzing Serum 
Exosomal miRNA in Patients with Hepatitis B or Hepatocellular Carcinoma, 
Identification of Endogenous Controls for Analyzing Serum Exosomal miRNA 
in Patients with Hepatitis B or Hepatocellular Carcinoma. Dis. Markers Dis. 
Markers 2015, 2015, e893594 (2015). 
106. Sugimachi, K. et al. Identification of a bona fide microRNA biomarker in 
serum exosomes that predicts hepatocellular carcinoma recurrence after liver 
transplantation. Br. J. Cancer 112, 532–538 (2015). 
107. Wang, H. et al. Expression of serum exosomal microRNA-21 in human 
hepatocellular carcinoma. BioMed Res. Int. 2014, 864894 (2014). 
108. Eichelser, C. et al. Increased serum levels of circulating exosomal microRNA-
373 in receptor-negative breast cancer patients. Oncotarget 5, 9650–9663 
(2014). 
109. Chiam, K. et al. Circulating Serum Exosomal miRNAs As Potential Biomarkers 
for Esophageal Adenocarcinoma. J. Gastrointest. Surg. Off. J. Soc. Surg. 
Aliment. Tract 19, 1208–1215 (2015). 
References 160 
110. Wang, J. et al. Combined detection of serum exosomal miR-21 and HOTAIR as 
diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. 
Med. Oncol. Northwood Lond. Engl. 31, 148 (2014). 
111. Alegre, E. et al. Study of circulating microRNA-125b levels in serum exosomes 
in advanced melanoma. Arch. Pathol. Lab. Med. 138, 828–832 (2014). 
112. Povero, D. et al. Circulating Extracellular Vesicles with Specific Proteome and 
Liver MicroRNAs Are Potential Biomarkers for Liver Injury in Experimental 
Fatty Liver Disease. PLoS ONE 9, (2014). 
113. Lugli, G. et al. Plasma Exosomal miRNAs in Persons with and without 
Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PloS 
One 10, e0139233 (2015). 
114. Huang, X. et al. Exosomal miR-1290 and miR-375 as prognostic markers in 
castration-resistant prostate cancer. Eur. Urol. 67, 33–41 (2015). 
115. Cazzoli, R. et al. microRNAs derived from circulating exosomes as noninvasive 
biomarkers for screening and diagnosing lung cancer. J. Thorac. Oncol. Off. 
Publ. Int. Assoc. Study Lung Cancer 8, 1156–1162 (2013). 
116. Halkein, J. et al. MicroRNA-146a is a therapeutic target and biomarker for 
peripartum cardiomyopathy. J. Clin. Invest. 123, 2143–2154 (2013). 
117. Corcoran, C., Rani, S. & O’Driscoll, L. miR-34a is an intracellular and 
exosomal predictive biomarker for response to docetaxel with clinical relevance 
to prostate cancer progression. The Prostate 74, 1320–1334 (2014). 
118. Cheng, Y. et al. A translational study of urine miRNAs in acute myocardial 
infarction. J. Mol. Cell. Cardiol. 53, 668–676 (2012). 
119. Wang, G. et al. Urinary miR-21, miR-29, and miR-93: novel biomarkers of 
fibrosis. Am. J. Nephrol. 36, 412–418 (2012). 
References 161 
120. Singh, J., Deshpande, M., Suhail, H., Rattan, R. & Giri, S. Targeted Stage-
Specific Inflammatory microRNA Profiling in Urine During Disease 
Progression in Experimental Autoimmune Encephalomyelitis: Markers of 
Disease Progression and Drug Response. J. Neuroimmune Pharmacol. Off. J. 
Soc. NeuroImmune Pharmacol. (2015). 
121. Zhou, J. et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian 
serous adenocarcinoma. Oncol. Rep. 33, 2915–2923 (2015). 
122. Ichii, O. et al. Decreased miR-26a expression correlates with the progression of 
podocyte injury in autoimmune glomerulonephritis. PloS One 9, e110383 
(2014). 
123. Solé, C., Cortés-Hernández, J., Felip, M. L., Vidal, M. & Ordi-Ros, J. miR-29c 
in urinary exosomes as predictor of early renal fibrosis in lupus nephritis. 
Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. 
Assoc. 30, 1488–1496 (2015). 
124. Yoshida, Y., Yamamoto, H. & Morita, R. Detection of DNA methylation of 
gastric juice-derived exosomes in gastric cancer. Integr. Mol. Med. (2014). 
125. Lázaro-Ibáñez, E. et al. Different gDNA content in the subpopulations of 
prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and 
exosomes. The Prostate 74, 1379–1390 (2014). 
126. Sung, B. H., Ketova, T., Hoshino, D., Zijlstra, A. & Weaver, A. M. Directional 
cell movement through tissues is controlled by exosome secretion. Nat. 
Commun. 6, (2015). 
127. Hannafon, B. N. & Ding, W.-Q. Intercellular Communication by Exosome-
Derived microRNAs in Cancer. Int. J. Mol. Sci. 14, 14240–14269 (2013). 
128. Lenassi, M. et al. HIV Nef is secreted in exosomes and triggers apoptosis in 
bystander CD4+ T cells. Traffic Cph. Den. 11, 110–122 (2010). 
References 162 
129. Bukong, T. N., Momen-Heravi, F., Kodys, K., Bala, S. & Szabo, G. Exosomes 
from Hepatitis C Infected Patients Transmit HCV Infection and Contain 
Replication Competent Viral RNA in Complex with Ago2-miR122-HSP90. 
PLoS Pathog 10, e1004424 (2014). 
130. Feng, D. et al. Cellular Internalization of Exosomes Occurs Through 
Phagocytosis. Traffic 11, 675–687 (2010). 
131. Frühbeis, C. et al. Neurotransmitter-Triggered Transfer of Exosomes Mediates 
Oligodendrocyte–Neuron Communication. PLoS Biol 11, e1001604 (2013). 
132. Parolini, I. et al. Microenvironmental pH Is a Key Factor for Exosome Traffic 
in Tumor Cells. J. Biol. Chem. 284, 34211–34222 (2009). 
133. Lai, C. P. et al. Visualization and tracking of tumour extracellular vesicle 
delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 
7029 (2015). 
134. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic 
injection of targeted exosomes. Nat. Biotechnol. 29, 341–345 (2011). 
135. Lotvall, J. & Valadi, H. Cell to Cell Signalling via Exosomes Through esRNA. 
Cell Adhes. Migr. 1, 156–158 (2007). 
136. Friedman, R. C., Farh, K. K.-H., Burge, C. B. & Bartel, D. P. Most mammalian 
mRNAs are conserved targets of microRNAs. Genome Res. 19, 92–105 (2009). 
137. Kosaka, N. & Ochiya, T. Unraveling the mystery of cancer by secretory 
microRNA: horizontal microRNA transfer between living cells. RNA 2, 97 
(2012). 
138. Khan, M. et al. Embryonic stem cell-derived exosomes promote endogenous 
repair mechanisms and enhance cardiac function following myocardial 
infarction. Circ. Res. 117, 52–64 (2015). 
References 163 
139. Ibrahim, A. G.-E., Cheng, K. & Marbán, E. Exosomes as Critical Agents of 
Cardiac Regeneration Triggered by Cell Therapy. Stem Cell Rep. 2, 606–619 
(2014). 
140. Momen-Heravi, F., Bala, S., Kodys, K. & Szabo, G. Exosomes derived from 
alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and 
sensitize monocytes to LPS. Sci. Rep. 5, 9991 (2015). 
141. Yoon, C. et al. Delivery of miR-155 to retinal pigment epithelial cells mediated 
by Burkitt’s lymphoma exosomes. Tumour Biol. J. Int. Soc. Oncodevelopmental 
Biol. Med. (2015). 
142. Bala, S. et al. Biodistribution and function of extracellular miRNA-155 in mice. 
Sci. Rep. 5, 10721 (2015). 
143. Alexander, M. et al. Exosome-delivered microRNAs modulate the 
inflammatory response to endotoxin. Nat. Commun. 6, 7321 (2015). 
144. Wang, X. et al. Exosomal miR-223 Contributes to Mesenchymal Stem Cell-
Elicited Cardioprotection in Polymicrobial Sepsis. Sci. Rep. 5, 13721 (2015). 
145. Deng, L. et al. miR-143 Activation Regulates Smooth Muscle and Endothelial 
Cell Crosstalk in Pulmonary Arterial Hypertension. Circ. Res. (2015). 
146. Chen, L., Chen, R., Kemper, S., Charrier, A. & Brigstock, D. R. Suppression of 
fibrogenic signaling in hepatic stellate cells by Twist1-dependent microRNA-
214 expression: Role of exosomes in horizontal transfer of Twist1. Am. J. 
Physiol. - Gastrointest. Liver Physiol. 309, G491–G499 (2015). 
147. Masyuk, A. I. et al. Biliary exosomes influence cholangiocyte regulatory 
mechanisms and proliferation through interaction with primary cilia. Am. J. 
Physiol. Gastrointest. Liver Physiol. 299, G990–999 (2010). 
148. Wei, Y. et al. Exosomal miR-221/222 enhances tamoxifen resistance in 
recipient ER-positive breast cancer cells. Breast Cancer Res. Treat. 147, 423–
431 (2014). 
References 164 
149. Ye, S.-B. et al. Tumor-derived exosomes promote tumor progression and T-cell 
dysfunction through the regulation of enriched exosomal microRNAs in human 
nasopharyngeal carcinoma. Oncotarget 5, 5439–5452 (2014). 
150. Bronisz, A. et al. Extracellular vesicles modulate the glioblastoma 
microenvironment via a tumor suppression signaling network directed by miR-
1. Cancer Res. 74, 738–750 (2014). 
151. Aucher, A., Rudnicka, D. & Davis, D. M. MicroRNAs transfer from human 
macrophages to hepato-carcinoma cells and inhibit proliferation. J. Immunol. 
Baltim. Md 1950 191, 6250–6260 (2013). 
152. Forterre, A. et al. Myotube-derived exosomal miRNAs downregulate Sirtuin1 
in myoblasts during muscle cell differentiation. Cell Cycle Georget. Tex 13, 78–
89 (2014). 
153. Van Balkom, B. W. M. et al. Endothelial cells require miR-214 to secrete 
exosomes that suppress senescence and induce angiogenesis in human and 
mouse endothelial cells. Blood 121, 3997–4006, S1–15 (2013). 
154. Esquilin, Y., Queenan, C., Calabro, A. & Leonardi, D. mtDNA Migration and 
the Role of Exosomes in Horizontal Gene Transfer. Microsc. Microanal. 18, 
286–287 (2012). 
155. Lamichhane, T. N., Raiker, R. S. & Jay, S. M. Exogenous DNA Loading into 
Extracellular Vesicles via Electroporation is Size-Dependent and Enables 
Limited Gene Delivery. Mol. Pharm. (2015). 
156. Hoorn, E. J., Pisitkun, T., Yu, M.-J. & Knepper, M. A. Proteomic approaches 
for the study of cell signaling in the renal collecting duct. Contrib. Nephrol. 
160, 172–185 (2008). 
157. Miranda, K. C. et al. Nucleic acids within urinary exosomes/microvesicles are 
potential biomarkers for renal disease. Kidney Int. 78, 191–199 (2010). 
References 165 
158. Alvarez, M. L., Khosroheidari, M., Ravi, R. K. & DiStefano, J. K. Comparison 
of protein, microRNA, and mRNA yields using different methods of urinary 
exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 
82, 1024–1032 (2012). 
159. Kozyraki, R. et al. The human intrinsic factor-vitamin B12 receptor, cubilin: 
molecular characterization and chromosomal mapping of the gene to 10p within 
the autosomal recessive megaloblastic anemia (MGA1) region. Blood 91, 3593–
3600 (1998). 
160. De, S., Kuwahara, S. & Saito, A. The Endocytic Receptor Megalin and its 
Associated Proteins in Proximal Tubule Epithelial Cells. Membranes 4, 333–
355 (2014). 
161. Corbetta, S. et al. Urinary exosomes in the diagnosis of Gitelman and Bartter 
syndromes. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - 
Eur. Ren. Assoc. 30, 621–630 (2015). 
162. Sonoda, H. et al. Decreased abundance of urinary exosomal aquaporin-1 in 
renal ischemia-reperfusion injury. Am. J. Physiol. - Ren. Physiol. 297, F1006–
F1016 (2009). 
163. Hoorn, E. J. et al. Prospects for urinary proteomics: Exosomes as a source of 
urinary biomarkers (Review Article). Nephrology 10, 283–290 (2005). 
164. Goodison, S., Rosser, C. J. & Urquidi, V. Bladder Cancer Detection and 
Monitoring: Assessment of Urine- and Blood-Based Marker Tests. Mol. Diagn. 
Ther. 17, 71–84 (2013). 
165. Gildea, J. J. et al. Exosomal transfer from human renal proximal tubule cells to 
distal tubule and collecting duct cells. Clin. Biochem. 47, 89–94 (2014). 
166. Van Koppen, A. et al. Human Embryonic Mesenchymal Stem Cell-Derived 
Conditioned Medium Rescues Kidney Function in Rats with Established 
Chronic Kidney Disease. PLoS ONE 7, e38746 (2012). 
References 166 
167. Bruno, S. et al. Microvesicles Derived from Mesenchymal Stem Cells Enhance 
Survival in a Lethal Model of Acute Kidney Injury. PLoS ONE 7, (2012). 
168. Tomasoni, S. et al. Transfer of growth factor receptor mRNA via exosomes 
unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 22, 
772–780 (2013). 
169. Burger, D. et al. Human endothelial colony-forming cells protect against acute 
kidney injury: role of exosomes. Am. J. Pathol. 185, 2309–2323 (2015). 
170. Borges, F. T. et al. TGF-β1–Containing Exosomes from Injured Epithelial Cells 
Activate Fibroblasts to Initiate Tissue Regenerative Responses and Fibrosis. J. 
Am. Soc. Nephrol. JASN 24, 385–392 (2013). 
171. Zhou, Y. et al. Exosomes released by human umbilical cord mesenchymal stem 
cells protect against cisplatin-induced renal oxidative stress and apoptosis in 
vivo and in vitro. Stem Cell Res. Ther. 4, 34 (2013). 
172. Zhang, L. et al. The 786-0 renal cancer cell-derived exosomes promote 
angiogenesis by downregulating the expression of hepatocyte cell adhesion 
molecule. Mol. Med. Rep. 8, 272–276 (2013). 
173. Yang, L., Wu, X., Wang, D., Luo, C. & Chen, L. Renal carcinoma cell-derived 
exosomes induce human immortalized line of Jurkat T lymphocyte apoptosis in 
vitro. Urol. Int. 91, 363–369 (2013). 
174. Mavani, G. P., DeVita, M. V. & Michelis, M. F. A Review of the Nonpressor 
and Nonantidiuretic Actions of the Hormone Vasopressin. Front. Med. 2, 
(2015). 
175. Knepper, M. A., Kwon, T.-H. & Nielsen, S. Molecular Physiology of Water 
Balance. N. Engl. J. Med. 372, 1349–1358 (2015). 
176. Vossenkämper, A. et al. Microtubules are needed for the perinuclear 
positioning of aquaporin-2 after its endocytic retrieval in renal principal cells. 
Am. J. Physiol. Cell Physiol. 293, C1129–1138 (2007). 
References 167 
177. Kamsteeg, E.-J. et al. Short-chain ubiquitination mediates the regulated 
endocytosis of the aquaporin-2 water channel. Proc. Natl. Acad. Sci. U. S. A. 
103, 18344–18349 (2006). 
178. Sandoval, P. C. et al. Proteome-Wide Measurement of Protein Half-Lives and 
Translation Rates in Vasopressin-Sensitive Collecting Duct Cells. J. Am. Soc. 
Nephrol. 24, 1793–1805 (2013). 
179. Ftouh, S. & Thomas, M. Acute kidney injury: summary of NICE guidance. The 
BMJ 347, f4930 (2013). 
180. Rahman, M., Shad, F. & Smith, M. C. Acute kidney injury: a guide to diagnosis 
and management. Am. Fam. Physician 86, 631–639 (2012). 
181. Solomon, R. & Dauerman, H. L. Contrast-Induced Acute Kidney Injury. 
Circulation 122, 2451–2455 (2010). 
182. Meinel, F. G., De Cecco, C. N., Schoepf, U. J. & Katzberg, R. Contrast-Induced 
Acute Kidney Injury: Definition, Epidemiology, and Outcome. BioMed Res. 
Int. 2014, e859328 (2014). 
183. Liu, Z. Z. et al. Iodinated contrast media cause direct tubular cell damage, 
leading to oxidative stress, low nitric oxide, and impairment of 
tubuloglomerular feedback. Am. J. Physiol. Renal Physiol. 306, F864–872 
(2014). 
184. Seeliger, E., Sendeski, M., Rihal, C. S. & Persson, P. B. Contrast-induced 
kidney injury: mechanisms, risk factors, and prevention. Eur. Heart J. 33, 
2007–2015 (2012). 
185. Doi, K. et al. Reduced Production of Creatinine Limits Its Use as Marker of 
Kidney Injury in Sepsis. J. Am. Soc. Nephrol. 20, 1217–1221 (2009). 
186. Edelstein, C. L. Biomarkers of Acute Kidney Injury. Adv. Chronic Kidney Dis. 
15, 222–234 (2008). 
References 168 
187. Mishra, J. et al. Identification of neutrophil gelatinase-associated lipocalin as a 
novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 
JASN 14, 2534–2543 (2003). 
188. Devarajan, P. Neutrophil gelatinase-associated lipocalin (NGAL). Scand. J. 
Clin. Lab. Investig. Suppl. 241, 89–94 (2008). 
189. Hirsch, R. et al. NGAL is an early predictive biomarker of contrast-induced 
nephropathy in children. Pediatr. Nephrol. Berl. Ger. 22, 2089–2095 (2007). 
190. Vaidya, V. S., Ramirez, V., Ichimura, T., Bobadilla, N. A. & Bonventre, J. V. 
Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early 
detection of kidney tubular injury. Am. J. Physiol. Renal Physiol. 290, F517–
529 (2006). 
191. Han, W. K., Bailly, V., Abichandani, R., Thadhani, R. & Bonventre, J. V. 
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal 
proximal tubule injury. Kidney Int. 62, 237–244 (2002). 
192. Vaidya, V. S., Ferguson, M. A. & Bonventre, J. V. Biomarkers of Acute Kidney 
Injury. Annu. Rev. Pharmacol. Toxicol. 48, 463–493 (2008). 
193. Neal, C. S. et al. Circulating microRNA expression is reduced in chronic 
kidney disease. Nephrol. Dial. Transplant. 26, 3794–3802 (2011). 
194. Zhou, H. et al. Urinary exosomal transcription factors, a new class of 
biomarkers for renal disease. Kidney Int. 74, 613–621 (2008). 
195. Dear, J. W., Street, J. M. & Bailey, M. A. Urinary exosomes: A reservoir for 
biomarker discovery and potential mediators of intrarenal signalling. 
PROTEOMICS 13, 1572–1580 (2013). 
196. Stewart, G. D. et al. Carbonic Anhydrase 9 Expression Increases with Vascular 
Endothelial Growth Factor–Targeted Therapy and Is Predictive of Outcome in 
Metastatic Clear Cell Renal Cancer. Eur. Urol. 66, 956–963 (2014). 
References 169 
197. Murakami, Y., Kanda, K., Tsuji, M., Kanayama, H. & Kagawa, S. MN/CA9 
gene expression as a potential biomarker in renal cell carcinoma. BJU Int. 83, 
743–747 (1999). 
198. Závada, J., Závadová, Z., Zat’ovičová, M., Hyršl, L. & Kawaciuk, I. Soluble 
form of carbonic anhydrase IX (CA IX) in the serum and urine of renal 
carcinoma patients. Br. J. Cancer 89, 1067–1071 (2003). 
199. Hosseini-Beheshti, E., Pham, S., Adomat, H., Li, N. & Guns, E. S. Exosomes as 
Biomarker Enriched Microvesicles: Characterization of Exosomal Proteins 
derived from a Panel of Prostate Cell Lines with distinct AR phenotypes. Mol. 
Cell. Proteomics MCP (2012). 
200. Reed, G. F., Lynn, F. & Meade, B. D. Use of Coefficient of Variation in 
Assessing Variability of Quantitative Assays. Clin. Diagn. Lab. Immunol. 9, 
1235–1239 (2002). 
201. Kanno, K. et al. Urinary Excretion of Aquaporin-2 in Patients with Diabetes 
Insipidus. N. Engl. J. Med. 332, 1540–1545 (1995). 
202. Zhou, H. et al. Collection, storage, preservation, and normalization of human 
urinary exosomes for biomarker discovery. Kidney Int. 69, 1471–1476 (2006). 
203. Tian, T. et al. Dynamics of exosome internalization and trafficking. J. Cell. 
Physiol. 228, 1487–1495 (2013). 
204. Collino, F. et al. AKI Recovery Induced by Mesenchymal Stromal Cell-Derived 
Extracellular Vesicles Carrying MicroRNAs. J. Am. Soc. Nephrol. JASN 
(2015). 
205. Oosthuyzen, W. et al. Quantification of human urinary exosomes by 
nanoparticle tracking analysis. J. Physiol. 591, 5833–5842 (2013). 
206. Gupta, I. R. et al. Protein Kinase A Is a Negative Regulator of Renal Branching 
Morphogenesis and Modulates Inhibitory and Stimulatory Bone Morphogenetic 
Proteins. J. Biol. Chem. 274, 26305–26314 (1999). 
References 170 
207. Kirchhausen, T., Macia, E. & Pelish, H. E. Use of dynasore, the small molecule 
inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol. 438, 
77–93 (2008). 
208. Butterworth, M. B., Edinger, R. S., Johnson, J. P. & Frizzell, R. A. Acute ENaC 
Stimulation by cAMP in a Kidney Cell Line is Mediated by Exocytic Insertion 
from a Recycling Channel Pool. J. Gen. Physiol. 125, 81–101 (2005). 
209. Umenishi, F., Narikiyo, T., Vandewalle, A. & Schrier, R. W. cAMP regulates 
vasopressin-induced AQP2 expression via protein kinase A-independent 
pathway. Biochim. Biophys. Acta BBA - Biomembr. 1758, 1100–1105 (2006). 
210. Caporali, A. et al. Deregulation of microRNA-503 Contributes to Diabetes 
Mellitus–Induced Impairment of Endothelial Function and Reparative 
Angiogenesis After Limb Ischemia. Circulation 123, 282–291 (2011). 
211. Knepper, M. A. & Star, R. A. Vasopressin: friend or foe? Nat. Med. 14, 14–16 
(2008). 
212. Kohan, D. E. Biology of endothelin receptors in the collecting duct. Kidney Int. 
76, 481–486 (2009). 
213. Musch, M. W. et al. Cyclic AMP-mediated endocytosis of intestinal epithelial 
NHE3 requires binding to synaptotagmin 1. Am. J. Physiol. Gastrointest. Liver 
Physiol. 298, G203–211 (2010). 
214. Macia, E. et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 
839–850 (2006). 
215. Zhou, B. et al. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor 
angiogenesis and growth. Cancer Lett. 333, 159–169 (2013). 
216. Nawaz, M. et al. The emerging role of extracellular vesicles as biomarkers for 
urogenital cancers. Nat. Rev. Urol. 11, 688–701 (2014). 
References 171 
217. Prunotto, M. et al. Proteomic analysis of podocyte exosome-enriched fraction 
from normal human urine. J. Proteomics 82, 193–229 (2013). 
218. Conde-Vancells, J. et al. Candidate biomarkers in exosome-like vesicles 
purified from rat and mouse urine samples. PROTEOMICS – Clin. Appl. 4, 
416–425 (2010). 
219. Tian, T. et al. Exosome uptake through clathrin-mediated endocytosis and 
macropinocytosis and mediating miR-21 delivery. J. Biol. Chem. 289, 22258–
22267 (2014). 
220. Charan, J. & Biswas, T. How to Calculate Sample Size for Different Study 
Designs in Medical Research? Indian J. Psychol. Med. 35, 121–126 (2013). 
221. Rieg, T., Richter, K., Osswald, H. & Vallon, V. Kidney function in mice: 
thiobutabarbital versus alpha-chloralose anesthesia. Naunyn. Schmiedebergs 
Arch. Pharmacol. 370, 320–323 (2004). 
222. Holstein-Rathlou, N. H., Christensen, P. & Leyssac, P. P. Effects of halothane-
nitrous oxide inhalation anesthesia and Inactin on overall renal and tubular 
function in Sprague-Dawley and Wistar rats. Acta Physiol. Scand. 114, 193–
201 (1982). 
223. Choi, H. S. et al. Renal Clearance of Nanoparticles. Nat. Biotechnol. 25, 1165–
1170 (2007). 
224. Liu, J., Yu, M., Zhou, C. & Zheng, J. Renal clearable inorganic nanoparticles: a 
new frontier of bionanotechnology. Mater. Today 16, 477–486 (2013). 
225. El Andaloussi, S., Lakhal, S., Mäger, I. & Wood, M. J. A. Exosomes for 
targeted siRNA delivery across biological barriers. Adv. Drug Deliv. Rev. 65, 
391–397 (2013). 
226. Devarajan, P. Biomarkers for the Early Detection of Acute Kidney Injury. Curr. 
Opin. Pediatr. 23, 194–200 (2011). 
References 172 
227. Sandilands, E. A. et al. Mechanisms for an effect of acetylcysteine on renal 
function after exposure to radio-graphic contrast material: study protocol. BMC 
Pharmacol. Toxicol. 12, 3 (2012). 
228. Hiemstra, T. F. et al. Human Urinary Exosomes as Innate Immune Effectors. J. 
Am. Soc. Nephrol. 25, 2017–2027 (2014). 
229. Krawczeski, C. D. et al. Temporal relationship and predictive value of urinary 
acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J. Am. 
Coll. Cardiol. 58, 2301–2309 (2011). 
230. Briguori, C. et al. Renal Insufficiency Following Contrast Media 
Administration Trial (REMEDIAL) A Randomized Comparison of 3 Preventive 
Strategies. Circulation 115, 1211–1217 (2007). 
231. Briguori, C., Quintavalle, C., Donnarumma, E. & Condorelli, G. Novel 
Biomarkers for Contrast-Induced Acute Kidney Injury. BioMed Res. Int. 2014, 
(2014). 
232. Matsui, K. et al. Clinical significance of tubular and podocyte biomarkers in 
acute kidney injury. Clin. Exp. Nephrol. 15, 220–225 (2010). 
233. Zeng, C. et al. Podocyte autophagic activity plays a protective role in renal 
injury and delays the progression of podocytopathies. J. Pathol. 234, 203–213 
(2014). 
234. Sekulic, M. & Pichler Sekulic, S. A compendium of urinary biomarkers 
indicative of glomerular podocytopathy. Pathol. Res. Int. 2013, 782395 (2013). 
235. Larsson, A. et al. Validation of podocalyxin-like protein as a biomarker of poor 
prognosis in colorectal cancer. BMC Cancer 12, 282 (2012). 
236. Hara, M. et al. Urinary podocalyxin is an early marker for podocyte injury in 
patients with diabetes: establishment of a highly sensitive ELISA to detect 
urinary podocalyxin. Diabetologia 55, 2913–2919 (2012). 
References 173 
237. Szymanski, C. J., Yi, H., Liu, J. L., Wright, E. R. & Payne, C. K. Imaging 
intracellular quantum dots: fluorescence microscopy and transmission electron 
microscopy. Methods Mol. Biol. Clifton NJ 1026, 21–33 (2013). 
238. Tang, K. W. A., Toh, Q. C. & Teo, B. W. Normalisation of urinary biomarkers 
to creatinine for clinical practice and research – when and why. Singapore Med. 
J. 56, 7–10 (2015). 
239. Wagner, B. D., Accurso, F. J. & Laguna, T. A. The applicability of urinary 
creatinine as a method of specimen normalization in the cystic fibrosis 
population. J. Cyst. Fibros. 9, 212–216 (2010). 
240. Preta, G., Cronin, J. G. & Sheldon, I. M. Dynasore - not just a dynamin 
inhibitor. Cell Commun. Signal. 13, 24 (2015). 
241. Ivanov, A. I. Pharmacological inhibition of endocytic pathways: is it specific 
enough to be useful? Methods Mol. Biol. Clifton NJ 440, 15–33 (2008). 
242. Chang, C.-C., Wu, M. & Yuan, F. Role of specific endocytic pathways in 
electrotransfection of cells. Mol. Ther. — Methods Clin. Dev. 1, 14058 (2014). 
243. Mulcahy, L. A., Pink, R. C. & Carter, D. R. F. Routes and mechanisms of 
extracellular vesicle uptake. J. Extracell. Vesicles 3, (2014). 
244. Christianson, H. C., Svensson, K. J., Kuppevelt, T. H. van, Li, J.-P. & Belting, 
M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans 
for their internalization and functional activity. Proc. Natl. Acad. Sci. 110, 
17380–17385 (2013). 
245. Weisbord, S. D. & Palevsky, P. M. Radiocontrast-induced acute renal failure. J. 
Intensive Care Med. 20, 63–75 (2005). 
 
